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The lung  
 
1.1 Anatomical and physiological aspects 
 
Anatomy of the lung 
 
The lung represents one very sensitive organ which gives animals and humans the breath of 
life. The primary functions of the lungs are to enable gas exchange between the blood and the 
external environment, and to maintain homeostatic systemic pH. To perform this very 
important task the lung consists of two distinct zones: i) conducting and ii) respiratory, within 
which the airway and vascular compartments are situated (Fig. 1). 
 
Figure 1: Schematic presentation of the lung showing conducting airways (blue) and alveolar gas 
exchange region (pink), adapted from [1]. 
 
The function of the conducting zone is to move air by bulk flow into and out of the lung 
during each breath. This zone consists of the first sixteen generations of airways and the air 
follows the way of the bronchi and bronchioles with low resistance. Generation zero 
represents the trachea, which bifurcates into the two main bronchi, which further subdivided 
into bronchi that enter respectively the left and right lung lobes. The intrapulmonary bronchi 
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continue to subdivide into progressively smaller diameter bronchi and bronchioles. The 
conducting zone ends with terminal bronchioles, which are devoid of alveoli (Fig.2).  
 
Figure 2: Scheme of airway branching in the human lung with the representative generation including 
in the upper and lower airways, containing their representative lung structures with their respective 
diameter (cm), length (cm), number, and total cross-sectional area (cm²), adapted from [2, 3]. 
 
Since the first 16 generations of airways contain no alveoli they are anatomically incapable of 
gas exchange with the venous blood and constitute the so-called anatomic dead space. The 
respiratory zone consists of all structures that participate in gas exchange and begins with 
respiratory bronchioles containing alveoli. These bronchioles subdivide into additional 
respiratory bronchioles eventually giving rise to alveolar ducts and finally to alveolar sacs. 
The acinus is defined as the unit comprised of a primary respiratory bronchiole, alveolar 
ducts, and alveolar sacs. The total cross-sectional area from trachea to terminal bronchioles 
(from 2.5 to180 cm²) [4] provides optimal conditions for bulk flow of air through the large 
airways down to the terminal bronchioles. In the terminal airways that comprise the 
respiratory zone and acini, airways continue dichotomous branching, but diameters of 
Introduction                                                                                                                    Chapter1 
 4 
respiratory bronchioles and alveolar ducts change very little with each generation (from 0.06 
to 0.024 cm). Thus, the total airway cross-sectional area nearly doubles with each generation 
beyond generation 16 (from 180 to 10 000 cm²). As a result of the enormous increase in 
surface area, bulk flow of air decreases rapidly within the respiratory zone until movement of 
air within alveoli occurs entirely by diffusion. The large area needed for molecular diffusion 
is provided by the respiratory zone, since 96 % of increase of the total cross-sectional area of 
airways occurs over the final 2.6 mm of the airway system and entirely within the respiratory 
zone.  
The structure of the airways varies considerably depending on their location in the 
tracheobronchial tree. The trachea is a fibromuscular tube supported ventrolaterally by c-
shaped cartilage and completed dorsally by smooth muscle. It provides the path of least 
resistance to airflow due to its large diameter. As the airways penetrate the lung parenchyma 
and continues dichotomous branching, cartilage continues to decrease in size and amount. 
Bronchioles are distinguished from bronchi by the lack of cartilage altogether, making them 
far less rigid and more distensible and collapsibale than bronchi. 
 
Pulmonary cell types  
 
The conducting airways condition the inspired air and clear it from many environmental 
pollutants before reaching the respiratory zone. While this partly depends upon the branching 
pattern, the cells lining the airways play an important role. 
In human four major cell types represent the surface epithelium and two main 
immunocompetent cell types are responsible for uptake and clearance of foreign materials like 
bacteria, pollutants or particles as well as communication to the cell environment: 
i) Ciliated cells 
Nearly half of the epithelial cells in the normal human airway are ciliated at all airway 
generations except for the respiratory units distal to the terminal bronchioles. 
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The surface of the ciliated cell is covered by cilia, about 200 per cell, each normally beating 
about 1000 times per minute with its effective stroke generally in the cranial direction and co-
ordinated with those on adjacent cells. The cilia move the overlying mucus layer only with 
their tips up to the airways, away from the alveoli and toward the pharynx. Mucus that 
reaches the pharynx is usually swallowed or expectorated.  
ii) Goblet cells 
In the human trachea there are between six and seven thousand mucus secreting goblet 
cells/mm². In adults 30 to 40 % of the total cells in the larger airways are mucus cells. The 
basal cells are thought to be major stem cells from which ciliated mucus cells derived. 
Numbers and activity of goblet cells are induced by a variety of acute and chronic 
inflammatory stimuli.  
iii) Clara cells 
Clara cells are nonciliated bronchiolar cells and are restricted to the terminal bronchioles, 
where they represent around 20 % of the cell population. They produce a bronchiolar 
surfactant and have oxidative activity as well as being involved in the fluid absorption. 
iv) Type I and type II epithelial cells 
The alveolar surface is mostly covered by alveolar epithelium, made up of type I cells or 
pneumocytes. Type I pneumocytes cover 5000 mm² of the alveolar surface by each cell, and 
measure only 0.2 mm in length, and with a low volume density of subcellular organelles, and 
they are connected to each other. There are approximately 300 milion alveoli in the lungs, 
with a combined surface area that is greater than 100 m², and with an alveolar epithelium as 
thin as 0.1 µm. Due to their thinness they prevent fluid loss, while facilitating rapid gas 
exchange, but make them extremely sensitive to injury. Type I pneumocytes are not capable 
of regeneration or reproduction in contrast to type II pneumocytes. Type II pneumocytes are 
smaller, more compact, and cuboidal with a high density of subcellular organelles and are 
twice as numerous as the type I cells, but cover only about 7 % of the surface area. Lamellar 
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bodies and surfactant-storing organelles characterized type II pneumocytes. They often 
occupy the corners of alveoli and their surface has abundant microvilli, and they are 
connected to each other by tight junction. Type II cells are metabolic active and responsible 
for both epithelial cell renewal and synthesis of surfactant, and acting as an ion and fluid 
pump to move fluid out of the air spaces. Its cuboidal shape facilitates rapid communication 
within the cells. In addition, there must be an extracellular signal following injury of type I 
cells that induces bordering type II cells to divide, hypertrophy, change their organelle 
composition, flatten out, and become new type I cells. 
v) Alveolar macrophages 
Alveolar macrophages are located at the interphase between air and lung tissue. They 
provided the first line of phagocytic defense against microbial invasion in the non-inflamed 
lower respiratory tract. Besides their phagocytic and mircobicidal functions, alveolar 
macrophages secrete numerous chemical mediators, mainly cytokines and chemokines, upon 
stimulation and playing an important role in inflammatory regulation in the lung.  
vi) Dendritic cells 
The lung is equipped with an elaborate network of dendritic cells (DCs) that can be found 
throughout the conducting airways, lung interstitium, lung vasculature, pleura, and bronchial 
lymph nodes. DCs perform an unique sentinel function in the pulmonary immune response in 
that they recognize inhaled antigens through expression of ancient pattern-recognition 
receptors such as Toll-like receptors, nucleotide-binding oligomerization domain (NOD)-like 
receptors, and C-type lectin receptors that will recognize motifs on virtually any inhaled 
pathogen, allergen, or substance. In addition, lung DCs express numerous receptors for 
inflammatory mediators that are released upon damage to tissue by pathogens, trauma, 
vascular damage, or necrosis. In summary, DCs bridge the innate and the adaptive immune 
system in humans.  
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1.2 Basic considerations for lung delivery 
 
Pulmonary ventilation, lung function parameter 
 
Alveolar ventilation is the exchange of gas between the alveoli and the external environment. 
In this process oxygen is brought into the lungs from the atmosphere and carbon dioxide 
carried into the lungs in the mixed venous blood is expelled from the body. Thus, alveolar 
ventilation is normally defined as the volume of gas per unit time that reaches the alveoli.  
The volume of air inspired or expired during a normal breath (tidal volume; Vt) of a 70 kg 
adult is about 500 ml per breath. The vital capacity (VC) is the volume of air that can be 
expired from the lungs after maximal inspiration (about 4.5 l in a healthy 70 kg adult). The 
residual volume (RV) is the volume of gas left in the lungs after maximal forced expiration. It 
is determined by the force generated by the muscles of expiration and the inward elastic recoil 
of the lungs as they oppose the outward elastic recoil of the chest wall. The total volume of air 
that a person breathes each minute is measured by the expired volume of air for each breath 
(represents Vt) and the number of breaths over a fixed period of time. To determine alveolar 
ventilation, the amount of air present in the conducting zone of the airways (where gas 
exchange does not occur) has to be subtracted out of this calculation. This volume is known 
as anatomic dead space (Vd) and is approximately 150 ml in the adult male. Thus, alveolar 
ventilation is defined as: Alveolar ventilation = (Vt – Vd) * respiratory rate, where Vt 
represents the tidal volume and Vd the dead volume. 
However, both tidal volume and respiratory rate vary enormously according to age and 
clinical status and should be kept in mind for drug delivery scenario. In addition, there are 
regional differences in ventilation due to topographical reasons, alteration in lung 
distensibility or airway resistance. Figure 3 shows the different lung capacities and volumes 
described above: 
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Figure 3: Capacities and volumes of the human lung, representing one breath showing the maximal 
inspiratory level and the maximal respiratory level with the resting expiratory level. Total lung 
capacity (TLC), vital capacity (VC), respiratory capacity, functional residual capacity (FRC), residual 
volume, expiratory reserve volume, are additionally presented, adapted from [2, 5]. 
 
Pulmonary administration, deposition modelling 
 
When using the inhalation route for local and systemic drug delivery an efficient and 
reproducible lung deposition of inhaled aerosol particles is essential. Once deposited, particles 
encounter a variety of physiochemical and biological barriers. These include mucus barriers 
and catabolic enzymes in the tracheobroncial region, and macrophages in the alveolar region. 
With the approval of inhaled insulin in 2006 an important milestone was achieved and more 
biotherapeutics will be tested for pulmonary administration. However, most pulmonary drug 
delivery technologies work with an efficiency of less than 20 % and lung dose might change 
from patient to patient by more than 100 %. Thus, the technology used for pulmonary drug 
delivery is quite important and must be suitable for patients to perform an efficient and 
reproducible delivery to the lungs.  
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The most important biophysical parameters determining regional drug deposition in human 
lungs are: 
i) aerodynamic particle behaviour 
ii) breathing pattern of particles 
iii) time of aerosol injection into the breathing cycle 
iv) airway anatomy and morphology of the patient 
The aerodynamic particle diameter (dae) is defined as the diameter of a sphere with a density 
of 1 g/cm³ that has the same aerodynamic behaviour as the particle which will be 
characterized:  dae= √ (ρ/ρa * dg) 
where ρ is the mass density of the particle, ρa the unit density (1 g/cm³) and dg is the 
geometric diameter. The dae is mainly depending on the diffusion of the particle and the 
equation follows the Stoke-Einstein relationship: D= k * T / 6 pi η r, where D is diffusion 
coefficent, k is the Boltzmann constant, T is temperature, η is viscosity, and r is aerodynamic 
radius. Thus, particles with different density and shape could be distinguished using their 
aerodynamic properties.  
The most relevant mechanisms for therapeutic aerosols in the airways are: 
i) Diffusion by Brownian motion (dae < 0.5 µm) 
Particle deposition by diffusion is based on Brownian motion. An aerosol particle, which is 
suspended in gas is moved by collisions with gas molecules. This leads to an irregular and 
unoriented movement of particles that causes contact with an airway wall. The propability 
that a particle is deposited on an airway wall by Brownian motion is dependent on the size of 
the particle and the residence time of the particle in the respiratory tract. Thus, the deposition 
by diffusion is defined as: DEdiff ~ t/dae, where DEdiff is deposition by diffusion, t represents 
the residence time in the respiratory tract and dae is the aerodynamic diameter of the particle. 
Deposition by diffusion is only relevant for aerosol particles with an aerodynamic diameter 
below 0.5 µm. Conventional drugs usually obtain diameters between 1-10 µm. Therefore, this 
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mechanism has no significant influence on drug deposition within the lung. But for 
nanoparticles less than 500 nm diffusion by Brownian motion could be important for 
deposition of such nanoparticles into the lungs (Fig. 4).  
 
Figure 4: Deposition mechanism of inhaled particles in the lungs are presented, adapted and modified 
from [6, 7]. The deposition of particles mainly depends on the aerodynamic diameter of the particles. 
To reach the upper airways particles with diameters of 3-5 µm are appropriated (impaction), whereas 
smaller particles with diameter between 0.5-3 µm are deposited in the lower airways by 
sedimentation. Diffusion occurs when particle size is smaller than 0.5 µm and particles are either 
exhaled or deposit in the lower airways depending on the rate of inspiration and expiration.  
 
ii) Sedimentation by gravitational force ( dae > 0.5 µm) 
Deposition by sedimentation is caused by the gravity of the earth. By this gravitational force 
an aerosol particle will be accelerated so long until the counterpoise caused by the resistance 
of the air equals the gravitational force. At this point the particle will deposit with a constant 
settling velocity. Deposition by sedimentation is described as: DEsed ~ dae² * t, where DEsed 
represents deposition by sedimentation, dae is the aerodynamic diameter, and t is the residence 
time in the respiratory tract. Particles with diameters < 1 µm have only negligible 
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sedimentation velocity. With increasing particle size, the settling velocity is so large that 
within the time of a breath the particle will reach an airway wall.  
iii) Impaction (dae > 3 µm) 
Impaction is caused by the inertia of aerosol particles. Larger particles with a diameter above 
3 µm are too inert and tend to fly straight ahead. This mechanism leads to particle deposition 
in the extrathoracic airways, but also on bifurcations at the intrathoracic airways. Deposition 
by impaction is defined as: DEim ~ dae² * V, where DEim is deposition by impaction, dae 
represents the aerodynamic diameter and V is the settling velocity of the particle. Particle 
deposition by impaction is the main cause that prevents aerosol particles from entering into 
the lungs. 
The upper human airways have anatomical structures acting as efficient filters for inhaled 
natural pollutants. Fast inhalation leads to enhanced deposition by impaction at the larynx and 
in the nose and prevents particle penetration into the lungs. This extrathoracic deposition 
efficiency has a high inter-subject variability because of biological and anatomical differences 
of mouth and throat. This variability can be reduced, when inhaling very slowly and/ or using 
smaller particles (1-3 µm), which leads to a small impaction parameter and results in minimal 
extrathoracic deposition. It has to be noted that particle size should be not too small because 
these particles are exhaled and tend to aggregated very fast. Particles with aerodynamic 
diameter of 1 to 3 µm have shown to deposit optimally in the alveolar region of the lungs [8, 
9] (Fig. 5). 
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Figure 5: Effect of particle size on the deposition of aerosol particles in the human 
respiratory tract following a slow inhalation and a five seconds breath hold, adapted from 
[10]. Light grey line shows the deposition of particles in the alveolar region, dark grey line 
represents the deposition in the airways, and the black line presents the deposition in mouth 
and trachea, depending on the particle diameter (µm).  
 
For particles > 1 µm deposition occurs by sedimentation or impaction and these mechanisms 
are responsible for the site of deposition within the respiratory system and is normally called 
regional deposition. Some mathematical models described the determination of the deposition 
in different regions in the respiratory system and allow the estimation of regional deposition 
of inhaled aerosol particles. 
Under normal breathing conditions the lungs usually contain only about half the volume of air 
they can hold. The airways contain only four percent of the lung air, the alveoli the rest. 
Depending on the breathing pattern regional deposition is changed dramatically in addition to 
the influence of the particle size. Thus, for pulmonary application not only an efficient 
therapeutic substance but also an efficient delivery system to transport the drug to its intended 
target in the lung is needed. Aerodynamic particle behaviour, breathing pattern and lung 
morphology have to be considered.  
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1.3 Cellular Transport mechanisms  
 
Intracellular membrane traffic guided cellular processes, which are trafficked lipids, proteins, 
receptor ligands and soluble molecules to distinct compartments within the cell. 
Compartmentalization is maintained through the organization of the cytoplasm into multiple 
intracellular structures that have their own distinct identity and function. Individual 
compartments are continually in flux and proteins and lipids are continually moving between 
compartments and the balance of traffic between them defines the steady-state localization. 
Macromolecular therapeutics and nanosized delivery systems are all candidates for cellular 
uptake by the mechanism of endocytosis [11]. Modern drug delivery design is characterized 
by the delivery of drugs to a specific cellular target. The target side of action may be 
exclusively within the inside of a range of organelles or the agent may require escape from 
endosomes or lysosomes prior to reaching its target. In most cases, it is also important that the 
drug is not exported from the cell following its entry into recycling or secretion pathways. 
The plasma membrane and downstream organelles therefore pose major barriers to effective 
drug delivery. Endocytosis describes multiple methods of internalisation that can be classified 
into two broad categories: i) phagocytosis (“cell eating - the uptake of large particles”) and ii) 
pinocytosis (“cell drinking – the uptake of fluid and solutes”) [12]. Phagocytosis is normally 
restricted to specialized cells, including macrophages, monocytes, and neutrophils. This 
mechanism is mainly responsible for clearance of pathogens such as bacteria and yeast, and 
large debris of cells. In contrast to that, pinocytosis occurs in all cell types and is currently 
subdivided into i) clathrin-mediated endocytosis, ii) macropinocytosis, iii) internalisation via 
caveoli, and iv) clathrin-and caveoli-independent endocytosis [12, 13] (Fig 6). Many agents 
that are delivered to cells will also be delivered to compartments outside of the classical 
endocytotic pathway.  
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Figure 6:  Endocytotic pathways into the mammalian cell adapted from [12]. Phagocytosis is 
characterized by particle uptake by specialized cells like macrophages, monocytes, or neutrophiles 
and represents the first way of defense against forgein material. Pinocytosis occurs in all cell types 
and is devided in four main subdivisions (i) macropinocytosis, (ii) clathrin-dependent, (iii) caveoli-
dependent, and (iv) clathrin-/caveoli-independent endocytotic pathway. Macropinocytosis (i) is 
represented by uptake of soluble particles with diameter above 300nm. Clathrin-mediated 
endocytosis (ii) allows the internalisation of proteins and other molecules into the cell by 
using specific receptors expressed on the cell surface, and represents the preferred pathway 
for microspheres up to 200 nm in size. Caveoli-mediated endocytosis (iii) is characterized by 
uptake via caveolae, small (50-80nm) invagination of the plasma membrane. The clathrin- 
and caveoli-independent pinocytosis (iv) used other cholesterol-rich microdomains on the 
plasma membrane than caveolae and clathrin, which are smaller in diameter and mainly 
located in the brain in neurons and neuroendocrine cells. 
 
Macropinocytosis is a nonselective endocytotic pathway for internalization of suspended 
macromolecules and the internalized vesicles or macropinosomes can have sizes up to 5 µm 
[14]. During macropinocytosis, membrane protusions, often called ruffles, are formed which 
can subsequently fuse with each other or with the plasma membrane to enclose large volumes. 
Clathrin-mediated endocytosis allows the internalisation of proteins and other molecules into 
the cell through the use of specific receptors expressed on the cell surface, e.g. ligand-
activated receptors such as the epidermal growth factor (EGF) receptor, transferring receptor, 
or low-density lipoprotein receptor. Clathrin-dependent endocytosis is said to be the preferred 
pathway for microspheres up to 200 nm in size [15], macropinocytosis is essential in the 
internalization of particles larger than 300 nm in diameter, and represent the first line of 
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defense against foreign material and removal of damaged host cells. Noncoated vesicle (non- 
clathrin/caveoli coated) formation (i.e. clathrin independent endocytosis) also contributes to 
internalization from the cell membrane. Although the details of this pathway have not been 
completely elucidated, it is currently subclassified based on the role of dynamin and several 
small GTPases [16]. These include uptake from lipid rafts in caveolae or via a flotillin-
dependent pathway, from which the caveolae-mediated endocytosis is probably the best 
characterized pathway. Caveolae are small (50 - 80 nm), smooth, flask-shaped invaginations 
of the plasma membrane that are characterized by the presence of caveolin-1. Certain 
pathogens like SV40 virus and cholera toxin subunit B specifically use this pathway to enter 
cells. However, a significant fraction of cholera toxin subunit B is also taken up on clathrin-
coated vesicles.  
A number of endocytotic pathways have been demonstrated to be involved in the uptake of 
DNA complexes [17], and this is highly dependent on cell type, the nature of the gene carrier, 
and the particle size [18]. This variability stresses the necessity of studying the internalization 
of each of the different types of non-viral gene carriers in an appropriate cell line model. A 
quantification of the contribution for each endocytotic pathway to the overall cellular uptake 
is essential for elucidating the corresponding intracellular pharmacokinetic models.  
For uptake of cationic complexes (cationic polymers with plasmid DNA) syndecans are 
proposed to be the main receptors involved in adherent cells, illustrated in Fig.7, adapted from 
[19]. Syndecans are ubiquitous transmembrane adhesion molecules. Their polyanionic 
heparin sulphate moities are bound at the distal end of their ectodomain, thus facilitating 
extracellular matrix binding, but also interaction with large cationic particles. PEI takes 
advantage of the extracellular matrix catabolism by adherent cells. After initial binding of 
PEI-nucleic acid complexes to their receptor, gradual electrostatic zippering of the plasma 
membrane around the particle is sustained by lateral diffusion of many syndecan molecules 
that cluster into cholesterol-rich rafts. Clustering, in turn, triggers protein kinase C (PKC) 
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activation and linker protein-mediated actin binding to the cytoplmatic tail of syndecan. 
Resulting tension fibers and a growing network of cortical actin can then pull the particle into 
the cell [20].  
 
Figure 7: A model for the uptake of cationic complexes by adherent cells, suggested  from 
Kopatz et al. [19]. The hypothesized mechanism for the entry of cationic complexes into adherent cells 
in culture was divided in five steps: 1) Electrostatic binding of the cationic particle to syndecans      
(transmembrane heparan sulphate proteoglycans (HSPGs)), 2) Particle-induced syndecan clustering 
into cholesterol-rich rafts, 3) protein kinase C (PKC) mediated phosphorylation, 4) actin binding 
through linker proteins, 5) actin-mediated engulfment of the particle. 
.
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1.4 Barriers for pulmonary administration 
In the lungs the major barriers for efficient local non-viral based gene delivery are the mucus 
layer secreted by goblet cells, the apical membrane glycol-conjugates, and the airway 
epithelium with tight junctions inhibiting the intracellular transport. Surfactant produced by 
type II pneumocytes may facilitate nucleic acid delivery due to increased complex stability 
and condensation [21-24]. In many airway diseases mucus viscosity and airway 
microenvironment are extremely altered and may enhance the barrier to airway gene transfer 
to the lungs [23, 25-27]. Normal airway mucus lines the epithelial surface and provides an 
important innate immune function by detoxifying noxious molecules and by trapping and 
removing pathogens and particulates from the airway via mucociliary clearance. The major 
macromolecular constituents of normal mucus, the mucin glycoproteins, are large, heavily 
glycosylated proteins with a defining feature of tandemly repeating sequences of amino acids 
rich in serine and threonine, the linkage sites for large carbohydrate structures. For normal 
function, mucus must be cleared by ciliary motion and this process requires a balance 
between the volume and composition of the mucus, adequate periciliary liquid volume, and 
normal ciliary beat frequency. Normal mucus has been found to inhibit gene delivery [28], but 
also sputum and broncho-alveolar fluid recovered from cystis fibrosis (CF) patients were 
shown to inhibit PEI-mediated gene transfer efficiency [29]. In addition, the role of bacteria 
infection in gene transfer specially the massive colonization of CF airways by Pseudomonas 
aeruginosa and other bacteria modified the microenvironment in the airways and has to be 
taken into account when non-viral vector systems are investigated. For example, it was 
described that mice infected with P.aeroginosa showed a 5-fold increase in gene transfer 
whereas infection with E.coli did not show any implementation on gene transfer [30].  
Surfactant produced by type II cells reduces surface tension in the lung and prevent the 
alveoli from collapsing. The amount of surfactant required by the lung is a function of tidal 
volume/functional residual capacity ratio (Vt/ FRC), the radius of curvature of the alveoli, and 
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the compliance of the chest wall. The lower the ratio Vt to FRC, the less surfactant needed. 
According to LaPlace’s law the greater the radius of the curvature of the lung, the less 
surfactant is required to prevent collapse. Interaction with surfactant proteins did not affect 
PEI-mediated gene transfer [21, 24, 31].  
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1.5 Non viral vector systems for pulmonary siRNA application 
 
RNA interference (RNAi) based therapeutics represent a fundamentally new way to treat 
human disease by addressing targets that are otherwise “undruggable” with existing 
medicines [32, 33]. The nobel-prize winning discovery of RNAi in the worm Caenorhabditis 
elegans in 1998 [34], and the subsequent demonstration that RNAi operates in mammalian 
cells revolutionized the current understanding of endogenous mechanisms of gene regulation 
and provided powerful new tools for biological research and drug discovery. RNAi pathways 
are guided by small RNAs that include small interfering RNAs (siRNAs) and mirco RNAs 
(miRNAs) with the latter deriving from imperfectly paired non-coding hairpin RNA 
structures that are naturally transcribed by the genome. Gene silencing can be induced by 
siRNA through sequence-specific cleavage of perfectly complementary messenger RNA 
(mRNA), whereas miRNAs mediate translational repression and transcript degradation for 
imperfectly complementary targets (Fig.8).  
 
Figure 8:   RNAi machinery adapated from [35]. Short hairpin RNAs (shRNAs) expressed from 
plasmid or delivered intracellularly are processed into 21-23 base pair siRNA fragments by enzyme 
Dicer. A multiprotein complex called RISC (RNA Induced Silencing Complex) assembles with the 
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siRNA, retaining the guide strand and discarding the passenger strand. The siRNA then guides RISC 
to complementary mRNA molecules in the cytosol and through Watson-Crick base pairing selectively 
binds and cleaves the mRNA in the region of homology. The mRNA is then degraded by the 
endonuclease region of the RISC complex, thus translation into protein cannot occur. 
 
The goal of RNAi-based therapy represents the activation of selective mRNA cleavage for 
efficient gene silencing. There are two possibilities to harness the endogenous pathway: either 
i) by using viral vector to express short hairpin RNA (shRNA) that resembles miRNA 
precursors, or (ii) by introducing siRNAs that mimic Dicer cleavage product into the 
cytoplasm. Synthetic siRNAs utilize the naturally occurring RNAi pathway in a manner that 
is consistent and predictable, thus making them particularly attractive as therapeutics. Since 
they enter RNAi pathway later, siRNAs are less likely to interfere with gene regulation by 
endogenous miRNAs [36, 37]. The most important characteristics for effective design and 
selection of siRNAs are potency, specificity, and nuclease stability. Two types of off-target 
effects need to be avoided or minimized: i) silencing of genes sharing partial homology to the 
siRNA and ii) immune stimulation induced by recognition of certain siRNAs by the innate 
immune system. The activation of the innate immune systems by siRNA could be induced by 
recognition of dsRNAs by the serine/threonine protein kinase receptor (PKR) [38]. This 
pathway is normally triggered by dsRNAs that are more than 30 nucleotides long, but at 
higher concentrations also siRNAs may be able to activate this pathway resulting in global 
translational blockade and cell death. The potential to activate toll-like receptors (TLRs) in 
the endosomal pathway is more likely to occur after siRNA delivery due to recognition of 
specific nucleotide sequence motifs (e.g. GU) by TLRs. TLR activation could trigger the 
production of type I interferons and pro-inflammatory cytokines, and induce nuclear factor 
kappa B (NF-kB) activation [39, 40]. For example, the presence of 2’-O-methyl modifications 
within the siRNA duplex could abrogate the binding to TLR7 in endosomes and abolish 
immunostimulatory response. In addition, these modifications also reduce sequence-
dependent off-target silencing and may be particularly beneficial in enhancing siRNA target 
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specificity [41-43]. Due to increasing mortality and morbidity caused by several lung 
diseases, RNAi strategies have attracted particular attention and the lung as target organ 
provides an attractive tool because of the accessibility via non-invasive routes, e.g. nasal or 
pulmonary applications. The clinical success of siRNA-mediated interventions critically 
depends upon the safety and efficacy of the delivery methods and agents. Naked siRNAs are 
degraded in human plasma with a half-life of minutes [44, 45]. Thus, the search for optimized 
nanocarriers to deliver siRNA is still under intensive investigation. The negative charge and 
chemical degradability of siRNA under physiologically relevant conditions make its delivery 
a major challenge [35]. Depending on their origin, two types of positively charged carriers 
could be distinguished: i) lipid–based and ii) polymeric-based carrier systems. Both systems 
provided several advantages to deliver siRNA. Liposome formation agents like Lipofectamine 
2000 [46, 47] and cardiolipin analogues [48, 49] have been successfully used for the delivery 
of siRNA. Negatively charged nucleic acids and positively charged lipids spontaneously form 
nanoparticles, known as lipoplexes, of 50-200 nm in diameter [50] Interaction with serum 
components represents one of the major hurdles that influence the performance when used 
systemically [27]. Recently, lipid-mediated delivery of siRNA against apolipoprotein B 
(ApoB) has been used to target ApoB mRNA to the liver [51, 52]. The in vivo use of cationic 
lipids especially by i.v. administration presents significant problems as these reagents can be 
quite toxic. Despite problems with i.v. use, cationic lipids are employed for i.p. injection [53-
55], for CNS injection [56, 57] or in topical epithelial surface application [58, 59] and 
intratracheal [60]. Toxicity varies with the precise chemical composition of the lipids 
employed, dose, and the delivering route. Variations in chemical composition can have a large 
impact on the functional properties of cationic lipid mixtures [61], and lipoplex/liposomal 
preparations have been devised with decreased toxicity that are more compatible with i.v. 
administration. Liposomes can be modified with ligands such as folate or small peptides, 
which assist with delivery and help target specific cell types or tissues [62, 63]. Through the 
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use of neutral polyethylene glycol-substituted surfaces and other approaches, liposomes can 
be stabilized and made more “stealthy” showing reduced clearance and improved 
pharmacokinetics [64, 65]. These kinds of lipid nanoparticles have been successfully used to 
deliver antisense oligonucleotides and siRNAs in vivo [48, 49, 66]. 
Similar to the lipid-based non viral vector systems, the positive charges of polycations allow 
an efficient interaction with siRNAs to form so-called polyplexes, which can bind onto cell 
plasma membrane and be endocytosed. In contrast to the lipid-based systems that rely on the 
fusogenic property of the liposomes to mediate endosomal escape, polymeric carriers such as 
poly(ethylene imine) (PEI) use the so-called “proton-sponge” effect to enhance endosomal 
release of endocytosed polyplexes [20, 67-70] (Fig.9).  
 
Figure 9:  Proton sponge mechanism adapted from [69]. Cationic polymers bind to negatively 
charged nucleic acids and forms so-called polyplexes with positive surface charge. Polyplexes binds 
with high affinity to negatively charged lipid groups on the plasma membrane and are endocytosed in 
the tight fitting vesicles (endosome). Once entered into an acidifying lysosomal compartment, the 
unsaturated amino groups are capable of sequestering protons that are supplied by the ATP-ase 
(proton pump). This process keeps the pump functioning and leads to the retention of one chloride ion 
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(Cl-) and one water molecule (H2O) per proton. Subsequent lysosomal swelling aand rupture leads to 
deposition of nucleic acid and polymer in the cytoplasm and the spillage of the lysosomal content. Due 
to the high buffering capacity in the lysosome positively charged polymers the mechanism is called 
proton sponge.  
 
According to this mechanism, the deprotonated amines with different pKa values confer a 
buffer effect over a wide range of pH. This buffering may protect the siRNA from 
degradation in the endosomal compartment during maturation of the early endosomes to late 
endosomes and their subsequent fusion with the lysosomes. The buffering property also 
allows the polycation to escape from the endosome. At lower pH the buffering capacity 
causes an influx of chloride ions and water into the endosomes, which burst due to osmotic 
pressure and facilitating intracellular release of PEI - siRNA polyplexes. PEI has been used 
for many years to facilitate nucleic acid delivery [20, 68]. However, due to toxicity and 
variable performance it has not found generalized acceptance as a delivery tool for either 
antisense oligonucleotides or siRNAs. Nevertheless, PEI can be used as a prototype for 
formulation of more complex particles with improved properties [71]. For example, a 
PEGylated PEI particle with a vasculature-targeting RDG peptide has been shown to deliver 
siRNAs successfully in a mouse xenograft tumor model [72]. Deacylation of PEI reduces 
toxicity and improves pulmonary delivery of siRNAs in mice [73] and folate-modified 
PEGylated PEI is being tested for siRNA delivery in tumor cells [74]. Although a large 
number of studies have reported successful in vivo delivery of nucleic acids using liposome or 
polyplex reagents, issues of toxicity persist and must be addressed. Much of the toxicity of 
cationic lipids relates to electrostatic effects, and precise complexation ratios of the positively 
charged reagent with the negatively charged cargo nucleic acid are important. Interaction with 
negatively charged serum proteins can inactivate the complex [75], and particle aggregation 
with clumping in capillary beds can be problematic; interaction with complement proteins can 
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lead to inflammation. When loaded with a nucleic acid cargo, cationic reagent can trigger the 
release of a variety of cytokines (see discussion of TLR activation above).  
Synthetic polymers and nanomaterials display selective phenotypic effects in cells and in the 
body that affect signal transduction mechanisms involved in inflammation, differentiation, 
proliferation, and apoptosis. When physically mixed or covalently conjugated with cytotoxic 
agents, bacterial DNA or antigens, polymers can drastically alter specific genetically 
controlled responses to these agents [76]. These effects, in part, result from cooperative 
interactions of polymers and nanomaterials with plasma cell membranes and trafficking of 
polymers and nanomaterials to intracellular organelles. Cells and whole organism responses 
to these materials can be phenotype or genotype dependent. In selected cases, polymer agents 
can bypass limitations to biological responses imposed by the genotype, for example, 
phenotypic correction of immune response by polyelectrolytes. Overall, these effects are 
relatively benign as they do not result in cytotoxicity or major toxicities in the body. 
Collectively, however, these studies support the need for thoroughly assessing 
pharmacogenomic effects of polymer materials to maximize clinical outcomes and understand 
the pharmacological and toxicological effects of polymer formulations of biological agents, 
i.e. polymer genomics. In addition, it is well described in the literature that cationic 
nanoparticles disrupt lipid bilayers [77, 78], induce oxidative stress inside the cell as a result 
of cell-type interplay and cause in some cases acute lung inflammation when administered 
intratracheally [79, 80]. Intensive efforts have to be focus on the issue of cytotoxicity to 
obtain more insight in the exact mechanisms behind, which are multidimensional and largely 
depend on the application route as well as the formulation that is delivered. Therefore, 
toxicity profiles are still needed and represent a great implement in improving non-viral 
delivery systems. 
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1.6 Aspects of Nanotoxicology in Nanomedicine 
Nanotechnology has the potential to revolutionize medicine, and has already presented new 
regulatory challenges. This technology represents a manipulation of matter near atomic-size 
scale (1 - 100 nm) to engineer new structures, materials, and devices. Considering the rapid 
growth of nanotechnology and the variety of nanomaterials potentially used in the future, 
identifying, quantifying and managing potential health risks is essential, especially in the 
respiratory tract that may serve as the portal of entry for inhaled nanoparticles and nanofibers. 
[81]. Nanoparticle behaviour and toxicity in the lungs and translocation from the lungs has 
been investigated over decades in the environmental health field with a focus on (ambient) 
ultrafine particles (UFP). UFP are defined as particles with an aerodynamic diameter below 
100 nm [82]. Their small size distinguishes them from larger coarse (aerodynamic diameter < 
10 µm, PM10) and fine (aerodynamic diameter < 2.5 µm, PM2.5) air pollution particles. 
Epidemiological studies have shown that a sudden surge in the level of particulate matter 
(PM) can be linked to increased cardio-respiratory morbidity and mortality including asthma, 
chronic obstructive pulmonary disease (COPD) and artherosclerosis [83, 84]. The small size 
and the huge surface area of UFPs might be the main factors contributing to their toxicity and 
adverse side-effects in humans. UFPs are taken up by lung cells and are able to cross the 
epithelial barrier to enter the blood and lymph stream by transcytosis and getting distributed 
to the body. The large surface area per mass of nanoparticles causes them to be more 
biologically active, thus initiated inflammatory and oxidative stress responses. 
Physicochemical particle properties such as size, surface charge and hydrophilicity define the 
fate of particles in vivo. Because synthetic nanomaterials often occur in size ranges similar to 
ultrafine airborne particles that are considered to be a major factor contributing to adverse 
health effects of air pollution, information on the biological reactivity of these particulates is 
also necessary to allow their safety evaluation. One important note is that these environmental 
toxicological studies focus on insoluble materials, such as carbon or titanium dioxide, 
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whereas therapeutic nanoparticulate systems are composed of materials that will eventually 
degrade into biocompatible components. Thus, depending on the speed of degradation, 
biodegradable nanoparticles may be anticipated to elicit toxicological responses quite 
different from non-biodegradable materials. Therefore, further investigations of the health 
ramifications of medical nanoparticles as a function of their physicochemical characteristics 
are still needed [81]. As exposure to PM from vehicle exhaust, combustion, road dust and 
windblown soil has been associated with increases in respiratory and cardiovascular 
morbidity and mortality biomarkers of inflammation and oxidative stress should be provided 
to predict and assess the risk of particulate therapeutic systems. Nel and colleagues have 
introduced a hierarchical oxidative stress model as a predictive toxicological tool for 
assessment of nanomaterial hazards [85]. They defined the predictive toxicological approach 
as establishing and using mechanisms and pathways of injury at a cellular and molecular level 
to prioritize screening for adverse biological effects and health outcomes in vivo [86]. 
Experimental evidence exists about the hazard that nanomaterials cause and a lot of studies 
dealt with the possible toxicological mechanisms and pathways behind each nanomaterial [83, 
86-95]. Currently, there is considerable debate about the right nanomaterial toxicity testing 
with regard to correct toxicological screening endpoints for the correct balance of in vitro and 
in vivo testing, the cost of the effort and who should responsible for screening and safety 
assessment of nanomaterials [96, 97]. The hierarchical oxidative stress paradigm postulates 
that oxidative stress leads to incremental cellular responses that can be classified as 
antioxidant defense (tier1), pro-inflammatory effects (tier2) and cytotoxicity (tier3) (Fig 10).  
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Figure 10:  Hierarchical oxidative stress model adapted from [86] – an example of a predictive 
paradigm. At a lower amount of oxidative stress (tier 1), phase II antioxidative enzymes are induced 
via transcriptional activation of the antioxidant response element by Nrf-2 to restore cellular redox 
homeostasis. At an intermediate amount of oxidative stress (tier2), activation of MAPK and Nf-kB 
cascades induces pro-inflammatory responses. At a high amount of oxidative stress (tier 3), 
perturbation of the mitochondrial PT pore and disruption of electron transfer results in apoptosis or 
necrosis. 
 
 
Each of these response tiers are initiated by specific biological sensors and activation 
mechanisms. In Tier 1, the transcription factor Nrf-2 is activated to enhance the expression of 
phase II enzymes, which attempt to restore redox equilibrium. If the level of oxidant injury 
increases (Tier 2), cells express pro-inflammatory cytokines by activating signalling pathways 
such as the mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (Nf-kB) 
cascades. At the highest level of oxidative stress (Tier 3), interference in mitochondrial inner 
membrane electron transfer or changing open/closed status of permeability transition pore 
could lead to effects on ATP synthesis and release of pro-apoptotic factors. 
Application of nanotechnology to medical problems – nanomedicine – offers a wide range of 
therapeutical and diagnostical approaches. Material at the nanometer scale exploits several 
novel physiochemical and biological properties. Mainly increased surface area and nano-sized 
effects provided higher reactivity, strength and electrical characteristics of nanomaterial. 
Nanotechnology provides many advantages also for drug delivery to improve targeted side of 
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action as well as more controlled release to better manage drug pharmacokinetics, 
pharmacodynamics, non-specific toxicity, immunogenicity and biorecognition of systems in 
the quest for improved efficacy [98]. Two main factors are important to investigate: i) drug 
formulation and ii) route of application. Demonstration of optimal drug loading and release 
properties, long shelf-life and low toxicity are the main issues to be overcome for 
development of successful drug carrier systems. The route of administration is as important as 
the drug itself for a therapeutic success. Nanocarriers for drug delivery are intended to cross 
physical barriers and avoid toxic effects [69].  
Implementation of RNAi technology and integration to nanomedicine may be of great clinical 
relevance to improve treatment strategies in a wide range of disorders. Table 1 summarized 
ongoing clinical trials using siRNAs for different targets. 
Table 1:  Summary of ongoing clinical trials for siRNA delivery 
Company siRNA target Disease/disorder Status 
Bevasiranib 
(Cand5) VEGF AMD, DME 
PhaseIIcompleted, 
Phase IIIplanned Acuity Pharmaceuticals 
 ACU-HTR-
OOX TGF-ß  fibrosis PhaseII 
ALN-RSV-01 
ALN-RSV-02 
RSV 
Pediatric 
RSV 
RSV 
Pediatric RSV 
Phase IIb 
preclinical Alnylam 
 
ALN-VSP KSP and VEGF Liver cancer Phase I 
Atu21  Advanced solid cancer Phase I Silence Therapeutics Atu134  Acute lung injury Preclinical 
Sirna Therapeutics 
(Quark Pharmaceuti-
cals & Pfizer) 
RTP801  DME Phase I 
Sirna Therapeutics 
(Quark 
Pharmaceuticals) 
 p53 Acute kidney injury Phase I 
Sirna Therapeutics 
(Calando 
Pharmaceuticals) 
CALAA-01 RRM2 Solid tumor cancer Phase I 
Sirna Therapeutics 
(TransDerm Inc.) TD101 
PC keratin 
K6a Pachyonychia congenita Phase Ib 
AGN211745 
(Sirna-027)  AMD, CNV & AMD Phase II 
I5NP  Delayed graft function, Kidney transplantation 
Phase I 
 
Phase II 
Sirna Therapeutics 
 
 
PAI-1 in 
monocytes Atherosclerosis preclinical 
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Table 1: Summary of ongoing clinical trials for siRNA delivery, source: 
http://clinicaltrials.ifpma.org/no_cache/en/search-trials-ongoing/all/index.htm, abbreviations used: 
VEGF: vascular endothelial growth factor, TGF-β: transforming growth factor beta, KSP: kinesin 
spindle protein; RSV: respiratory syntical virus; RRM2: ribonucleotide reductase M2 polypeptide; 
PC: Pachyonychia congenital; PAI-1: plasminogen activator inhibitor; AMD: age related macular 
degeneration; DME: diabetic macular edema,; CNV: choroidale Neovascularization 
 
In conclusion, recently discovered posttranscriptional gene silencing, material science and 
nanotechnology represent the basis of innovative delivery techniques that offer great potential 
benefits to patients and new markets to pharmaceutical and drug delivery companies. 
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1.7 Aim of this thesis 
 
Pulmonary application of nucleic acids such as pDNA and siRNA gained increasing attention 
for treatment of various lung disorders, e.g. viral infections (influenza, RSV), lung cancer or 
acute lung injury. Because of the high lability of nucleic acids, various non-viral vector 
systems for the improved nucleic acids delivery were developed and intensively investigated. 
Many studies focused on physicochemical characterization and transfection studies, but failed 
to elucidate in more detail the cytotoxicity of the nanocarriers and the nanocomplexes. 
Several clinical trials using gene therapy or siRNA to treat different kind of hereditary or 
acquired diseases are ongoing, but mostly failed to enter the clinics due to safety and efficacy 
reasons. The aim of this thesis was to gain more detailed insight in the toxicity pathways of 
non-viral vector system, especially poly(ethylene imine) (PEI)-based nanocarriers, for 
pulmonary siRNA delivery. PEI serves as gold standard for in vitro transfection of pDNA [20, 
68, 70, 99] and has been shown to successfully deliver pDNA via the inhalative route [22, 
100, 101] to the lungs. In our group, some promising PEI-modifications for siRNA delivery 
were developed and investigated for their efficacy, and (within this thesis) for their toxicity, 
especially in lung cells. The overall aim of this thesis presents the development of tools to 
predict toxicity and immunomodulation of non-viral vector systems for pulmonary siRNA 
delivery and to evaluate in more detail the mechanisms behind the toxicity of PEI-based non-
viral vector systems.  
Basic informations of the lung anatomy and physiology as well as considerations for 
pulmonary application, and nanotoxicology when using polymeric non-viral vector systems 
were provided in Chapter 1 of this thesis. The first part of this thesis (Chapter 2-5) deals with 
in vitro evaluation of different PEI-based nanocarriers regarding their cytotoxicity and 
immunomodulatory effects in different lung cells. The second part (Chapeter 6-7) represents 
in vivo studies for toxicity and efficacy of pre-selected PEI-based nanocomplexes with siRNA 
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in mice. Chapter 8 summarizes the in vitro and in vivo results and gives an outlook of further 
investigations on optimized polymeric nanocarriers.  
The search for predictive toxicity tools is still needed and the mechanisms behind the toxicity 
of PEI-based nanocarriers should be further investigated with regard to optimization of the 
cationic polymers on the one hand and on the other with regard to establishment of opitimized 
and predictive toxicity models.  
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2.1 Abstract 
 
Polyethylenimines (PEI) are potent non-viral nucleic acid delivery vehicles used for gene 
delivery and RNA interference (RNAi). For non-invasive pulmonary RNAi therapy the 
respiratory tissue is an attractive application route, but offers particularly unwanted side 
effects like cytotoxicity as well as inflammatory and immune responses. 
In the current study, we determined the most crucial issues of pulmonary applications for two 
low molecular weight PEIs in comparison to the well known lung toxic crystalline silica. 
Cytotoxic effects and inflammatory responses were evaluated in three murine pulmonary 
target cell lines, the alveolar epithelial (LA4), the alveolar macrophage (MH-S) and the 
macrophage-monocyte-like (RAW 264.7) cell line.  
For both PEIs, cytotoxicity was detected most prominently in the alveolar epithelial cells and 
only at high doses. Cytokine responses, in contrast were observed already at low PEI 
concentrations and could be divided into three groups, induced (i) by free PEI (IL-6, TNF-α, 
G-CSF), (ii) by PEI/siRNA complexes (CCL2, CCL5, CXCL1, CXCL10), or (iii) unaffected 
by either treatment (IL-2, -4,-7, -9, and CCL3). 
We conclude that even for the respiratory tissue both PEIs represent powerful siRNA delivery 
tools with reduced cytotoxicity and minor proinflammatory potency. However, in relation to 
response levels observed upon crystalline silica exposures, some PEI induced proapoptotic 
and proinflammatory responses might not be considered completely harmless, therefore 
further in vivo investigations are advisable. 
 
Keywords: Polyethylenimine, Pulmonary inflammation, Nanocarrier, Cytotoxicity 
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2.2 Introduction  
 
RNA interference (RNAi) represents a powerful method for specific gene silencing and RNAi 
therapeutics achieve a fundamentally new way to treat human diseases by activating selective 
mRNA cleavage for efficient ablation of the expression of any target gene [1, 2]. Due to their 
instability and poor tissue and cell penetration, the delivery of RNAs to their sites of action is 
one of the most challenging aspects, particularly in vivo. The use of nanoparticles for 
encapsulating therapeutic agents represents an advanced class of drug delivery systems for 
both conventional drugs as well as for nucleic acids, i.e. plasmid DNA, coding for 
therapeutically relevant genes, antisense oligonucleotides and small interfering RNA 
(siRNA). For the induction of siRNA-mediated gene-targeting in vivo the efficient protection 
of siRNAs against enzymatic or non-enzymatic degradation is most important due to their 
short biological half-life. One promising strategy is the complexation of siRNAs with 
poly(ethylene imine) (PEI). Initially, PEI was introduced as an efficient non-viral transfection 
reagent for the delivery of plasmid DNA, demonstrating high transfection efficiency in vitro 
and in vivo [3]. In more recent studies, the PEI-mediated delivery of nucleic acids was 
extended towards small RNA molecules, i.e. siRNAs [4]. Due to its high cationic charge 
density and a large number of protonable nitrogen atoms, PEI is able to form stable, water-
soluble non-covalent complexes with nucleic acids. These complexes are efficiently taken up 
by cells through endocytosis and subsequently, based on the so-called ‘proton-sponge effect’ 
[5], intracellularly released without the support of endosome disruptive agents for lysosomal 
escape. Since a high efficacy of nucleic acid delivery generally requires an excess of PEI thus 
leading to a net positive surface charge, non-specific interactions of the complexes with 
negatively charged cellular structures may result in decreased efficiency and increased 
toxicity. To reduce PEI cytotoxicity, several studies have introduced modified PEIs such as 
block or graft copolymers containing cationic and hydrophilic non-ionic components [6]. 
Furthermore, increased biocompatibility without modifications of the polymer structure was 
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achieved by employing low molecular weight PEIs, which displayed significantly reduced 
cytotoxicity [7, 8]. Additionally, it was shown that certain low molecular weight PEIs provide 
increased transfection efficacies for DNA as well as for siRNA. This is particularly true for 
the commercially available linear 22 kDa jet-PEI (Polyplus, France) as well as for the 
branched 4-10 kDa PEI F25-LMW, which was obtained through size fractionation of 
commercially available 25 kDa branched PEI by gel permeation chromatography [9].  
With regard to the therapeutic application in humans, high efficacy as well as safety and 
biocompatibility are among the most critical issues for any gene delivery system including 
PEI. Therefore, in this study we focused on the two low molecular weight PEIs of different 
structure described above, which have already been employed in vitro and in vivo, and thus 
have been established as relevant delivery reagents for systemic application [4, 9-11]. 
Targeted delivery of polyplexes to the lung is an emerging area of gene therapy research. The 
main attraction of using sub-micron sized particles, particularly below 300 nm in size for 
pulmonary delivery, is the observation that these particles tend to escape the detection by the 
macrophage clearance system and remain in the lung sufficiently long enough to release their 
'payload' in a controlled manner [12]. However, instilled non-biodegradable polystyrene 
nanospheres with small diameters and thus large surface areas have been shown to induce 
pulmonary inflammation [13]. In comparison to micron-sized particles, a given mass of the 
sub-micron fraction is considered to be in particular hazardous and might be more reactive 
due to their increased surface area-to-mass ratio, since they not only escape clearance 
mechanisms resulting in increased retention time [12]. In addition, upon pulmonary delivery 
of positively charged amine-polystyrene particles even systemic effects like enhanced 
thrombosis via platelet activation have been observed [14]. Thus, in vitro toxicity studies are 
considered as an important adjunct to in vivo studies [15] and, due to possible toxic or 
inflammatory effects of the particles employed, need to precede any in vivo study also with 
regard to identifying optimal and maximum dosages.  
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To study cytotoxic and proinflammatory effects of nanoplexes in the lung, three cell lines 
were selected: the alveolar epithelial cells (LA4), the alveolar macrophages (MH-S) and the 
macrophage-monocyte like cell line RAW 264.7. This selection of relevant cell lines is based 
on the fact that (i) for inhaled particles, the fragile, alveolar epithelium represents the first 
barrier, and (ii) macrophages are vital to the regulation of immune response and the 
development of inflammation. 
In our study, cell-based assays for cytotoxic and proinflammatory endpoints were performed 
with two already established PEIs, namely branched PEI F25-LMW and linear jet-PEI, and 
their corresponding PEI/siRNA complexes, since the complexes may dissociate making the 
toxicity of free PEI a relevant issue [16]. To benchmark putative adverse effects related to PEI 
exposure, we included respirable crystalline silica particles (α-quartz) as lung toxic positive 
control, which are considered as a well recognized health hazard known to cause pulmonary 
inflammation and severe lung diseases [12, 17]. 
Hence, the goal of this study was to evaluate the (dose-dependent) inflammatory and toxic 
effects of PEI and PEI/siRNA complexes, in order to assess the safety of these nanoplexes 
formulated as therapeutic aerosols. The correlation of these data with physicochemical 
particle properties may also help to design novel, optimized, non-viral vector systems for 
pulmonary application and to establish, which molecules are relevant to estimate.  
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2.3 Materials and Methods 
 
Polymers and particles 
PEI F25-LMW was purified from 25 kDa branched PEI (Al 25-kDa, free base, water free, 
Sigma-Aldrich, Taufkirchen, Germany) by gel permeation chromatography as described 
previously [9]. The obtained low molecular weight fraction of 25 kDa PEI was characterized 
by a size of 4-10 kDa and accordingly termed PEI F25-LMW. PEI F25-LMW featured 
highest transfection efficiency for different stable tumor cell lines (SKOV-3, SW-13, and ME-
180) which was comparable to the commercially available jetPEI. For details see [9, 11]. 
JetPEI was purchased from Polyplus (Ilkirch, France), and represents a linear 
polyethylenimine (PEI) with a molecular weight of ~22 kDa according to the informations 
provided by the manufacturer. Min-U-Sil 5 (crystalline silica, α-quartz) was obtained from 
U.S. Silica Company, Berkeley Springs, WV, USA. According to the datasheet this frequently 
used reference material is characterized by a median diameter of 1.7 µm and a purity of 98 % 
SiO2. 
Cell culture 
Cell culture experiments were carried out using murine alveolar epithelial – like type II cells 
(LA4; ATCC No. CCL-196TM) and murine alveolar macrophages (MH-S; ATCC No. CRL-
2019) as well as the mouse leukaemic monocyte macrophage cell line RAW 264.7 (ATCC 
No. TIB-71). LA4 cells were grown in HAM’s F12 medium with stable L-glutamine 
(Biochrom AG, Seromed, Germany) containing 15 % fetal bovine serum (FBS, Gibco, 
Germany) and 1 % non essential amino acids (Biochrom AG, Seromed, Germany) and 100 
U/ml penicillin and 100 mg/ml streptomycin (Biochrom AG Seromed, Germany), MH-S cells 
were cultured in RPMI 1640 (Biochrom AG, Seromd, Germany) with stable L-glutamine 
supplemented with 10 % fetal bovine serum (FBS, Gibco, Germany), 50 µM 2-
mercaptoethanol (Gibco, Germany), 10 mM HEPES (Gibco, Germany), 1 mM Na-pyruvate 
(Gibco, Germany), 50 U/ml penicillin and 50 mg/ml streptomycin (Biochrom AG Seromed, 
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Germany), RAW 264.7 cells were grown in Dulbecco’s modified Eagle’s medium with stable 
L-glutamine (DMEM, Biochrom AG, Seromed, Germany) supplemented with 10 % fetal 
bovine serum (FBS, Gibco, Germany) and 100 U/ml penicillin and 100 mg/ml streptomycin 
(Biochrom AG Seromed, Germany). All cells were grown in a humidified incubator at 37 ° C 
and 5 % CO2 and passaged every 2-3 days.  
Exposure experiments 
Cells were exposed to pure polymer (PEI F25-LMW, jetPEI), the corresponding polyplexes 
with siGL3, or Min-U-Sil 5 particles as reference particle. Polyplexes were prepared with the 
siRNA siGL3 (Sense: 5’ – CUU-ACG-CUG-AGU-ACU-UCG-ATT-3’; Antisense: 5’ – 
UCG-AAG-UAC-UCA-GCG-UAA-GTT-3’ MWG, Ebersberg, Germany) as described 
previously [4, 9, 11]. Briefly, appropriate amounts of siGL3 (10 µg) and PEI solution were 
each separately diluted in 50 µl HEPES (10 mM) buffered sodium chloride solution (150 
mM), pH 7.4. After 10 min the siRNA solution was mixed with the PEI solution, resulting in 
a final volume of 100 µl, followed by an incubation of 30 min at room temperature. 
PEI/siGL3 ratios were calculated on the basis of PEI nitrogen per siRNA phosphate and 
expressed as PEI/siRNA equivalent (N/P ratio). In the current study we used N/P ratios in the 
range of 0.05 – 5 to obtain the desired concentration of PEI from 0.5-50 µg/ml, which 
corresponds to a dose range of 0.25-25 µg/cm²/0.5*106cells. The suspension of Min-U-Sil 5 
was prepared in double-distilled, sterile water. The stock solution was sonicated for 15 min, 
and rigorously vortexed and then diluted in double-distilled, sterile water. 
0.25*106 cells/ well were seeded in 24-well-plates (FALCON, Germany) with a final volume 
of 500 µl cell culture medium supplemented with 10 % serum (DMEM and RPMI 1640, 
respectively), or 15 % serum (HAM’s F12) and containing antibiotics 24 h prior to particle 
treatment. After 24 h cell culture medium was replaced and 400 µl of fresh, prewarmed cell 
culture medium without antibiotics and reduced serum (2 %) was added to each well. 100 µl 
of the appropriate concentration of polymer, polyplex as well as Min-U-Sil suspension was 
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added to obtain a final volume of 500 µl per well. Previous experiments confirmed, that 
regarding cell viability and cytotoxicity untreated cells and solvent treated cells, i.e. cells 
treated with 100 µl of HEPES(10 mM) buffered sodium chloride solution (150 mM) or 100 µl 
double-distilled, sterile water in 400 µl cell culture medium (supplemented with 2 % FBS and 
without antibiotics) for 24 h revealed no detectable responses (data not shown). Therefore, we 
tested the particle treated cells in comparison to untreated cells as control. After 24 h 
treatment aliquots of the supernatants were taken for cytokine and LDH release studies and 
cells were subsequently incubated with the WST-1 reagent for cell viability determination. 
Each single experiment was carried out in triplicates and was repeated three times. 
Cell viability 
Cell viability was determined using the Cell Proliferation Reagent WST-1 (Roche 
Diagnostics, Germany) to quantify mitochondrial activity according to the method of 
Mosmann [18]. After 24 h exposure the relative viability [%] related to control samples 
(untreated cells) was calculated by the following equation:  
Cell viability   =  ( ODsample/ ODcontrol ) * 100.  
Cytotoxicity (LDH-assay) 
For detection of the cytosolic enzyme lactate dehydrogenase (LDH) characteristic for 
membrane damaging effects we used the Cytotoxicity Detection Kit (Roche Diagnostics, 
Germany) according to the manufacturer’s instructions. After 24 h exposure, the LDH 
concentration in the cell culture supernatant was spectrophotometrically determined with an 
ELISA reader (Labsystems iEMS Reader MF, Helsinki, Finland) at a wavelength of 492 nm. 
Cells treated with 2 % (w/v) Triton X-100 served as high control and were set as maximum of 
LDH release (100 %) according to the manufacturer’s instructions. The relative LDH release 
is defined by the ratio of LDH released over total LDH in the intact cells (high control). Less 
than 10 % LDH release was regarded as non-toxic effect level in our experiments [19].  
Cytokine detection 
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Multiplexed Immunoassays  (Multi-Analyte Profiling) 
In all cell lines, 22 cytokines/chemokines were detected simultaneously in cell culture 
supernatant by using a microsphere based multiplexing system (Linco Research, St. Charles, 
MO). In this study, the secretion of the following cytokines/chemokines was investigated: IL-
1α, IL-1ß, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, TNF-alpha, 
INF-γ, G-CSF, GM-CSF, CXCL1 CXCL10, CCL2, CCL3, and CCL5. The assay was 
performed as described previously [20] . The mean fluorescence intensity (MFI) was detected 
by the Multiplex plate reader (Luminex System, Bio-Rad Laboratories, Germany) for each 
sample (50 µl) with a minimum of 50 beads per region being analyzed. Raw data (MFI) was 
captured using the Multiplex plate reader software (Bioplex Manager, Version 2.0). For data 
analysis, a 4-parameter logistic curve fit was applied to each standard curve and sample. 
ELISA studies 
Additionally, supernatants of LA4 and RAW 264.7 cells were used to quantify the secretion 
of four proinflammatory, acute phase cytokines by enzyme-linked immunsorbent assays 
(ELISA) using the following kits according to the manufacturer’s protocols: BD OptEIATM 
Mouse TNF ELISA Kit II,BD OptEIATM Set Mouse IL-1β, BD OptEIATM Mouse IL-6 
ELISA Kit and Quantikine® Mouse KC (R&D Systems) according to the manufacturer’s 
protocols. Briefly, samples and standards diluted in the assay diluent provided with the kit 
were incubated at room temperature either in wells already supplied or in 96-well plates 
(NUNC, Wiesbaden, Germany) freshly precoated with specific capturing antibodies in the 
case of IL-1β. After washing steps, the detection antibody-conjugate was added and incubated 
at room temperature prior to washing steps. The subsequent addition of substrate solution then 
resulted in color development and after the addition of stop solution the color intensity was 
measured with an ELISA reader (Labsystems iEMS Reader MF, Helsinki, Finland) at the 
corresponding wavelength with wavelength correction as detailed in the kits.  
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Detection limits for each cytokine in the multiplex-ELISA and the ELISA studies were listed 
in Table S1.  
Statistics 
All values are presented as mean ±standard error (SEM) of three independent experiments for 
the polymer and five for the quartz exposures with all experiments run in triplicates. 
Significant differences between two groups were evaluated by Student’s t-test or between 
more than two groups by one-way ANOVA followed by Tukey’s multiple comparison test. 
Statistical analysis was performed using the program STATGRAPHICS PLUS Version 5.0 
(Statpoint, Inc., Virginia, USA).  
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2.4 Results 
 
PEI polymers induce cell-type-dependent decrease in metabolic activity  
Treatment of the selected cell lines with various amounts of polymers or polyplexes, 
respectively, revealed marked differences in their cellular sensitivity with the alveolar 
epithelial cells (LA4) being more susceptible than the two macrophage-like cell lines (Figures 
1 A-F).  
 
Figure 1: Cell viability 
 
 
Figure 1 A-F: Cell viability as determined by WST-1 Cell Proliferation Assay. Values are expressed as 
mean±SEM (n=3 for PEI and PEI/siRNA treatment and n=5 for Min-U-Sil exposure). Cells were 
exposed with three different concentrations (0.5, 5, 50 µg/ml) of PEI F25-LMW (black bars), jetPEI 
(grey bars) or Min-U-Sil 5 (100 µg/ml), which served as benchmark. Figures A-C showed the cell 
viability after treatment with free PEI, figures D-F represented the cell viability after treatment of the 
corresponding PEI/siRNA complexes. Differences to control (untreated cells) with (p)<0.05 were 
considered statistically signifcant and marked with an asterisk, n.d.= not detectable. 
 
More specifically, in LA4 cells the lowest dose of the branched PEI F25-LMW (0.5 µg/ml) 
caused already more than 50 % decrease in cell viability, thus exceeding even the effects of 
crystalline silica which served as a benchmark for particle induced pulmonary toxicity. In 
contrast, viability of macrophages remained unaffected at this concentration with decreased 
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metabolic activity only being observed at higher doses of 5 µg/ml (MH-S) or 50 µg/ml (RAW 
264.7). The linear jetPEI caused a dose-dependent decrease in metabolic activity, but 
appeared generally less toxic (Figures 1 A-C). Furthermore, in all three cell lines, polyplexes 
were less toxic compared to the free polymers (Figures 1 D-F), and complexes based on PEI 
F25-LMW generated stronger decreases in cell viability than jetPEI, but differences failed to 
be statistically significant. 
PEI polymers cause only marginal membrane damage 
In agreement with the WST-1 data, the release of LDH after 24h particle exposure indicating 
membrane damage proved to depend on the cell line, on the polymer/complex and on the 
concentration (Figures 2 A-F).  
 
Figure 2: Cytotoxicity 
 
 
Figure 2 A-F: Influence of cell membrane integrity was observed by measuring LDH in the cell 
culture supernatant after 24h exposure of three different concentrations of PEI (0.5, 5, 50 µg/ml) with 
PEI F25-LMW (black bars), jetPEI (grey bars) and Min-U-Sil 5 (white bars). Values are expressed as 
mean±SEM (n=3 for PEI and PEI/siRNA treatment and n=5 for Min-U-Sil exposure). Min-U-Sil 5 
(100 µg/ml) served as benchmark. Figures A-C represented the cytotoxicity upon free PEI exposure 
and figures D-F upon PEI/siRNA complex exposure. Propability (p)<0.05 was considered as 
signifcant compared to control (untreated cells) and indicated with an asterisk. 
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More specifically, for the macrophage cell lines, the LDH release in response to the polyplex 
or free polymer was negligible with values around the non-toxic threshold of 10 % LDH 
release [19] only being observed at the highest PEI concentration (50 µg/ml). Again, in 
comparison to the macrophages, the alveolar epithelial cells were more susceptible to both 
polymers and polyplexes. In contrast, crystalline silica particles caused a high LDH release 
only in the macrophage cell line RAW 264.7. On the other hand, the membrane integrity of 
the epithelial cells was not affected by crystalline silica, regardless of the reduced viability 
determined by the WST assay (compare Figures 1C and 2C). Both PEIs, the branched PEI 
F25-LMW, as well as the linear jetPEI, revealed significant membrane toxicity only at the 
highest dose of 50 µg/ml and the alveolar epithelial cells yielded the most prominent dose-
dependent LDH release. No differences in LDH release were detected comparing free 
polymers to PEI/siRNA complexes.  
Multiplex cytokine profiling of PEI/siRNA exposed cells 
Cytokine secretion in response to the particles was determined 24 h after exposure in all three 
cell lines. Remarkably, for five cytokines (IL-1α, CCL2, CCL5, CXCL1, and CXCL10) 
increased concentrations were observed after 24 h PEI/siRNA treatment in the alveolar cell 
lines MH-S and LA4 (see table S2B and S2C), but not in RAW 264.7 macrophages. Highest 
induction rates in cytokine release were detected for the CXC chemokines CXCL1, the 
murine functional homologue of human IL-8, and CXCL10, also called interferon-γ (IFN-γ) 
inducible protein 10. For both chemokines PEI/siRNA exposure caused 10-fold increased 
levels, which for CXCL1 was confined to LA4 cells (PEI F25 LMW/siRNA 50 µg/ml: 
1530±188 pg/ml vs. ctrl. 104±45 pg/ml). PEI F25-LMW/siRNA polyplexes yielded a 
statistically significantly (p<0.05) 3-fold higher release of CXCL1 compared to jetPEI/siRNA 
polyplexes (jetPEI/siRNA 50 µg/ml: 500±144 pg/ml vs. ctrl. 104±45 pg/ml). In contrast, the 
CXCL10 concentration was 10 times elevated only after jetPEI/siRNA treatment 
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(jetPEI/siRNA 5 µg/ml: 1903±1844 pg/ml vs. PEI F25 LMW/siRNA 5 µg/ml: 195±57 pg/ml 
and vs. 196±47 pg/ml for ctrl) (Tables S2B and S2C and Figure 3).  
Interestingly, the often in the field of inhalation toxicology used macrophage-monocyte cell 
line RAW 264.7, did not match these response pattern described above, as CCL2 and CXCL1 
failed to respond, and CCL5 and CXCL10 at the lowest dose showed even reduced cytokine 
levels upon PEI/siRNA complexes treatment relative to controls (for CXCL10: PEI F25 
LMW/siRNA 50 µg/ml: 1152±391 pg/ml and jetPEI/siRNA 50 µg/ml 1556±1004 pg/ml vs. 
1644±980 pg/ml for ctrl. and for CCL5: PEIF25 LMW/siRNA 50 µg/ml: 3±2 pg/ml  and 
jetPEI/siRNA 50 mg/ml: 6±4 pg/ml vs. 12±3 pg/ml for ctrl.) (Table S2A). Statistically 
significant (p<0.05) changes in cytokine release were only detected in the epithelial cell line 
(LA4) after PEI/siRNA treatment for CCL2 and CXCL1 in a dose-dependent manner (Figure 
3). For the high dose response of these two chemokines the exposures with jetPEI/siRNA 
complexes resulted in significant weaker effects.  
In contrast, a different set of cytokines was affected by exposure to crystalline silica used as 
lung toxicity benchmark particles. In fact, of the cytokines released upon polyplex treatment 
(IL-1a, CCL2, -5, CXCL1, and -10), crystalline silica affected only the release of CXCL10 in 
LA4 cells (Tables S2A-C) was detected. In agreement to the PEI data, the most prominent 
effects following exposure to silica particles were detected in LA4 cells.  
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Figure 3: Cytokine release of PEI LMW/siRNA polyplexes 
 
 
Figure 3: Quantification of cytokine concentrations after 24h exposure to PEI F25-LMW/siGL3 
polyplexes (black bars), and jetPEI/siGL3 poylplexes (grey bars) at three different PEI concentratons 
0.5, 5, 50µg/ml, and Min-U-Sil 5 (100µg/ml) (white bars) in LA4 alveolar epithelial cells using a multi 
analyte detection immunoassay. Values represent relative changes (mean±SEM) of three independent 
experiments compared to levels of untreated cells. Asterisk indicates statistically significant changes 
(p-value<0.05). 
 
Multiplex cytokine profiling of PEI exposed cells 
In order to distinguish between polymer and polyplex effects possibly related to the different 
physicochemical properties of the free PEI and the nucleic acid/PEI complexes, the cytokine 
responses were analyzed with a comprehensive panel. In view of our data from the cytokine 
profiling of PEI/siRNA exposed cells, we focused here on the most relevant cytokines 
showing at least 1.5 induction either by polyplexes or by the silica benchmark (IL-6, TNF-α, 
CXCL1, CXCL10, CCL2, G-CSF). In addition to that IL-1β was included in the panel 
because of its immunological potency. The highest response levels were observed in the 
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RAW 264.7 cells for the acute phase cytokines TNF-α, IL-6, and the granulocyte-colony-
stimulating factor (G-CSF) and to lesser extent for the IFN-γ inducible Th1 cytokine CXCL10 
(Figure 4 and Table S2A). Here the most prominent changes were detected for G-CSF already 
at the moderate dose of 5 µg/ml PEI with increased levels up to 20- or 80-fold for PEI F25-
LMW (414±310 pg/ml vs. 15±1 pg/ml for ctrl.) and jetPEI (1131±935 pg/ml vs. 15±1 pg/ml 
for ctrl.) respectively. Crystalline silica particles actually caused nearly identical response 
pattern with a two-fold increase in G-CSF in all three cell lines (LA4: 47±15 pg/ml vs. 23±2 
pg/ml for ctrl., MH-S: 87±25 pg/ml vs. 47±5 pg/ml for ctrl., RAW264.7. 593±434 pg/ml vs. 
260±159 pg/ml for ctrl.).  
In RAW 264.7 cells IL-6 levels were more than 10-fold elevated following jetPEI exposure 
(139±56 pg/ml vs. 11±4 pg/ml for ctrl.) and more than 5-fold due to PEI F25-LMW treatment 
(80±53 pg/ml vs. 11±4 pg/ml for ctrl.), but changes were characterized by high variability. 
However, no changes in IL-6 release were detected for the two alveolar cell lines (LA4 and 
MH-S). TNF-α levels were up to 4-fold increased after both polymer exposure, and again 
confined to RAW 264.7 cells (PEI F25 LMW 5 µg/ml: 154±39 pg/ml and jetPEI 5 µg/ml: 
150±23 pg/ml vs. 37±16 pg/ml for ctrl.). Notably, the cytokines induced by free PEI polymer 
(IL-6, G-CSF, CXCL10, and TNFα) were also increased upon silica exposures in all three 
cell lines, with epithelial LA4 cells demonstrating the highest responsiveness. 
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Figure 4: Cytokine release of LMW PEIs 
 
 
 
Figure 4: Quantification of cytokine concentrations in RAW 264.7 cultures after 24h exposure to 0.5, 
5, 50 µg/ml PEI F25-LMW (black bars), and jetPEI (grey bars), and Min-U-Sil 5 (100 µg/ml) (white 
bars) cells using a multi analyte detection immunoassay. Values represent relative changes 
(mean±SEM) of three independent experiments compared to levels of untreated cells. Statistically 
significance was represented as asterisk with a p-value of 0.05. 
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ELISA based reexamination of acute phase cytokines  
To compare our multiplex cytokine profiling data with the most commonly used ELISA-
based results, the levels of the four major pro-inflammatory cytokines (IL-1β, IL-6, CXCL-1 
and TNF-α) were additionally quantified by ELISA (Table S3). Measurements were restricted 
to LA4 and RAW 264.7 cells, since these two cell lines revealed to be the most sensitive to 
the PEI exposures described above. After treatment with the lowest dose of jetPEI (0.5 
µg/ml), TNF-α levels increased 3-fold in RAW 264.7 cells (3459.4±470.9 pg/ml vs. 
986.5±74.7 pg/ml for ctrl.), which confirmed our multiplex data. IL-6 secretion in the ELISA 
experiments corresponded well with the multiplex data and seems to be more prominent in the 
macrophages than in the epithelial cells, but again the values were close to the lower detection 
limit of the assay. As with the multiplex profiling, exposure related changes in IL-1ß release 
were not detectable with the traditional ELISA technique.  
Noteworthy, the statistically significant changes (p<0.05) in cytokine levels matched well in 
both test systems: CXCL1 concentrations were increased up to 15-fold detected by multiplex 
technique after treatment of LA4 cells with 50µg/ml PEI F25-LMW/siRNA (1530±188 pg/ml 
vs. ctrl. 104±45 pg/ml) compared to a 7-fold increase observed by ELISA (605.7±13.9 pg/ml 
vs. 81.9±30.5 pg/ml). In the RAW 264.7 macrophages, both systems revealed a 3-fold 
increase for TNF-α after treatment with 0.5 µg/ml jetPEI (ELISA: 3459.4±470.9 pg/ml vs. 
986.5±74.7 pg/ml for ctrl. and multiplex: 122±30 pg/ml vs. 37±16 pg/ml for ctrl.). 
In summary, we categorized the proinflammatory response pattern in two groups: (i) an acute 
phase like cytokine group consisting of IL-6, G-CSF and TNFa, which showed to be induced 
by free PEI polymer, and mainly in proinflammatory macrophages, and (ii) a chemokine 
group, in particular represented by CCL2, CCL5, CXCL1, and CXCL10 being induced 
primarily in by PEI/siRNA complexes exposed to the resident alveolar cell types (LA4 and 
MH-S), see table 1.  
                                                                                                                                       Chapter 2 
  56 
Table 1:  Cytokine release induced by  
 
         I.    II.    III. 
 
free PEI   PEI/siRNA complexes  unaffected by either  
                      treatment in all cell lines 
LA4 
PEI F25 LMW   G-CSF   CXCL1>CCL2    
jetPEI      CXCL10>CXCL1>CCL5 
 
Min-U-Sil 5   IL-6>TNF-a>CXCL10>G-CSF 
        
MH-S   
PEI F25 LMW      CCL5>IL-1a          IL-2, -4,-7, -9, and CCL3 
JetPEI    G-CSF   CXCL10>CCL5 
 
Min-U-Sil 5    TNF-a>G-CSF 
 
RAW264.7  
PEI F25 LMW   G-CSF>TNF-a>IL-6 
jetPEI   G-CSF>IL-6>TNFa>CXCL10 
 
Min-U-Sil 5    G-CSF 
 
 
Category        “acute-phase-cytokines”      “viral defense”  “non responder” 
 
Table 1: Cytokine release induced by (I.) free PEI (first column), (II.) PEI/siRNA polyplexes (second 
column), and (III.) unaffected by either treatment (thrid column). The mainly observed cytokines were 
listed in descendent manner of released levels in the three different cell lines (LA4, MH-S,RAW264.7). 
Min-U-Sil 5 100 µg/ml represented the reference for highly, acute phase cytokine release in the lung.  
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2.5 Discussion 
 
Our study aimed at an in vitro assessment of the cytotoxic and in particular of the 
immunomodulatory effects of two low molecular weight PEI polymers, namely the branched 
PEI F25-LMW and the commercially available linear jetPEI, as well as their corresponding 
siRNA polyplexes, to allow a prediction for safe in vivo dosing. For better correlation to 
further in vivo studies in mice, the murine system was chosen at the in vitro level. To analyze 
cell interactions in response to particle, we investigated different cell types which represent 
professional phagocytes (macrophages) but also cell types contributing to the innate immune 
response in the lung (alveolar macrophages and epithelial type II cells). Classical submerse 
culture conditions of these adherent cells were chosen to screen for unwanted side-effects of 
the non-viral gene carriers in regard to a prospective aerosol therapy by using those non-viral 
gene carriers. In addition, crystalline silica was used as a reference particle at a concentration 
of 100 µg/ml corresponding to a surface dose of 25 µg/cm². This dose was deduced from our 
previous cytotoxic and inflammation dose-response data covering a range from 5 to 250 
µg/cm². In that study 25 µg/cm² (100 µg/ml) crystalline silica yielded moderate but significant 
effects on cytotoxicity as well as on the inflammatory response in lung target cells (data not 
shown). A crucial issue represents the specific selection of an optimal reference particle, in 
our study crystalline silica served as benchmark particle although it causes toxic and 
proinflammatory effects to the lung via different pathways as compared to our PEI based 
carriers. Nevertheless, we selected crystalline silica, because it is one of the best described 
lung toxic substances, that causes cytotoxicity and inflamatory responses in vitro and in vivo 
[17]. 
PEI particles were exposed to the cells in a dose range from 0.5 to 50 µg/ml representing a 
broad range of concentrations generally used for transfection studies in vitro and in vivo (0.5-
5 µg/ml), up to an extremely high PEI dose of 50 µg/ml to demonstrate a worst case scenario 
regarding cytotoxic effects. We did not investigate the effects of free siRNA treatment to the 
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cells, because it is well described in the literature that without any vehicle, siRNA is rapidly 
degraded by nucleases and thus would not effectively reach its intracellular site of action 
without any vehicle or techniques like electroporation [16].  
Cytotoxic response  
In the present study, we demonstrated a cell-type dependent reduction of the cell viability in 
response to two different low molecular weight PEIs and their corresponding PEI/siRNA 
complexes, which clearly showed the epithelial cell line to be the most sensitive. Since the 
decrease in cell viability was not accompanied by membrane damage (Fig. 1 and 2), necrosis 
could be excluded as underlying cell death pathway, respectively at low doses. Therefore, we 
suggest rather an apoptotic-like way, according to Moghimi and colleagues who recently 
demonstrated that PEI can react as an proapoptotic agent [21]. Only the highest dose of PEI 
reduced the metabolic activity of the two macrophage cell lines to levels below 50 %. This 
cell type dependence suggests that PEI polymer and polyplex uptake by phagocytosis has no 
major contribution to carrier toxicity, on the contrary endocytotic uptake processes involving 
epithelial cell surface proteins, like sulfate group rich, negatively charged proteoglycans 
might rather be of importance [22]. 
Our data also indicate that the exposure to the corresponding polyplexes caused generally less 
cytotoxicity regarding mitochondrial dehydrogenases activity and membrane integrity. A 
similar relation has been demonstrated for PEGylated PEIs by Malek and colleagues [23]. 
Both could argue for the importance of charge based cell particle interactions. 
With regard to safety, based on our in vitro cytotoxicity data, and in view of a reduced 
toxicity of the PEI/siRNA polyplexes, the dose range of 0.5 – 5 µg/ml might be considered as 
adequate for future in vivo studies. However, the proapotitic potency for susceptible cells, like  
the alveolar epithelium might bring along some perturbation that would have to be examined 
in vitro in more detail before starting in vivo studies. Caution is also advised, since both PEIs 
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affected cell viability even at moderate doses much more than our lung toxicity benchmark, 
the crystalline silica particles.  
Cell membrane toxicity followed a different cell-type-dependence for Min-U-Sil (LA4 < MH-
S << RAW246.7) as compared to PEI particles (MH-S < RAW264.7 << LA4). Accordingly 
for the silica exposure phago- rather than endocytosis seems to be responsible for the 
macrophage susceptibility, and necrosis is in this case indicated by a significant release of 
cellular LDH (Fig. 2A and D).  
Immunomodulatory effects  
The PEI particles investigated here are characterized by a size below 100nm for the polymers 
and around 50-200 nm for the polyplexes with siRNA [4, 9, 10] and could thus be classified 
to the category of nanoparticles. Because of the fraction of molecules represented at the 
surface of the particle, it is generally accepted, that at a given mass, smaller sized particles 
(nanoparticles) are more reactive or even toxic than larger sized particles [15]. However, for 
PEI or PEI/siRNA the surface toxicity and in particular the inflammatory potential to lung 
tissue, which will be one critical factor for their pulmonary administration, is largely 
unknown. So far, only few studies dealt with the immunomodulatory effects of PEI [24] and 
[25], but the rapidly increasing application of siRNA requires a high attention to the innate 
immune response not merely caused by the siRNA itself [26], but also by the non-viral vector 
systems [24]. 
In our study we screened the release of cytokines using the broadest available panel of pro- 
and anti-inflammatory mouse cytokines in three different immune competent lung target cells. 
Upon exposures to free PEI the acute phase response cytokines IL-6, G-CSF and TNF-α were 
much more pronounced in the macrophage-monocyte like (RAW 264.7) cells as compared to 
the alveolar resident like MH-S cells. Alveolar MH-S cells otherwise mediated, similar to the 
epithelial LA4 cells, a significant release of CCL and CXCL chemokines upon siRNA 
complexed PEI, see table 1. In the case of the alveolar epithelial cells statistically significant 
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increases in CCL2 and CXCL1 levels were detected with the highest dose of 50 µg/ml PEI 
F25-LMW/siRNA polyplexes. In addition, CCL5 and CXCL10 concentrations were 5- to 10-
fold elevated after jetPEI/siRNA exposure at the lower dose regime, but changes were 
statistically not significant. The chemokines CCL5 and CXCL10 but also CXCL1 could 
functionally be called ‘viral defense’ like cytokines, characterized by the IFN-stimulated 
response promoter element and their ability to be immediately expressed and released due to 
cellular detection of viral infections [27]. This observation allows us to categorize the 
proinflammatory response pattern in two groups: (i) the acute phase cytokines, like IL-6, G-
CSF and TNFa, which are induced by free PEI polymer, and mainly in proinflammatory 
macrophages, and (ii) the ‘viral defense’ like cytokines, in particular represented by CCL2, 
CCL5, CXCL1, and CXCL10 which are induced primarily in by PEI/siRNA complexes 
exposed resident alveolar cell types (LA4 and MH-S). Upon endocytosis of PEI polyplexes 
and subsequent endosomal RNA release into the cytoplasm it might be speculated, that 
specific intracellular receptors of the innate immune system, like TLR3, could activate an 
antiviral like cytokine response [28]. According to this hypothesis, the highly inflammatory 
crystalline silica particles induced only IL-6, G-CSF and TNF-α (and to a minor extend 
CXCL10) but not CCL2, CCL5 or CXCL1. Therefore CCL2 and CCL5 might represent the 
primary ‘RNA’ specific indicators under these conditions.  
Interestingly, the release levels of IL-1β were not affected by the particle exposures. This 
finding could either be related to the fact that the here assessed exposure setting did not 
induce IL-1β expression or, that pathways upstream the subsequent secretion of mature IL-1β 
have not been triggered in a cell-autonomous way. 
Our study confirms that cell types differ in their responsiveness and susceptibility to the 
respective particles analyzed, hence the validity of studies limited to only one cell line might 
be not sufficient. Moreover our cytokine screen demonstrated that the best known and thus 
most often analyzed cytokines, like TNF or IL-1 might not necessarily be the most sensitive 
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representatives for proinflammatory changes, therefore we suggest to analyze a 
comprehensive panel of cytokines/chemokines. 
In summary in our in vitro experiments both PEIs either as polyplex or free polymers 
provoked within a therapeutically relevant concentration range corresponding to 0.5 – 5 µg/ml 
PEI, no cytotoxicity and only minor immunomodulatory responses since the dose effective to 
cause statistically significant cytokine releases exceeded any realistic exposure deduced from 
the dose range used for in vitro or in vivo transfection studies. Nevertheless, the high dose 
effects even exceeded the effect levels of crystalline silica which was used as lung toxic 
benchmark control, and thus should be considered for further in vivo application studies.  
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Table S2A: Cytokine repsonse in RAW 264.7 
 
RAW 264.7  IL-1a IL-2 IL-4 IL-6 IL-7 IL-9   G-CSF       CXCL10   TNFalpha   CCL3     CCL2           CCL5      CXCL1 
 
PEI F25 LMW  
0.5µg/ml + siRNA b.d.l. b.d.l. b.d.l. b.d.l.   b.d.l. 0.7±0.2    b.d.l.       0.3±0.1    0.4±0.0      0.9±0.4      0.4±0.2 0.2±0.1       b.d.l. 
5µg/ml + siRNA b.d.l. b.d.l. b.d.l. b.d.l.   b.d.l. 1.0±0.3    b.d.l.       0.9±0.5    0.5±0.1      1.3±0.0     0.8±0.2 0.4±0.1       b.d.l. 
50µg/ml + siRNA b.d.l. b.d.l. b.d.l. b.d.l.   b.d.l. 1.2±0.5    b.d.l.       0.7±0.3    0.5±0.2      0.8±0.4     0.6±0.4 0.3±0.1       b.d.l. 
jetPEI  
0.5 µg/ml+siRNA b.d.l. b.d.l. b.d.l. b.d.l.   b.d.l. 1.0±0.3    b.d.l.       0.5±0.1    0.4±0.7 1.2±0.0     0.6±0.1 0.3±0.2       b.d.l. 
5 µg/ml+siRNA b.d.l. b.d.l. b.d.l. b.d.l.   b.d.l. 0.7±0.1    b.d.l.        0.6±0.1    0.4±0.1 1.3±0.0     0.9±0.2 0.3±0.1       b.d.l. 
50 µg/ml+siRNA b.d.l. b.d.l. b.d.l. b.d.l.   b.d.l. 0.7±0.1    b.d.l.        0.9±0.4    1.1±0.7 1.3±0.1     1.2±0.4 0.6±0.2       b.d.l.  
PEI F25 LMW 
0.5µg/ml  b.d.l n.d. n.d. 7.1±4.7    n.d. n.d.   15.3±7.8     1.9±0.4    2.9±0.5 n.d.      1.3±0.0   n.d.        b.d.l. 
5µg/ml  b.d.l. n.d. n.d. 6.3±3.2    n.d. n.d.   28.2±12.2   1.9±0.5    4.2±1.1 n.d.      1.2±0.0   n.d.        b.d.l.  
50µg/ml  b.d.l n.d. n.d. 1.4±0.8    n.d. n.d.     1.8±2.0     0.6±0.3    0.5±0.2 n.d.      0.8±0.3   n.d.        b.d.l.  
jetPEI  
0.5 µg/ml  b.d.l. n.d. n.d. 11.1±8.9  n.d. n.d. 19.4±12.7     2.0±0.4    3.3±0.8 n.d.      1.3±0.0   n.d.        b.d.l. 
5.0µg/ml  b.d.l. n.d. n.d. 12.4±5.1  n.d. n.d. 77.2±36.9     1.7±0.4    4.0±0.6 n.d.      1.1±0.2   n.d.        b.d.l 
50µg/ml  b.d.l n.d.     n.d. n.d     n.d. n.d.     n.d.              n.d.        n.d. n.d.       n.d    n.d.        n.d.  
Min-U-Sil  
100µg/ml  b.d.l. b.d.l. b.d.l. 1.7±1.1   b.d.l. 0.7±0.1   2.3±1.7      0.6±0.2    1.4±0.4      1.1±0.1       b.d.l.        0.9±0.2        b.d.l. 
 
Table S2A:  
Relative cytokine secretion (fold change) in RAW 264.7 cells after exposure to free PEI or PEI/siRNA complexes for 24h, as detected by a multiple analyte 
detection immunoassay. Means were normalized to control cells (untreated cells). Values represent mean ± SEM, n=2-3; b.d.l. = below detection limit; 
statistically significant (p<0.05) changes compared to control levels (untreated cells) are marked with an asterisk; n.d.= not done. 
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Table S 2B: Cytokine response in MH-S 
 
MH-S   IL-1a    IL-2     IL-4        IL-6         IL-7       IL-9     G-CSF  CXCL1 TNFalpha CCL3   CCL2      CCL5 CXCL1 
 
PEI F25 LMW 
0.5µg/ml+siRNA 1.0±0.1  1.1±0.5  1.0±0.1  0.1±0.1    0.8±0.3     b.d.l.    b.d.l.      0.8±0.2     1.0±0.0         1.1±0.0   0.8±0.2     1.2±0.5    b.d.l.  
5   µg/ml+siRNA 1.0±0.2  0.3±0.1  1.0±0.1  0.5±0.1    0.8±0.4     b.d.l.    b.d.l.      1.0±0.2   1.0±0.2 1.1±0.0   1.1±0.5    1.1±0.3  b.d.l.  
50 µg/ml+siRNA 2.6±1.7  1.7±0.5  1.0±0.1  0.6±0.0    0.9±0.3     b.d.l.    b.d.l.      1.6±0.8   0.9±0.2 0.8±0.3   1.8±1.5    5.2±4.4  b.d.l.  
jetPEI 
0.5µg/ml+siRNA 0.3±0.6  0.8±0.5  1.0±0.0  0.5±0.9    0.8±0.2     b.d.l.    b.d.l.        7.0±3.0   0.5±0.5 1.1±0.0   1.4±0.0     3.2±1.2 b.d.l.  
5   µg/ml+siRNA 1.1±0.0  0.3±0.1  0.9±0.0  0.9±0.5 1.0±0.5     b.d.l.    b.d.l.      10.7±7.6   0.9±0.6 1.0±0.1   1.1±0.3     2.1±1.4 b.d.l. 
50 µg/ml+siRNA 0.4±0.2  1.2±0.0  1.0±0.0  0.5±0.1 0.7±0.3     b.d.l.    b.d.l.        2.2±0.9   1.7±1.6 0.2±0.2   0.5±0.1     1.6±0.6 b.d.l.  
PEI F25 LMW  
0.5µg/ml  b.d.l.     n.d.        n.d.     0.4±0.4 n.d.      n.d.      1.7±1.7      1.0±0.0  0.6±0.3 n.d.    1.0±0.0 n.d. 1.2±0.4 
5   µg/ml  b.d.l.     n.d.        n.d.     0.3±0.3 n.d.      n.d.      1.6±1.6 1.0±0.0  0.3±0.2 n.d.    0.9±0.0 n.d. 0.6±0.3 
50 µg/ml  b.d.l.     n.d.        n.d.     0.2±0.2 n.d.      n.d.      0.4±0.3 1.0±0.0  0.3±0.2 n.d.    0.3±0.1 n.d. 1.4±0.6 
jetPEI  
0.5µg/ml  b.d.l.     n.d.        n.d.     0.4±0.4 n.d.      n.d.      2.4±1.9 1.0±0.0   0.3±0.2 n.d.    1.0±0.0 n.d. 0.8±0.0 
5  µg/ml  b.d.l.     n.d.        n.d.     0.3±0.3 n.d.      n.d.      2.0±1.7 1.0±0.0   0.3±0.2 n.d.    1.0±0.0 n.d. 0.5±0.0 
50µg/ml  b.d.l.     n.d.        n.d. n.d n.d.      n.d.        n.d   n.d       n.d  n.d.       n.d  n.d. n.d  
Min-U-Sil  
100µg/ml  1.4±0.3   1.1±0.6  1.0±0.0 1.5±0.3 1.4±0.1   1.4±0.7  2.4±0.7     1.6±0.6   2.6±1.0         0.8±0.1    0.9±0.2    0.8±0.0 1.3±0.2 
 
Table S2B:  
Relative cytokine secretion (fold change) in MH-S cells after exposure to free PEI or PEI/siRNA complexes for 24h, as detected by a multiple analyte detection 
immunoassay. Means were normalized to control cells (untreated cells). Values represent mean ± SEM, n=2-3; b.d.l. = below detection limit; statistically 
significant (p<0.05) changes compared to control levels (untreated cells) are marked with an asterisk; n.d.= not done. 
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Table S2C: Cytokine response in LA4 
 
LA4   IL-1a     IL-2       IL-4 IL-6   IL-7     IL-9   G-CSF CXCL10   TNFalpha   CCL3    CCL2   CCL5 CXCL1 
PEI F25 LMW  
0.5µg/ml+siRNA 0.3±0.0  0.2±0.0   1.1±0.0   1.0±0.0   0.7±0.3   b.d.l.    b.d.l. 0.4±0.2       1.4±0.3   0.9±0.1  1.1±0.2   1.1±0.1   1.5±0.4 
5µg/ml+siRNA 0.4±0.0  0.2±0.1   0.9±0.1   0.8±0.2   1.2±0.2   b.d.l.    b.d.l. 1.0±0.3       1.1±0.0   0.8±0.1  1.1±0.2   1.1±0.1 2.7±1.1 
50 µg/ml+siRNA 1.0±0.2  0.7±0.1   1.0±0.1   1.6±0.8   0.9±0.1   b.d.l.    b.d.l. 2.1±0.5       1.2±0.1    0.8±0.1*2.3±0.4  1.4±0.1 *14.7±2.6 
jetPEI  
0.5 µg/ml+siRNA 0.2±0.2  0.3±0.0   1.1±0.0   1.5±0.4  1.1±0.1   b.d.l.    b.d.l. 10.1±6.6      0.7±0.3    0.9±0.0  1.6±0.1  4.7±2.4 2.0±0.3 
5µg/ml+siRNA 0.3±0.1  0.2±0.1   1.1±0.0   1.1±0.1  1.1±0.1   b.d.l.    b.d.l.   9.7±8.8      0.9±0.1    0.3±0.2  1.3±0.2  3.0±1.8 2.0±0.3 
50µg/ml+siRNA 1.8±0.6  0.7±0.2   1.0±0.0   1.7±0.7  0.8±0.2   b.d.l.    b.d.l.   7.3±4.1      1.1±0.2    0.9±0.0  1.1±0.1   2.4±0.6 4.8±2.1 
PEI F25 LMW  
0.5 µg/ml  b.d.l.      n.d.  n.d.    0.4±0.1      n.d.      n.d.    6.3±5.5   1.2±0.6 b.d.l.        n.d.     1.1±0.5 n.d. 1.2±0.4 
5µg/ml  b.d.l.      n.d.  n.d.     0.0±0.0      n.d.     n.d.    1.4±0.9   0.7±0.7 b.d.l.        n.d.     1.0±0.5 n.d. 1.3±0.3 
50µg/ml  b.d.l.      n.d.  n.d.     0.4±0.2      n.d.     n.d.    7.6±6.8   0.9±0.6 b.d.l.        n.d.     1.1±0.5 n.d. 1.2±0.5 
jetPEI 
0.5µg/ml  b.d.l.      n.d.  n.d. 0.1±0.1     n.d.     n.d.    0.7±0.3   0.9±0.6 b.d.l.        n.d.     1.0±0.5 n.d. 1.2±0.5 
5µg/ml  b.d.l.      n.d.  n.d. 0.1±0.1     n.d.     n.d.    0.5±0.3   0.7±0.6 b.d.l.        n.d.     0.2±0.1 n.d. 0.6±0.5 
50µg/ml  b.d.l.      n.d.  n.d. n.d      n.d.     n.d.        n.d      n.d  n.d        n.d. n.d n.d.    n.d 
  
Min-U-Sil  
100µg/ml  1.2±0.0  0.6±0.1 0.8±0.0 4.6±2.3  0.8±0.3  b.d.l.  2.0±0.6    2.9±2.9 3.4±2.5     0.7±0.3   1.6±0.8  1.2±0.8 1.1±0.5 
 
Table S2:  
Relative cytokine secretion (fold change) in LA4 cells after exposure to free PEI or PEI/siRNA complexes for 24h, as detected by a multiple analyte detection 
immunoassay. Means were normalized to control cells (untreated cells). Values represent mean ± SEM, n=2-3; b.d.l. = below detection limit; statistically 
significant (p<0.05) changes compared to control levels (untreated cells) are marked with an asterisk; n.d.= not done. 
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Table S3: Cytokine secretion of LA4 and RAW264.7 detected by ELISA technique 
 
     CXCL1     TNFα   
    LA-4  RAW 264.7  LA-4     RAW 264.7 
 
control    81.9±30.5 b.d.l.   b.d.l.    986.5±74.7 
 
0.5µg/ml polymer 
PEI F25-LMW/siGL3  100.0±4.3 b.d.l.   b.d.l. 1380.7±120.5 
jetPEI/siGL3   74.6±19.4 b.d.l.   b.d.l. 1921.7±389.3 
PEI F25-LMW   81.6±5.1 b.d.l.   b.d.l. 1179.3±319.6 
jetPEI    133.0±11.6 b.d.l.   b.d.l. *3459.4±470.9 
 
5µg/ml polymer           
        
PEI F25-LMW/siGL3  98.7±13.7 b.d.l.   b.d.l. 1237.5±151.7 
jetPEI/siGL3   91.6±15.6 b.d.l.   b.d.l. 1279.3±172.3 
PEI F25-LMW   69.4±11.7 b.d.l.   b.d.l. 1494.3±214.3 
jetPEI    112.3±20.0 b.d.l.   b.d.l. 1487.1±210.3 
 
50µg/ml polymer          
         
PEI F25-LMW/siGL3  *605.7±13.9   b.d.l.   b.d.l. 1197.8±73.3 
jetPEI/siGL3   157.4±25.1 b.d.l.   b.d.l. 1612.0±432.9 
PEI F25-LMW   342.3±13.2 b.d.l.   b.d.l. 1620.4±291.3 
jetPEI    129.9±17.6   b.d.l.   b.d.l. 1187.4±140.6 
 
 
Table S3: Cytokine secretion [pg/ml] in LA4(left) and RAW 264.7 cells (right)  
after exposure to free PEI or PEI/siRNA complexes for 24h, as detected by  
enzyme-linked immunosorbent assay. Values represented mean±SEM, n=5,  
statistically significance was marked as an asterisk with a p-value of 0.05 and  
b.d.l. means below detection limit. 
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3.1 Abstract 
Poly(ethylene imine) (PEI) has widely been used as non-viral gene carrier due to its capability 
to form stable complexes by electrostatic interactions with nucleic acids. To reduce 
cytotoxicity of PEI, several studies have addressed modified PEIs such as block or graft 
copolymers containing cationic and hydrophilic non-ionic components. Copolymers of PEI 
and hydrophilic poly(ethylene glycol) (PEG) with various molecular weights and graft 
densities were shown to exhibit decreased cytotoxicity and potential for DNA and siRNA 
delivery.  
In this study, we evaluated the cytotoxicity and cell-compatibility of different PEGylated PEI 
polymers in two murine lung cell lines. We found that the degree of PEGylation correlated 
with both cytotoxicity and oxidative stress, but not with proinflammatory effects. AB type 
copolymers with long PEG blocks caused high membrane damage and significantly decreased 
the metabolic activity of lung cells. In addition, they significantly increased the release of two 
lipid mediators such as 8-isoprostanes (8-IP) and prostaglandin E2 (PGE2) in a dose-
dependent manner. In contrast, the cytokine profiles which indicated high levels of acute-
phase cytokines such as TNF-α, IL-6, and G-CSF did not follow any clear structure-function 
relationship. 
In conclusion, we found that modification of PEI 25 kDa with high degree of  
PEGylation and low PEG chain length reduced cytotoxic and oxidative stress response in lung 
cells, while the proinflammatory potential remained unaffected. A degree of substitution in 
the range of 10 to 30 and PEG-chain lengths up to 2000 Da seem to be beneficial and merit 
further investigations. 
 
Key Words: poly(ethylene imine), lung, cytotoxicity, inflammation, membrane interaction 
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3.2 Introduction 
The modification of cytotoxic properties of polycations remains a considerable challenge as 
biocompatible polymers are needed for repeated biomedical applications. A fundamental 
understanding of cytotoxic effects is of particular importance for the design of pulmonary 
delivery systems containing siRNA and plasmid DNA (pDNA). Targeted loco-regional 
delivery of polyplexes to the lung represents an emerging area of gene therapy research [1-3] . 
Poly(ethylene imine) (PEI) is one of the most extensively investigated polymers for gene 
delivery. One drawback of PEI is its relatively high cytotoxicity due to the aggregation of 
huge clusters of PEI on cell membranes, which can induce necrosis [4], and its interaction 
with blood components [5, 6]. The functionality of PEI as a gene carrier was significantly 
improved by grafting with hydrophilic poly(ethylene glycol) (PEG) to yield PEG-PEI 
copolymers [7, 8]. Complexation of PEG-PEI copolymers with nucleic acids generated nano-
scale polyelectrolyte complexes (polyplexes) with a core-shell structure. In general, 
PEGylation improved solubility and colloidal stability [9], reduced surface charges [8], 
prolonged circulation time [6], and reduced complement activation [10], hence reducing 
interactions with plasma proteins and cells. The precise effect of PEGylation depends on 
many factors including molecular weight of PEG and PEI, density of PEG grafting, type of 
nucleic acid, and environment. PEG-PEIs were extensively studied for delivery of plasmids 
[11, 12] as well as recently for oligonucleotides [13] and siRNA [14]. Often the molecular 
weight of PEG was suggested as the main factor determining polyplex size and colloidal 
stability [15]. However, the chain length and grafting density of PEG strongly affects pDNA 
and siRNA condensation and stability in different ways [8, 14]. Therefore, siRNA delivery 
and gene transfer should be considered separately regarding transfection efficiency [16]. 
Studies of PEG-PEI as a carrier for nucleic acids focused mainly on polyplex properties, but 
failed to report the toxicity profiles of copolymers alone [15]. PEI based polyplexes usually 
contain an excess of uncomplexed PEI which cannot be degraded in the body [5, 17]. 
  Chapter 3 
  72 
Therefore, we focused in this study on the free PEI based polymers. As cationic nanoparticles 
disrupt lipid bilayers [18, 19], we studied the structure-function relationship of four different 
PEGylated PEI25kDa copolymers concerning cytotoxicity and cell-compatibility. With regard 
to the therapeutic application in humans, high efficiency as well as safety and 
biocompatibility are the most critical issues for any gene delivery system. The interaction of 
cationic polymers with the negatively charged cell surface has been described in the literature 
to cause high cytotoxicity [20] but only a few studies systematically investigated the 
interaction of soluble polymers with the cell surface [21, 22]. To our knowledge, no 
mechanistic study of the cytotoxicity and cell-compatibility of polymeric non-viral vector 
systems alone have been reported so far.  
Promising results of pulmonary application of PEI-based non-viral nucleic acid vector 
systems were recently communicated under in vivo conditions after inhalation [23, 24]. One 
potential advantage of nanocarriers could be that these particles tend to escape the detection 
by the macrophage clearance system and remain in the lung sufficiently long to release their 
'payload' in a controlled manner [25]. However, instilled non-biodegradable polystyrene 
nanospheres have been shown to induce pulmonary inflammation [26] and pulmonary 
delivery of positively charged amine-polystyrene particles caused systemic effects like 
enhanced thrombosis via platelet activation [27]. Thus, in vitro toxicity studies are considered 
as an important adjunct to in vivo studies [25] and need to precede any in vivo study.  
In this study we evaluated structure-function relationships of polymeric non-viral vector 
systems regarding cytotoxicity and cell-compatibility. The cytotoxic and proinflammatory 
effects as well as the oxidative potential of four different PEI-PEG copolymers was evaluated 
in comparison to PEI 25kDa (standard). Two murine alveolar cell lines were selected based 
on the fact that (i) for inhaled particles, the fragile, alveolar epithelium represents the first 
barrier, and that (ii) macrophages are vital to the regulation of immune response and the 
development of inflammation. Our aim was an increased understanding of the toxicity of PEI-
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based polymeric non-viral vector systems on a cellular level to delineate optimal structure-
function properties for optimized synthesis of such vector systems for in vivo applications.  
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3.3 Materials and Methods 
Materials 
Branched poly(ethylene imine) (PEI) with a molecular weight of 25 kDa (Polymin, water-
free, 99 %) was a gift of BASF, Ludwigshafen. The copolymers poly(ethylene imine)-graft-
poly(ethylene glycol) (PEI-PEG) with a PEG content of approximately 50 % (w/w) were 
synthesized as previously described [8, 11] by grafting linear PEG of 0.55, 2, 5, and 20 kDa 
onto branched PEI 25 kDa. These graft copolymers were designated using following 
nomenclature: PEI(25k)-g-PEG(x)n. The number in brackets (25k or x, where x= 0.55 k, 2 k, 
5 k, and 20 k) represents the molecular weight of the PEI or PEG block in Da, and the index n 
is the average number of PEG blocks per PEI molecule. This number was calculated on the 
basis of 1H-NMR spectra as described previously [11]. Polymer dilutions were prepared in 
sterile, sodium chloride solution (0.9 %). 
Polymer buffer capacity 
The buffer capacity of all polymers was measured in potentiometric titration assays using a 
Mettler Toledo DL50 Titrator (Mettler-Toledo GmbH, Giessen, Germany). Polymers were 
dissolved in distilled water and briefly sonicated. All polymer solutions were prepared to 
contain the same number of PEI amine groups (20 mg PEI 25 kDa in 20 ml, equivalent to 23 
mM amines), which allows for a direct comparison of the buffering capacity of each polymer 
per mole of amine. The pH of the polymer was measured during slow addition of 0.1 N HCl 
under vigorous stirring. All experiments were run in duplicate and evaluated by the LabX 
Software (Mettler-Toledo GmbH, Giessen, Germany) concerning equivalence points and pKa 
values.  
Cell culture 
Experiments were carried out using murine alveolar epithelial – like type II cells (LA4; 
ATCC No. CCL-196TM) and murine alveolar macrophages (MH-S; ATCC No. CRL-2019). 
LA4 cells were grown in HAM’s F12 medium with stable L-glutamine containing 15 % fetal 
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bovine serum (FBS, Gibco, Germany) and 1 % non essential amino acids and 100U/ml 
penicillin and 100mg/ml streptomycin. MH-S cells were cultured in DMEM medium with 
stable L-glutamine supplemented with 10 % fetal bovine serum (FBS, Gibco, Germany) and 
100 U/ml penicillin and 100 mg/ml streptomycin at 37 ° C and 5 % CO2. All cells were 
passaged every 2-3 days. All cell culture reagents were obtained from Biochrom AG, 
Seromed, Germany, unless otherwise stated. 
Cell Proliferation assay 
The metabolic cell activity was determined using the Cell Proliferation Reagent WST-1 
(Roche Diagnostics, Germany) according to [28]. Briefly, LA4 and MH-S cells were seeded 
at a density of 8*103 cells/well in 96-well-plate in cell culture medium containing FBS and 
grown overnight in an incubator at 37 ° C and 5 % CO2. Medium was replaced before cells 
were treated. The polymer dilutions were prepared as described above and added to the 
appropriate wells. After 72 h of incubation, the relative viability [%] related to control 
samples (untreated cells) was calculated by following equation: Cell viability= 
(ODsample/ODcontrol) * 100. All data represent three independent experiments. IC50 values were 
calculated as polymer concentration which inhibits growth of 50 % of cells relative to 
untreated control cells according to [29]. The results of optical density measurements were 
fitted logistically by the Levenberg-Marquardt method of least-squares minimization for 
nonlinear equations under default conditions using Origin 7.0 (Origin LabSoftware, 
Northampton, USA) by the following equation:Y=Y0+(Ym-Y0)/(1+(C/C0)), where C0 is the 
IC50 dose, Y is the optical density in a well containing a particular polymer/extract of 
concentration C. Y0 and Ym are the optical densities corresponding to 0 % viability and 100 % 
viability,  respectively.  
Cytotoxicity (LDH-assay) 
For detection of the cytosolic enzyme lactate dehydrogenase (LDH) the Cytotoxicity 
Detection Kit (Roche Diagnostics, Germany) was used according to the manufacturer’s 
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protocol. Briefly, cells were cultured in 24-well-plates at a density of 0.25*106 cells/well and 
incubated in an incubator overnight for adherence. To avoid interference with the assay 
reagents, the cell culture medium was replaced with serum-reduced (2% FBS) cell culture 
medium without antibiotics before addition of polymers. The polymer dilutions were added to 
the appropriate wells and LDH kinetic was observed after 0.5 h, 1 h, 2 h, 4 h, 6 h, and 24 h 
exposure time. The LDH concentration in the cell culture supernatant was determined 
spectrophotometrically at a wavelength of 492 nm using an ELISA reader (Labsystems iEMS 
Reader MF). Cells treated with 2 % (w/v) Triton X-100 served as a control according to the 
manufacturer’s protocol and revealed maximum LDH release (100 %) corresponding to 
ODhigh control. The relative LDH release is defined by the ratio of LDH released over total LDH 
(high control) and was calculated as follows: Cytotoxicity [%] = (ODsample – ODlow 
control)/(ODhigh control – ODlow control) *100, where ODlow control was the absorption from the 
supernatant of the untreated cells. Less than 10 % LDH release was regarded as non-toxic 
effect level in our experiments according to [21]. All data represents three independent 
experiments. 
Lipid mediators 
Extracellular appearance of 8-Isoprostanes (8-IP) and prostaglandin E2 (PGE2) was 
investigated in the cell culture supernatants according to [30]. Briefly, the supernatants of the 
cell culture experiments were deproteinized by adding an 8-fold volume of 90 % methanol 
containing 0.5 mM EDTA and 1mM 4-hydroxy-2,2,6,6,-tetramethylpiperidine-1oxyl, pH 7.4. 
To completely remove proteins, the suspensions were stored at -80°C for 24h followed by a 
centrifugation step at 10.000 g for 20 min at 4 ° C. Aliquots of the supernatants were dried in 
a vacuum centrifuge, dissolved in assay buffer, and used for quantification of 8-IP and PGE2 
using their specific enzyme immunoassays (Cayman Chemical Company, Ann Arbor, MI, 
USA) according to the manufacturer’s instructions. 
Cytokine release 
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In a multiplexing Luminex assay (Linco Research, St. Charles, MO), 8 cytokines/chemokines 
were simultaneously detected in the cell culture supernatant. In this study, the secretion of the 
following cytokines/chemokines was investigated: IL-1α, IL-6, TNF−α, G-CSF, CXCL1 
CXCL10, CCL2, and CCL3. The assay was performed as described previously [31]  and 
mean fluorescence intensity (MFI) was detected by the Multiplex plate reader (Luminex 
System, Bio-Rad Laboratories, Germany) for each sample (50 µl) with a minimum of 100 
beads per region being analyzed. The raw data (MFI) were captured using the Multiplex plate 
reader software (Bioplex Manager, Version 2.0). For data analysis, a 5-parameter logistic 
curve fit was applied to each standard curve and sample.  
Quantitative reverse –transcriptase polymerase chain reaction (qRT-PCR) 
Cells were seeded at a density of 0.5*106 cells/well (2ml) in 6-well-plates (FALCON, 
Germany) and were allowed to adhere overnight in an incubator at 37 ° C and 5 % CO2. After 
24 h, cell culture medium was replaced and the appropriate amount of polymer dilution was 
added to the well in a final volume of 2ml/well. Cells were treated with the polymers for 2 h 
or 6 h, respectively. At these two different time points, RNA was isolated from the cells using 
the RNeasy Mini Kit (Qiagen, Hilden, Germany). DNAse digestion was carried out using 
DNAse I (Qiagen, Hilden, Germany). The quality of RNA was checked in an agarose-gel 
(1%) containing SYBRSafe (Invitrogen, Karlsruhe, Germany) and the RNA amount was 
quantified using an ND-1000 Spectrophotometer (NanoDrop Technologies, Inc., Wilmington, 
DE, US) at the absorbance ratio of 260 and 280 nm. 1 µg of total DNAse I treated RNA was 
used for the first-strand cDNA reaction using nonamer primers (Metabion, München, 
Germany) and Superscript II reverse transcriptase (Invitrogen, Karlsruhe, Germany). 
Quantitative transcript levels were analyzed using Absolute QPCR SYBR Green Mix plus 
ROX kit (ABgene, Hamburg, Germany) with the ABI Prism 7000 Sequence detection System 
(Applied Biosystems, Foster City, CA, USA). The comparative threshold cycle (CT) method 
was carried out to calculate the relative abundance of transscript [32].  Following genes were 
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investigated and normalized to the house keeping gene hydroxanthine guanine 
phosphoribosyltransferase 1 (Hprt1): glutathione-S-transferase, alpha 1 (Gst1a), 
glutathionreductase 1 (Gsr), heme oxygenase (Hmox-1), metallothionein 2 (Mt2) and 
cyclooxygenase 2 (Ptgs2). The primer pairs, which were used for the gene expression 
profiling are listed in table 1.  
Statistical analyses 
All values are presented as mean±standard error (SEM) of at least three independent 
experiments, unless otherwise stated. Significant differences between two groups were 
evaluated by Student’s t-test and between more than two groups by one-way analysis of 
variance followed by Tukey’s multiple comparison test. In case of highly different variances, 
we evaluated significant differences by using the two-tailed t-test with Welch’s correction. 
Statistical analysis were performed using the program STATGRAPHICS PLUS Version 5.0 
(Statpoint, Inc., Virginia, USA) and GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, 
CA 92037 USA). 
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Table 1: List of primer sequences 
Ref.sequence1  Gene abbr.1 Gene name               forward primer sequence2          reverse primer sequence2             
NM_008181  Gst1a  glutathione-S-transferase,  
alpha 1   AGG AGA GAG CCC TGA TTG         CTG TTG CCC ACA AGG TAG 
NM_010344  Gsr  glutathione reductase 1        AGG GCC ACA TCC TAG TAG AC      GTC GCT GAA GAC CAC AGT AG  
NM_ 010442  Hmox-1 heme oxygenase  
(decycling) 1   TTCTGGTATGGGCCTCACTGG         ACCTCGTGGAGACGCTTTACA 
NM_008630  Mt2  metallothionein 2  TAG ATG GAT CCT GCT CCT GC       CAC TTG TCG GAA GCC CTC TT 
NM_011198  Ptgs2  prostaglandin-endoperoxide 
synthase 2   CAA CAC CTG AGC GGT TAC         GTT CCA GGA GGA TGG AGT  
NM_013556    Hprt1  hypoxanthine    
   guanine phosphor- 
ribosyltransferase 1      GTT GGA TAC AGG CCA GAC TTT GT        CAC AGG CTA GAA CAC CTG C 
 
1All genes are abbreviated by their official MGI symbol (Mouse Genome Informatics, http://www.informatics.jax.org).  
2Transcript sequences are identified by the NCBI Reference Sequences ID. Primer were derived by Primer3 open source software, (http://primer3.sourceforge.net/) using the 
primer picking conditions: GC: 55-60%; annealing: 55°C.
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3.4 Results 
In this study, we investigated the structure-function relationship of PEGylated PEI 
copolymers concerning their cytotoxicity and cell-compatibility in comparison to the 
backbone polymer, PEI 25kDa. PEI 25kDa was grafted with PEG chains of different 
molecular weights (0.55 kDa, 2 kDa, 5 kDa, and 20 kDa), but the PEG weight ratio of 
approximately 50 % was kept constant. We hypothesized that the degree of PEGylation and 
the PEG chain length might affect not only cytotoxicity but might also modify their 
biocompatibility, especially their proinflammatory effects.  
Buffer capacity 
Polymer solutions of equivalent nitrogen concentrations were examined by potentiometric 
titration to evaluate the influence of PEGylation on the buffer capacity. Potentiometric 
titration curves are shown in supplementary material, S1. PEGylation reduced the buffer 
capacity of the polymers. Higher degrees of PEGylation caused lower pKa values due to PEG 
grafting of amino groups. The reduced buffer capacity could be explained by the reduced 
amount of secondary amines which were less abundant in the stronger PEGylated PEI 
copolymers, namely PEI(25)-PEG(0.55)30 and PEI(25)-PEI(2)10. The buffer capacities of 
stronger PEGylated PEI-PEG copolymers were approximately at the physiological pH of 7.4, 
whereas the AB diblock-copolymer PEI(25)-PEG(20)1 yielded a similar pKa value to 
unmodified PEI 25 kDa of 8.36. It has to be noted that in the range of pH 4-6, usually 
attributed to the lyso-/ endosomal compartment, buffer capacity was not significantly different 
for all polymers. In general, regarding the pKa values, PEI 25kDa and PEI(25)- PEG(20)1 
had more basic properties compare to the higher modified PEG-PEI copolymers. It can 
therefore be hypothesized that these polymers have a more pronounced ability to balance the 
acidic endosomal environment and chloride influx during the endosomal ripening and 
strongly promote the osmotic swelling of endosomes. 
 
  Chapter 3 
  81 
Cell proliferation study 
For each polymer, the influence on metabolic activity was analyzed in two cell types by 
estimating the IC50 values (Table 2). The IC50 values clearly depended on the grafting degree 
of PEG on PEI 25 kDa and were similar in both cell lines. The higher the degree of 
PEGylation, the higher was the IC50 value, pointing out that PEI(25)-PEG(0.55)30 and 
PEI(25)-PEG(2)10 were the most favourable copolymers for further in vivo investigation with 
regard to their reduced impact on cell viability.  
Table 2: IC50 values 
Polymer   LA41   r²  MH-S1                  r² 
PEI25kDa   0.002±1.94*10E-4 0.996  0.005± 6,46*10E-4   0.983 
PEI(25)-PEG(20)1  0.014± 0.0035  0.967  0.011± 0.0031            0.98 
PEI(25)-PEG(5)4  0.014± 0.003  0.985  0.007± 3.71*10E-4    0.998 
PEI(25)-PEG(2)10  0.022± 0.0088  0.988  0.027± 0.003  0.99 
PEI(25)-PEG(0.55)30 0.033± 0.004  0.968  0.021± 0.006              0.995 
 
1IC50 values were given in mg/ml as mean±SD of three independent experiments. Cell proliferation in LA4 and 
MH-S was analyzed using WST-1 assay after 72h particle exposure and IC50 values were calculated using 
sigmoidal fitting as described in material and methods.   
 
Cytotoxicity 
In addition to the influence of metabolic activity, the kinetics of membrane damage effects 
caused by PEI-PEG derivates and PEI 25 kDa were analyzed. In both cell lines, the maximal 
leakage of LDH was determined after 6h for all PEI-PEG molecules and PEI 25 kDa (Fig. 1).  
  
 
 
  Chapter 3 
  82 
Figure 1: Cytotoxicity 
 
Figure 1: Cytotoxicity 
LDH leakage correlated to degree of PEGylation [11] at the highest dose of 50 µg/ml PEI. LDH 
release was determined using Cytotoxicity detection kit (Roche) after 0.5, 1, 2, 4, 6, and 24 h polymer 
treatment in LA4 cells (A) and MH-s cells (B). For each time point three independent experiments 
were carried out and the values were expressed as mean±SD. Less than 10% LDH release were 
regarded as non-toxic effect level in our experiments [21]. Significant difference to control was 
presented as asterisk with *p<0.05. 
 
According to the IC50 values, the degree of PEGylation on PEI 25 kDa correlated well with 
the cytotoxic effect at high PEI concentrations and the membrane damage in a time-dependent 
manner. Again, the higher the PEGylation degree and the lower the molecular weight of PEG, 
the lower was the cytotoxic effect.  
Lipid mediators 
Because polycations are in general known for their strong interaction with the plasma-
membrane, it was assumed that the generation of lipid mediators could be one toxicological 
mechanism explaining the cytotoxic behaviour of PEI-PEG and PEI. Therefore, the 
extracellular release of two major lipid mediators, namely 8-isoprostanes (8-IP) and 
prostaglandin E2 (PGE2) was investigated. After treatment for 24 h, the release of the lipid 
mediators were similar in both cell lines. PEI 25 kDa, PEI(25)-PEG(20)1, and PEI(25)-
PEG(5)4 caused the strongest release of the two lipid mediators, which was detected to be 
more than 25-fold increased compared to control. The higher the degree of PEGylation on 
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PEI 25 kDa, the lower were the levels of 8-IP and PGE2, showing the same trend as observed 
for the metabolic activity and LDH leakage (Fig. 2).  
Figure 2: Release of lipid mediators 
 
Figure 2: Release of lipid mediators 
Determination of 8-Isprostanes (upper panel) and Prostaglandin E2 (lower panel) in the supernatant, 
after 24 h polymer treatment of LA4 cells (A and C) and MH-S cells (B and D). Control is given in 
white bars, PEI 25 kDa in black bars, PEI(25)-PEG(20)1 in bars with vertical lines, PEI(25)-PEG(5)4 
in dark grey bars, PEI(25)-PEG(2)10 in chequered bars and PEI(25)-PEG(0.55)30 in light grey bars. 
Polymer concentrations were indicated as increasing triangle with concentration of 0.5 µg/ml,5 µg/ml 
and 50 µg/ml PEI. Each value was normalized to the protein amount of the supernatant and was 
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presented as mean±SEM, n=3; n.d.= not determined. Asterisks expressed significant changes vs. 
control (supernatant from untreated cells), *p<0.05 and **p<0.01. 
 
Proinflammatory effects 
As any inflammatory reaction related to the therapeutic application of PEI-based vectors 
could be of general concern, the release of eight proinflammatory cytokines after treatment 
for 24 h with different PEI-PEG copolymers was investigated. The cytokine release was 
highly different for all polymers and caused mainly high levels of acute-phase cytokines such 
as IL-1a, IL-6, TNF−α, and G-CSF. None of the investigated polymers elevated the 
chemokines levels of CXCL1, CXCL10, CCL2, and CCL3 after polymer treatment compared 
to control (data not shown). A clear dose-response or difference in the pattern of cytokine 
response regarding the degree of PEGylation of the polymers could not be found, (Fig. 3).  
Figure 3 A-B: Cytokine response 
 
Figure 3 A-B: Cytokine response 
G-CSF release was measured after 24h polymer treatment in LA4 cells (A) and MH-S cells (B). Three 
polymer concentrations (0.5, 5, 50 µg/ml) were exposed to the cells; control is given in white bars, 
PEI 25 kDa in black bars, PEI(25)-PEG(20)1 in bars with vertical lines, PEI(25)-PEG(5)4 in dark 
grey bars, PEI(25)-PEG(2)10 in chequered bars and PEI(25)-PEG(0.55)30 in light grey bars. Values 
were presented as mean±SEM and asterisks expressed significant changes vs. control (supernatant 
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from untreated cells), * p<0.05 and **p<0.01, values under the detection limit of each cytokine were 
indicated with b.d.l: below detection limit. 
 
The highly grafted polymer PEI(25)-PEG(0.55)30 caused the lowest proinflammatory 
response in the alveolar epithelial cells, but high levels of IL-6 were found in an inverted 
dose-response (0.5 µg/ml: 37.91±7.35 pg/ml, 5 µg/ml: 22.35±8.1 pg/ml, 50 µg/ml: 15.1±2.23 
pg/ml vs. ctrl. 2.48 pg/ml). In the alveolar macrophages, 5µg/ml PEI(25)-PEG(0.55)30 caused 
elevated levels of TNF−α and G-CSF (TNF−α: 23.92±2.97 pg/ml vs. ctrl. 6.07 pg/ml, G-
CSF: 11.78±1.34 pg/ml vs. ctrl. 2.49 pg/ml). In comparison, PEI 25 kDa elicited IL-6 levels 
in the epithelial cells in a similar inverted dose-response manner like PEI(25)-PEG(0.55)30 
(IL-6 values for PEI 25 kDa: 0.5 µg/ml: 15.18±6.96 pg/ml, 5 µg/ml: 12.31±3.58 pg/ml, 50 
µg/ml: 2.96±0.32 pg/ml vs. ctrl. 2.48 pg/ml) and yielded high levels of G-CSF in the 
macrophages in a dose-dependent manner (0.5 µg/ml: 11.73±4 pg/ml, 5 µg/ml: 4.77±0.57 
pg/ml, 50 µg/ml: 52.81±5.61 pg/ml vs. ctrl. 2.49 pg/ml) . Interestingly, PEI(25)-PEG(2)10 
caused the highest proinflammatory response and released high levels of IL-6, G-CSF and 
TNF-α in both cell lines. Despite no clear structure-function relationship of the cytokine 
profile, cytokine response was cell type dependent. In the alveolar epithelial cells, IL-6 
release seemed to be more prominent and in most cases non linear to the dose, whereas in the 
alveolar macrophages the growth factor G-CSF and TNF-α were in most cases significantly 
elevated after treatment with high doses of polymer.  
Gene expression analysis  
To get an insight in the underlying pathways related to the observed polymer-cell interactions, 
first the expression profile of prostaglandin endoperoxide synthase (Ptgs2, the rate-limiting 
enzyme in the conversion of membrane derived inflammatory intermediates like 
prostaglandin E2) and second four genes mainly related to oxidative stress response (Hmox-1, 
Gst1a, Gsr, and Mt2) were analyzed upon PEI treatment over 2 h and 6 h. 
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In both cell lines, the levels of Ptgs2 expression were strongly induced by PEI polymer 
treatment (Fig. 4).  
Figure 4 A-B: Gene expression of prostaglandin endoperoxide synthase 2 (Ptgs2) 
 
Figure 4 A-B: Gene expression of prostaglandin endoperoxide synthase 2 (Ptgs2) 
Gene expression of Ptgs2 after 2 h (gray bars) and 6 h (sparsed bars) treatment of polymer in LA4 (A) 
and MH-S (B) cells; PEI 25 kDa and PEI-PEG copolymers were fold induction was calculated using 
comparative cycle threshold (CT) method normalized to the house keeping gene Hprt 1. Values were 
presented as mean±SD and asterisks expressed significant changes vs. control (untreated cells), 
*p<0.05.  
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Strongest expressions were detected upon treatment with 50 µg/ml PEI(25)-PEG(5)4 yielding 
11-fold induction after 6 h in LA-4 and 4-fold induction after 2 h in MH-S cells. Other 
polymers like PEI(25)-PEG(0.55)30, PEI(25)-PEG(2)10 and PEI25 kDa caused moderate 
Ptgs2 expression of 4-fold induction in LA-4 and 2-fold induction in MH-S cells. Overall, 
Ptgs2 expression matches well with the release pattern of the arachidonic acid derivates 8-IP 
and PGE2. To address the oxidative stress potential of the polymers, four additional genes 
related to antioxidative stress response were investigated. The mean induction of all four 
genes was calculated and is shown in Table 3 for both cell lines. PEI 25 kDa yielded the 
highest induction (4.5-fold) of the four oxidative stress genes in MH-S cells after 2 h. 
PEI(25)-PEG(20)1 and PEI(25)-PEG(5)4 showed induction levels of more than 1.5-fold, and 
stronger PEGylated PEI copolymers induced oxidative stress response less than 1.5-fold 
induction after incubation for 2 h and 6 h. Oxidative stress responses differed between 
epithelial and macrophage cells, but respective transcript levels were overall higher after 2 h 
exposure compared to 6h. Regarding their potency to induce intracellular oxidative stress, the 
polymers can be arranged in the following ascending order: LA4: PEI(25)-(20)1 = PEI(25)-
(2)10 < PEI(25)-(0.55)30 < PEI25 kDa < PEI(25)-(5)4 and MH-S: PEI(25)-(2)10 = PEI(25)-
(0.55)30 < PEI(25)-(20)1 = PEI(25)-(5)4 < PEI25 kDa. In both cell lines, PEI25 kDa revealed 
to be one of the highly active polymer inducing an antioxidative response.  
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Table 3:  Oxidative stress response1    
 
GstYa Gsr  Hmox-1 Mt-2  
 
2h   LA4 MH-S LA4 MH-S LA4 MH-S LA4 MH-S 
 
PEI 25kDa  
0.5µg/ml  0.87 0.90 0.66 1.13 0.97 1.31 1.81 2.86 
5µg/ml   0.99 0.75 0.75 1.05 1.32 1.25 *7.64 3.69 
50µg/ml  n.d. 1.00 n.d. 1.54 n.d. 1.65 n.d. 0.79  
 
PEI(25)-PEG(20)1 
0.5µg/ml  1.00 0.91 1.00 1.05 0.91 1.00 2.14 2.20 
5µg/ml   1.03 1.06 0.79 0.93 0.88 1.08 0.48 3.41 
50µg/ml  1.23 n.d. 0.74 n.d. 0.99 n.d. 0.63 n.d. 
 
PEI(25)-PEG(5)4 
0.5µg/ml  1.41 0.97 1.07 0.95 0.65 0.69 5.60 1.84 
5µg/ml   1.17 1.14 1.15 1.16 0.96 0.72 5.84 1.97 
50µg/ml  1.09 n.d. 1.12 n.d. 1.61 n.d. 1.35 n.d. 
 
PEI(25)-PEG(2)10 
0.5µg/ml  0.88 0.99 0.94 0.98 0.81 0.98 1.00 1.64 
5µg/ml   0.79 0.83 0.96 0.94 0.84 0.97 0.93 1.54 
50µg/ml  0.80 0.83 1.04 1.04 0.88 0.99 0.88 1.15 
 
PEI(25)-PEG(0.55)30 
0.5µg/ml  1.37 1.21 1.00 1.00 0.78 0.92 2.49 1.50 
5µg/ml   1.28 1.14 0.95 1.01 0.73 0.87 4.13 1.73 
50µg/ml  1.14 0.97 0.95 0.95 0.73 1.10 3.87 1.74 
           
6h  
 
PEI 25kDa 
0.5µg/ml  0.95 0.71 1.01 1.25 1.26 1.32 1.37 3.74 
5µg/ml   0.95 1.20 1.00 1.02 1.77 1.06 2.69 3.49 
50µg/ml  n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.  
 
PEI(25)-PEG(20)1 
0.5µg/ml  1.06 0.71 0.95 0.94 1.17 1.07 1.43 3.81 
5µg/ml   0.87 1.20 1.13 1.18 1.32 1.14 1.45 1.64 
50µg/ml  n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
 
PEI(25)-PEG(5)4 
0.5µg/ml  1.06 0.91 0.93 1.62 1.36 0.93 1.53 2.75 
5µg/ml   1.07 1.17 0.81 1.19 1.55 1.38 2.29 3.86 
50µg/ml  3.16 n.d. 1.46 n.d. *11.50 n.d. *9.60 n.d. 
 
PEI(25)-PEG(2)10 
0.5µg/ml  1.23 0.79 1.23 0.86 1.18 0.82 1.37 1.65 
5µg/ml   1.10 0.75 0.90 0.89 1.04 0.76 1.33 1.77 
50µg/ml  0.77 0.73 0.87 0.91 1.15 0.78 1.00 1.24 
 
PEI(25)-PEG(0.55)30 
0.5µg/ml  0.82 0.71 0.88 0.90 1.26 0.81 1.20 1.65 
5µg/ml   0.83 1.04 0.83 1.06 1.19 1.04 1.34 2.04 
50µg/ml  0.70 1.16 0.78 0.91 1.38 1.10 1.13 1.87 
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1Oxidative stress response expressed as fold induction of  glutathione-S-transferase, alpha 1 (Gst1a), glutathione 
reductase (Gsr), heme oxygenase 1 (Hmox-1), and metallothionein 2 (Mt2) after 2h and 6h in LA4 (left) and 
MH-S cells (right) after treatment with PEI 25kDa and PEI-PEG copolymers (0.5µg/ml, 5.0µg/ml and 50µg/ml).  
Gene induction more than 2-fold increase were bold highlighted, asterisks expressed significant changes vs. control 
(untreated cells), *p<0.05. 
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3.5 Discussion 
Cytotoxicity 
PEI is one of the most efficient non-viral vector system for transfection of plasmid DNA 
(pDNA) and siRNA in cell culture as well as in vivo [33, 34]. However, pronounced cellular 
toxicity of PEI and severe systemic side effects limit the use of PEI polyplexes in vivo [5, 20]. 
Since there was evidence that toxicity is attributed to free PEI present in polyplexes, we 
intensively analyzed the structure-function relationship with regard to cytotoxicity and 
biocompatibility for pulmonary application of four differently PEGylated PEI 25 kDa 
copolymers in comparison to PEI 25 kDa. We evaluated a broad range of PEI concentrations 
(0.5-50 µg/ml) that were in a therapeutically relevant concentration range. The highest 
concentration of 50 µg/ml represented an overload dose of PEI to mimic the worst case 
scenario. In regard to patients or animal experiments, 50 µg/ml corresponds to 25 µg/cm² dose 
and 6 mg/lung in small animals like mice [35]. Such high concentrations possibly also occur 
after repeated administrations and retention of PEI in the lung due to the lack of 
biodegradability of PEI. However, 0.5 µg/ml (or 0.25 µg/cm²) and 5 µg/ml (or 2.5 µg/cm²) 
were in the range of therapeutically applied PEI doses with N/P ratios up to 20 when siRNA 
is administered in a range of 2-5 nmol. According to the cytotoxicity studies, there was clear 
evidence that the higher the degree of PEGylation and the lower the PEG chain length, the 
less was the cytotoxic effects observed by regarding metabolic activity and LDH release 
(Table 2 and Fig. 1). Interestingly, the LDH kinetic in this report corresponded well with the 
proposed proton sponge effect for PEI. Polyplexes were taken up by cells via endocytosis and 
the high buffering capacity of PEI and the passive chloride ion influx into the endosome is 
reported to cause osmotic swelling and subsequent endosome disrupture and release of pDNA 
or siRNA into the cytoplasm during 4-6 h after application [36-39]. For all PEI-PEG 
polymers and PEI 25 kDa, maximal leakage of LDH could be detected in the first 4-6 h after 
treatment, except for PEI(25)-PEG(2)10 and PEI(25)-PEG(0.55)30 in MH-S cells.  
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Inflammatory potential 
A lot of studies described apoptotic cell death as one event in PEI mediated toxicity [40, 41], 
but Fischer et al. (2003) postulated necrosis as alternative pathway of cell death for PEI 
treated cells [20]. In our study, the cytokine profile did not match the structure-function 
relationship of cytotoxicity and lipid peroxidation. Mainly four acute-phase cytokines such 
TNF-α, IL-6, IL-1α and G-CSF were released after polymer treatment. PEI(25)-PEG(2)10 
caused the highest proinflammatory response in both cell lines, e.g. up to 80-fold elevated 
levels of G-CSF (Fig. 3), whereas this polymer was one of the very promising polymers for in 
vivo application because of its low cytotoxic and oxidative stress potential. For all other 
polymers, the four acute-phase cytokine levels (TNF- α, IL-6, IL-1α and G-CSF) were up to 
5-fold elevated in both cell lines without any structure-function relationship. The apoptotic 
cell death seemed to be more prominent because of the highly dose-dependent reduction of 
metabolic activity in the mitochondria and the alteration of the mitochondrial membrane 
potential and most probably the mitochondrial membrane itself. Due to very high cytoxicity 
of PEI 25 kDa and the lower PEGylated PEI-PEG copolymers it could be suggested that the 
cells were leaking of energy and therefore could not release any cytokine for their defence at 
24h treatment. Nevertheless, these data highlighted the membrane interaction with PEI as one 
of the most prominent effect to understand the toxicity of this polymer. PEI (25)-PEG(2)10 
and PEI(25)-PEG(0.55)30 seemed to be promising non-viral vector systems for pulmonary 
application of siRNA or pDNA in vivo regarding their cytotoxic profiles. 
Oxidative stress responses 
Oxidative stress response caused by PEI polymers in the cell was investigated. It is well 
known and described in the literature that oxidative stress caused by nanomaterials exposed to 
the lung is a critical issue [42-44]. Nel and colleagues introduced a hierarchical oxidative 
stress model [43, 45] that divided the oxidative stress caused by nanoparticles deposited in the 
lung into a tripartite tier hierarchy. Tier 1 is the lowest oxidative stress level, characterized by 
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antioxidative responses like activation of transcription factors Nrf2. Tier 2 described 
subsequent ongoing inflammatory processes based on the ability of reactive oxygen species 
(ROS) to induce redox-sensitive signalling pathways such as MAP kinases and NFκB 
cascades, and tier 3 is the highest oxidative stress level, where cytotoxic events occur like 
alteration of the mitochondrial activity, apoptotic or necrotic cell death pathways. To 
investigate the underlying mechanisms of polymer-mediated toxicity, the release of two major 
lipid mediators, 8-IP and PGE2, both known to be indicative for cellular ROS production and 
lipid peroxidation [30], was determined. Remarkably, in both cell lines PEI-PEG copolymers 
caused similar release pattern of the two lipid mediators in comparison to the cytotoxic data 
(Fig.2).  
To confirm the underlying pathway of the lipid peroxidation, gene induction of 
cyclooxygenase 2 (Ptgs2) and four characteristically oxidative stress genes like heme 
oxygenase 1 (Hmox-1), glutathione-S-transferase, alpha 1 (Gst1a), glutathione reductase 
(Gsr), and metallothionein 2 (Mt2) was investigated in response to the polymer treatment for 
2h and 6h. At this point, it should be mentioned that mRNA could not be isolated after 
exposures with high doses (50 µg/ml) of PEI25 kDa in both cell lines and PEI(25)-PEG(20)1 
in MH-S cells. The failure to prepare RNA could be explained by the high toxic properties of 
these polymers and their strong binding to RNA due to their high positive surface charge. 
Thus, no gene expressions analysis could be performed in these cases. The gene expression 
profile of Ptgs2 yielded similar pattern as the PGE2 release after 24 h in both cell lines. Again, 
a high shielding effect of PEG on PEI 25 kDa reduced lipid peroxidation. PEI 25 kDa and two 
of the PEG modified PEI polymers, namely PEI (25)-PEG(5)4 and PEI(25)-PEG(20)1 caused 
statistically significantly elevated levels of 8-IP as well as PGE2 in the same manner at high 
doses of 50 µg/ml. The increased levels of the two lipid mediators have to be kept in mind 
because PGE2 acts as an immune modulator to promote humoral and Th2-type immune 
responses and represents a key regulator of inflammation [46]. Additionally, 8-IP is driven by 
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non-enzymatic events like reactive oxygen species or free radicals which are responsible for 
modulation of inflammation and are generally considered as oxidative stress markers, 
especially in the lung. From these data, we concluded that PEG shielded not only the 
cytotoxic effect of the highly positively charged polymer PEI but also protected cells from 
lipid peroxidation via the non enzymatic pathway (8-IP) and cyclooxygenase mediated 
pathway (PGE2). To confirm our hypothesis that PEI-based copolymers caused oxidative 
stress inside the cell and that generation of reactive oxygen species occurred, the induction of 
Hmox-1, Gst1a, Gsr, and Mt2 as oxidative stress markers was analyzed. The results clearly 
showed high levels of oxidative stress response, especially for PEI 25 kDa and the AB 
diblock-copolymer, PEI(25)-PEG(20)1. The stress response was much more prominent in the 
macrophages than in the epithelial cells. The cell type difference could be explained by the 
differences in gene induction of the genes analyzed. Therefore, it was concluded that the non-
enzymatic pathway caused by free radical-initiated peroxidation of arachidonic acid, should 
be taken in consideration. High levels of 8-IP play a dominant role in pulmonary disorders 
like cystic fibrosis, chronic obstructive pulmonary disease and asthma [47, 48] and might 
interfere with possible therapeutic approaches. 
Concluding Remarks for pulmonary application 
The structure-function-relationships of the investigated PEI-PEG copolymers resulted in clear 
evidence that PEI 25 kDa highly grafted with short PEG chain length strongly reduced 
cytotoxicity from PEI 25 kDa and in addition yielded less release of lipid mediators, but still 
showed high proinflammtory cytokine levels. Tier 2 represented ongoing inflammatory 
processes induced by redox-sensitive signalling in the cells and could be evaluated as a strong 
unwanted side-effect, especially for loco-regional administration into the lung. A lot of 
studies described negative outcomes like cardiovascular events [27, 49, 50] and 
carcinogenesis [51] resulted from initial acute inflammatory processes in the lung, but 
cytotoxicity is one event which should be reduced when regarding repetitive application of 
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such non-viral vector systems. Concerning the respective treatment of lung disorders like 
cystic fibrosis, allergic asthma or chronic obstructive pulmonary disease we hypothesized that 
cytotoxicity has to be avoided much stronger than proinflammatory events, but especially for 
pulmonary application proinflammatory events should be kept in mind and need intensively 
mechanistic evaluation in vivo. 
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3.6 Supplementary material 
 
S1: Buffer capacity 
 
S1: Buffer capacity 
Buffer capacity of four different PEI-PEG copolymers in comparison to PEI 25kDa; pKa values were 
calculated with LabX (Mettler Toledo GmbH, Giessen, Germany). Equivalent nitrogen amount of each 
polymer were titrated in duplicate 
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4.1 Abstract 
 
Polyethylene imine (PEI) based polycations, successfully used for gene therapy or RNA 
interference in vitro as well as in vivo have been shown to cause well known adverse side 
effects, especially high cytotoxicity. Therefore, various modifications have been developed to 
improve safety and efficiency of these non-viral vector systems, but profound knowledge 
about the underlying mechanisms responsible for the high cytotoxicity of PEI is still missing.  
In this in vitro study, we focused on stress and toxicity pathways triggered by PEI-based 
vector systems to be used for pulmonary application in comparison to two well known lung 
toxic particles: fine crystalline silica (CS) and nano-sized ZnO (NZO). The cytotoxicity 
profiles of all stressors were investigated in alveolar epithelial like type II cells (LA4) to 
define concentrations with matching toxicity levels (cell viability >60 % and LDH release 
<10%) for subsequent qRT-PCR based gene array analysis.  
Within the first 6 h pathway analysis revealed for CS an extrinsic apoptotic signaling (TNF 
pathway) in contrast to the intrinsic apoptotic pathway (mitochondrial signaling) which was 
induced by PEI25kDa after 24 h treatment. The following causative chain of events seems 
conceivable: reactive oxygen species derived from particle surface toxicity triggers TNF 
signaling in the case of CS, whereby endosomal swelling and rupture upon endocytotic PEI 
25 kDa uptake causes intracellular stress and mitochondrial alterations, finally leading to 
apoptotic cell death at higher doses. 
PEG modification most notably reduced the cytotoxicity of PEI 25 kDa but increased 
proinflammatory signaling on mRNA and even protein level. Hence in view of the lung as a 
sensitive target organ this inflammatory stimulation might cause unwanted side-effects related 
to respiratory and cardiovascular disorders. Thus further optimization of the PEI-based vector 
systems is still needed for pulmonary application. 
Keywords: toxicity, gene expression profiling, poly(ethylene imine), inflammation, 
pulmonary application
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4.2 Introduction 
Viral and non-viral vectors have widely been used in gene therapy as delivery systems for 
nucleic acids. The transfer of viral vector technology to clinical gene therapy trials has raised 
safety issues such as unexplained cytotoxicity and immunogenicity in target cells and tissues 
despite their high transfection efficiency [1, 2]. Therefore, non-viral vector systems were 
promoted as promising and safer alternatives for gene and siRNA delivery [3, 4]. So far, the 
main focus of gene therapy and RNA interference was on increasing efficiency and 
bioavailability while decreasing toxicity on a systemic and cellular level [5-8].  
In this context the identification of mechanisms and pathways underlying cellular perturbation 
and toxicity caused by exposure of target cells and tissues to polymeric non-viral delivery 
systems would help to improve their safety profile dramatically. In particular toxicogenomics 
have proved to be a powerful tool for the direct monitoring of patterns of cellular perturbation 
by various exogenous agents at the molecular level [9]. To study alteration of gene expression 
caused by the interaction between the structure and activity of a defined stressor and a 
selected cellular system can be an effective method to gain a first insight into this complex 
biological response. One major issue of PEI-based non-viral vector systems is their strong 
cytotoxicity [10, 11] In fact PEI-based vector systems have been shown to cause considerable 
changes of gene expression in vitro, effects that might also have the potential to enhance off-
target effects also in vivo like it has been observed for siRNA targeting [12, 13]. Indeed in the 
literature cationic polymers, dendrimers, and lipid-based transfection reagents were shown to 
alter cellular gene expression, but the consequences of these expression changes on biological 
systems remain largely unknown at present.  
The lung represents a promising target organ for non invasive local therapy of pulmonary 
diseases including asthma, chronic obstructive pulmonary disorder, cystic fibrosis, ischemic 
reperfusion injury and infection with respiratory viruses. Hence this study focuses on the use 
of poly(ethylene imine) (PEI) based carrier systems for pulmonary delivery of nucleic acids 
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like siRNA. Respective PEI polymers were selected from previous studies [14] because of 
their promising cytotoxic profile, and CS and NZO particles were chosen due to their well-
known lung toxicity. CS it is a long established lung carcinogen which induces severe 
pulmonary inflammation often resulting in fibrosis [15, 16]. For NZO several studies 
described the high proinflammatory potential, possibly caused by the fraction of soluble Zn 
ions released in acidic cell compartments like endosomes [10]. Moreover, exposure to zinc 
fume can cause metal fume fever, an illness usually related to inhalation of fumes from 
welding, cutting, or brazing, on galvanized metal [17, 18]. The detected gene expression 
pattern were classified on the basis of the hierarchical oxidative stress model [7, 19] 
developed for ambient particulate matter and nanoparticles. Nel and colleagues introduced a 
three tier hierarchy that subdivided oxidative stress caused by (nano)particles deposited in the 
lung in three categories. Tier 1 represents the lowest oxidative stress level characterized by 
expression of genes important for the cellular antioxidant response and which are regulated 
via the antioxidant response element binding transcription factor Nrf2. Tier 2 describes 
subsequent ongoing inflammatory processes based on the ability of unbalanced reactive 
oxygen species (ROS) to induce redox-sensitive signalling pathways such as MAP kinases 
and NFκB cascades. Finally the highest oxidative stress level is named tier 3, where cytotoxic 
events occur like alterations of the mitochondrial activity, cell cycle progression and apoptotic 
or necrotic cell death pathways optimal doses for each of the five stressors, which causes a 
moderate, comparable level of cytotoxicity, therefore to allow for the subsequent comparative 
mechanistic investigations based on mRNA and protein expression levels. Secondly, we 
evaluated alterations in gene expression pattern after treatment of alveolar epithelial like type 
II cells with the two lung benchmark particles and the three different PEI-based polymers 
applying a qRT-PCR based pathway focused gene array covering 84 genes related to 
oxidative stress, inflammation, cell growth and proliferation, or cell death (necrosis and 
apoptosis). Since upon treatment with PEG modified PEI copolymers significant inductions of 
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proinflammatory gene expression were detected, we followed the inflammatory response on 
protein level by cytokine quantification.  
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4.3 Experimental Section 
Particles  
Branched poly(ethylene imine) (PEI) with a molecular weight of 25 kDa (Polymin™, water-
free, 99 %) was a gift of BASF, Ludwigshafen. The polyethylene imine-graft-poly(ethylene 
glycol)s (PEI-PEG) with a PEG content of approximately 50 % (w/w) were synthesized as 
previously described [6, 20] by grafting linear PEG of 0.55 kDa and 2 kDa, respectively, onto 
branched PEI 25 kDa. These graft copolymers were designated using following nomenclature: 
PEI(25k)-g-PEG(x)n. The number in brackets (25k or x, where x=0.55 k, 2 k) represents the 
molecular weight of PEI or PEG block in Daltons, and the index n is the average number of 
PEG blocks per PEI molecule. The number was calculated on the basic of 1H-NMR spectra as 
described previously [20]. Min-U-Sil 5 (crystalline silica) was obtained from U.S. Silica 
Company, Berkerly Springs, WV, USA, with a median diameter of 1.7 µm as specified by the 
manufacturer. Zinc oxide (CAS-No: 1314-13-2) was obtained from Alfa Aesar (A Johnson 
Matthey Company, Karlsruhe, Germany) with a nominal average diameter of 70nm, it is 
designated as nano-sized ZnO (NZO).  
Polymers were diluted in sterile sodium chloride (150 mM) solution and vigorously vortexed 
directly before use. Crystalline silica and nano-sized ZnO suspensions were prepared in 
sterile, double-distilled water. Stock solutions (10 mg/ml) were sonicated for 15 min prior to 
serial dilution and each suspension was sonicated for 10 min directly before use. 
Cell culture 
Cell culture experiments were performed using the murine alveolar epithelial – like type II 
cells (LA4; ATCC No. CCL-196TM). Cells were grown in HAM’s F12 medium with stable 
Glutamax containing 15 % fetal bovine serum (FBS, Gibco, Germany) and 1% non essential 
amino acids and 100 U/ml penicillin and 100 mg/ml streptomycin at 37 ° C and 5 % CO2. All 
cells were passaged every 2-3 days. All reagents were obtained from Biochrom AG, Seromed, 
Germany or otherwise signed. LA4 cells were seeded at a density of 0.5*106 cells/well (2 ml) 
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in 6-well-plates (FALCON, Germany) and were allowed to adhere overnight in an incubator 
at 37 ° C and 5 % CO2. After 24 h cell culture medium was replaced and the appropriate 
amount of the particle dilution was added to the well in a final volume of 2 ml/well. Cells 
were treated with the polymers and particles for 6 h and 24 h.  
Cell viability 
Cell viability was determined using the Cell Proliferation Reagent WST-1 (Roche 
Diagnostics, Germany) according to the method of Mosmann[21]. Briefly, LA4 cells were 
seeded at a density of 0.25*106 cells/well/2cm² in 24-well-plates in cell culture medium 
containing 15 % FBS and grown overnight in an incubator at 37 ° C and 5 % CO2. For the 
treatment, the cell culture medium was replaced by freshly, pre-warmed, serum-reduced (2 % 
FBS) cell culture medium without antibiotics. Particles were exposed to the cells for 24h and 
the relative viability [%] related to control samples (untreated cells) was calculated by 
following equation: Cell viability = (ODsample/ ODcontrol)*100. All data represent at least three 
independent experiments. In addition IC50 values were determined following a 72 h 
incubation of LA4 cells (8000 cells/well) in 96-well-plate with particle and polymer 
concentrations in the range from 0.001-1 mg/ml. After 72 h treatment metabolic activity was 
detected as described above and IC50 values were calculated as concentration which inhibits 
cell viability by 50 % relative to untreated control cells according to Minko [22] . The results 
of optical density measurements were fitted logistically by the Levenberg-Marquardt method 
of least-squares minimization for nonlinear equations under default conditions using Origin 
7.0 (Origin LabSoftware, Northampton, USA) by the following equation: Y=Y0+(Ym-
Y0)/(1+(C/C0)), where C0 is the IC50 dose, Y is the optical density in a well containing a 
particular polymer/extract of concentration C. Y0 and Ym are the optical densities 
corresponding to 0 % viability and 100 % viability,  respectively.  
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Cytotoxicity 
For detection of the cytosolic enzyme lactate dehydrogenase (LDH) in the culture supernatant, 
a characteristic of membrane damage we used the Cytotoxicity Detection Kit (Roche 
Diagnostics, Germany) according to the manufacturer’s protocol. The experiments were 
carried out according to the conditions of WST-1 assay. After 24 h the LDH concentration in 
the cell culture supernatant was spectrophotometrically determined in an ELISA reader 
(Labsystems iEMS Reader MF) at a wavelength of 492 nm. According to the manufacturer’s 
protocol cells treated with 2 % (w/v) Triton X-100 served as control and set as maximum of 
LDH release (100 %). The relative LDH release is defined by the ratio of LDH released over 
total LDH in the intact cells (high control). Less than 10 % LDH release were regarded as 
non-toxic effect level in our experiment [23]. All data represent at least three independent 
experiments. 
RNA isolation 
After 6 h and 24 h incubation RNA was isolated from the cells by using RNeasy Mini Kit 
(Qiagen, Hilden, Germany). Briefly, cell culture medium was removed and cells were washed 
two times with pre-warmed, sterile PBS without Mg2+ and Ca2+, pH 7.4. Cells were lysed with 
350µl RLT buffer containing 1 % (v/v) 2-mercaptoethanol. The cell lysate was collected in an 
Eppendorf tube and the tube was vigorously vortexed. 350 µl cold (4 ° C) ethanol (70 %) was 
added to each cell lysate to precipitate the RNA. 700 µl lysate was placed onto a Qiagen 
column and were centrifuged at 15.000 g for 1 min. The flow through was discarded and 
DNAse digestion was carried out using DNAse I (Qiagen, Hilden, Germany). 350 µl RW1 
buffer was added to the column and the column was centrifuged at 15.000 g x 1 min. The 
flow through was discarded and the column was placed in a new collection tube. In the same 
way 500 µl RPE buffer containing ethanol was added twice and centrifuged at first 15.000 g 
for 1 min, and at the second time 15.000 g for 2 min. The column was placed in a new tube 
and the RNA was eluted from the column with 30 µl RNase-free water by centrifugation at 
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15.000 g for 1 min. RNA was directly frozen at -80 ° C and stored for further investigations. 
The quality of RNA was checked in an agarose-gel (1 %) containing SYBRGold (Invitrogen, 
Germany, Karlsruhe) and the RNA amount was quantified using ND-1000 Spectrophotometer 
(NanoDrop Technologies, Inc., Wilmington, DE, US) at the absorbance ratio of 260 and 280 
nm.  
Gene expression profiling  
cDNA synthesis was performed using RT² First Strand Kit (Superarray, Catalog-No.: C-03) 
following the instructions of the manufacturer. Briefly, genomic DNA was eliminated using 
Genomic DNA Elimination Mixture provided in the Kit. RT Cocktail was prepared and First 
Strand cDNA synthesis reaction was carried out according to the manufacturer’s instructions. 
For detailed information regarding the genes applied on this array RT² Profiler™ PCR Array 
Mouse Stress & Toxicity Pathway Finder (Superarray, Cat-no.: APMM-003A) see 
supplementary material S1. 
Array was performed according to the instructions of the manufacturer and the qRT-PCR was 
carried out with ABI Prism 7000 Sequence detection System (Applied Biosystems, Foster 
City, CA, USA). Briefly, cDNA was diluted in appropriate amount of master mix (RT2 Real- 
Time SYBR Green/ ROX PCR Master Mix) and RNAse-free water and loaded onto the array 
plate. The qRT-PCR was performed using a two-step cycling program with an initial heating 
for 2 min. at 50 ° C followed by two stages with one cycle of 10 min at 95 ° C and 40 cycles 
of 15 sec at 95 ° C and 1min at 60 ° C. Immediately after the cycling program a melting curve 
program was running to generate a first derivative dissociation curve.  
Genes were clustered according to the seven clusters of the RT² Profiler™ PCR Array Mouse 
Stress & Toxicity Pathway Finder provided from the manufacturer and the gene expression 
pattern was illustrated in a heat map (Supporting information S2) using free software called 
CARMAweb from Graz University of Technology, Institute of Genomics and 
Bioinformatics,[24] https://carmaweb.genome.tugraz.at/carma/. Log2 ratios were used as 
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input, with red colours indicating up-regulation (treated vs control) and green colours 
indicating down-regulation of the respective genes. Biological network interactions of genes 
regulated more than 2-fold were analyzed using the Ingenuity Systems pathway software 
(http://www.ingenuity.com), which is based on an expert curated interaction database. For 
clarity, some interactions were not shown. A small number of relations were added manually 
based on literature research, Fig.2A and B.  
Cytokine release 
Eight cytokines/chemokines were detected simultaneously in the cell culture supernatant 
using Luminex technology (Linco Research, St. Charles, MO). In this study, the secretion of 
following cytokines/chemokines was investigated: IL-1α, IL-6, TNF-alpha, G-CSF, CXCL1 
CXCL10, CCL2, and CCL3. The assay was performed as described previously [25] . The 
mean fluorescence intensity (MFI) was detected by the Multiplex plate reader (Luminex 
System, Bio-Rad Laboratories, Germany) for each sample (50 µl) with a minimum of 100 
beads per region being analyzed. The raw data (MFI) were captured using the Multiplex plate 
reader software (Bioplex Manager, Version 2.0). For data analysis, a 5-parameter logistic 
curve fit was applied to each standard curve and sample.  
Statistics 
 
All values are presented as mean±standard error (SEM) of at least three independent 
experiments. Significant differences between two groups were evaluated by Student’s t-test or 
between more than two groups by one-way ANOVA followed by Tukey’s multiple 
comparison test. Statistical analysis was performed using the program STATGRAPHICS 
PLUS Version 5.0 (Statpoint, Inc., Virginia, US).  
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4.4 Results 
 
Cytotoxicity evaluation 
For all particles and polymers a clear dose-dependent cytotoxicity was found after 24 h 
treatment (Fig. 1A-F).  
Figure 1: Cytotoxicity evaluation  
 
 
 
 
 
Figure 1: Cytotoxicity evaluation 
Left panel (A-C) shows cell viability and right panel (D-F) cytotoxicity (LDH release) in LA4 cells 
after 24h treatment with nano-sized ZnO (NZO), crystalline silica (CS), PEI 25kDa (black), PEI(25)-
PEG(2)10 (grey), and PEI(25)-PEG(0.55)30 (white). Values are given in mean±SEM, experiments 
were repeated three times in case of the PEI based polymers and five times in case of NZO and CS. 
  Chapter 4 
  111 
Statistically significant changes were represented by an asterisk with p-value < 0.05 vs. control 
(untreated cells). 
 
Considering a mass based dose metric NZO was the most cytotoxic agent, resulting in cell 
viability reduction of over 90% and cell membrane damage (LDH release) of 15 % already at 
a dose of 5 µg/ml. Particles and polymers show decreasing cytotoxicity as estimated by their 
IC50 values in the following order: PEI25 kDa > NZO > PEI(25)-PEG(2)10 > PEI(25)-
PEG(0.55)30 > CS (Table 1).  
 
Table 1: IC50 value 
 
Particle/polymer   IC50 [mg/ml] 
 
CS     > 1 
NZO     0.014±0.003 
PEI25kDa    0.003±0.000 
PEI(25)-PEG(2)10   0.022±0.009 
PEI(25)-PEG(0.55)30  0.033±0.004 
 
Table 1: IC50 values were presented as mean±SD of three independent experiments. Cell proliferation 
in LA4 cells was analyzed using WST-1 assay after 72 h particle exposure and IC50 values were 
calculated using sigmoidal fitting using Boltzmann equation.   
 
In comparison to PEI 25 kDa, PEGylated PEI co-polymers showed significantly reduced 
cytotoxicity (p<0.05) (Fig. 1C and F and Table 1). For PEI 25 kDa the highest concentration 
of 50 µg/ml caused severe toxicity yielding cell viability levels below detection and 
significantly elevated levels of LDH (15.03±2.86, p<0.05). To ensure sufficient RNA 
integrity for the subsequent qRT-PCR based toxicity pathways focused gene array we used 
conditions resulting in low to moderate cytotoxicity levels as characterized by the WST-
related toxicity below 40 %, and the membrane toxicity (LDH) below 10 %. The following 
doses were selected in the gene array study: 400 µg/ml for CS, 2.5 µg/ml for NZO, and 5 
µg/ml for each of the three PEI-based polymers.  
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Toxicological focused gene expression profiling 
We selected a pathway focused design with a representative set of genes indicative for a broad 
range of toxicological responses covering seven different stress and toxicity pathway clusters: 
Metabolic and Oxidative Stress (1), Heat Shock (2), Proliferation and Carcinogenesis (3), 
Growth Arrest and Senescence (4), Inflammation (5), Necrosis or Apoptosis: DNA Damage 
and Repair (6) and Necrosis or Apoptosis: Apoptosis Signalling (7) (Supporting information 
S1). 
Two time points were investigated to detect acute and prolonged effects, namely 6 h and 24 h 
after treatment. From the 84 genes analyzed the expression of 35 genes (42 %) was altered for 
all particles and polymers investigated at both time points (Supporting information S2). For a 
more comprehensive arrangement of the observed expression changes we categorized them 
according to the three tier levels of the hierarchical oxidative stress model from Nel and 
colleagues [19] (Table 2). 
Table 2: Gene expression profiling 
Particle/polymer pathway gene name  GenBank      fold change            fold change 
             Early response      Late response 
         6h  24h________             
   Cytotoxicity E2f1  NM_007891 3.7  0.6 
   Cytotoxicity Tnfsf10  NM_009425 3.4  n.d. 
   Cytotoxicity Gadd45a NM_007836 3.0  0.7 
   Cytotoxicity Cdkn1a  NM_007669 2.4  0.8 
   Cytotoxicity Ddit3  NM_007837 2.3  0.7 
   Cytotoxicity Bax  NM_007527 2.2  0.4 
   Cytotoxicity Tnfrsf1a  NM_011609 2.0  0.3 
   Cytotoxicity Ccng1  NM_009831 2.0  0.2 
   Inflammation Cxcl10  NM_021274 11.6  6.6 
   Inflammation Casp1  NM_009807 8.0  0.1 
CS  Inflammation Nos2  NM_010927 7.8  0.8 
Inflammation Nfkbia  NM_010907 4.4  1.1 
   Inflammation IL18  NM_008360 3.9  0.0 
   Inflammation Lta  NM_010735 3.0  0.6 
   Inflammation Serpine1 NM_008871 -3.3  3.9 
   Inflammation Csf2  NM_009969 1.0  2.9 
   Ox.stress Ugt1a2  NM_013701 14.9  0.3 
   Ox.stress Cryab  NM_009964 6.1  0.1 
   Ox.stress Hspa1b  NM_010478 2.2  0.5 
   Ox.stress Mt2  NM_008630 1.8  2.3 
   Ox.stress Hmox1  NM_010442 1.7  2.1 
 NZO  Inflammation Nfkbia  NM_010907 3.9  0.4 
   Inflammation Cxcl10  NM_021274 2.2  0.5 
   Ox.stress Hspb1  NM_013560 9.8  0.4 
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Table 2: Gene expression profiling (continued) 
Particle/polymer pathway gene name  GenBank      fold change            fold change 
 NZO  Ox.stress Ugt1a2  NM_013701 6.8  0.6 
   Ox.stress Hmox1  NM_010442 3.0  0.4 
   Ox.stress Mt2  NM_008630 2.2  0.3 
   Cytotoxicity E2f1  NM_007891 2.1  1.5 
   Cytotoxicity Bcl2l1  NM_009743 -1.5  3.2 
   Cytotoxicity Bax  NM_007527 1.0  2.4 
   Cytotoxicity Atm  NM_007499 -1.3  2.2 
   Cytotoxicity Ercc4  NM_015769 -1.3  2.0 
 PEI 25kDa Cytotoxicity Anxa5  NM_009673 1.3  2.0 
   Inflammation Nfkbia  NM_010907 3.3  1.5 
Inflammation Csf2  NM_009969 2.4  0.8 
   Ox.stress Ugt1a2  NM_013701 10.0  0.7 
   Ox.stress Mt2  NM_008630 2.1  0.8 
   Ox.stress Hspa1b  NM_010478 -1.4  4.7 
   Ox.stress Cyp1b1  NM_009994 -2.8  2.6 
   Ox.stress Hmox2  NM_010443 -2.5  2.4 
   Cytotoxicity E2f1  NM_007891 2  0.7 
   Inflammation Cxcl10  NM_021274 4.1  0.1 
   Inflammation Nfkbia  NM_010907 3.5  1.7 
   Inflammation Casp1  NM_009807 2.1  1.0 
   Inflammation Nos2  NM_010927 2.0  0.9 
PEI(25)-PEG(2)10 Ox.stress Ugt1a2  NM_013701 7.1  0.4 
   Ox.stress Cryab  NM_009964 3.0  0.9 
   Ox.stress Hspa1b  NM_010478 1.6  3.1 
   Cytotoxicity E2f1  NM_007891 3.0  0.9 
   Inflammation Nfkbia  NM_010907 7.4  2.7 
   Inflammation Nos2  NM_010927 4.5  2.8 
   Inflammation Casp1  NM_009807 4.1  1.1 
PEI(25)-PEG(0.55)30 Inflammation Cxcl10  NM_021274 2.5  0.3 
   Inflammation Mif  NM_010798 2.1  0.8 
   Inflammation Serpine1 NM_008871 2.0  1.4 
   Inflammation IL1b  NM_008361 1.3  5.9 
   Ox.stress Ugt1a2  NM_013701 10.0  0.8 
   Ox.stress Cryab  NM_009964 2.5  1.2 
   Ox.stress Hspa1b  NM_010478 1.7  4.8 
 
Table 2: Genes were clustered in three tier levels (Tier 3: cytotoxicity, tier 2: inflammation, tier 1: 
oxidative stress) according to the hierarchical oxidative stress model from Nel and colleagues [19]. 
Shown are genes with change of expression of more than 2-fold after 6h and 24h treatment with CS 
(Min-U-Sil 5 400 µg/ml), NZO (2.5 µg/ml), PEI25 kDa (5 µg/ml), PEI(25)-PEG(2)10 (5 µg/ml), and 
PEI(25)-PEG(0.55)30 (5 µg/ml). Fold changes (linear) were calculated using comparative cycle 
threshold (CT) method and normalized to the house keeping gene Hprt 1.  
 
Lung toxic benchmarks  
The highest number of changes in gene expression was observed upon treatment with CS after 
6 h and 24 h (Table 2). The following genes were more than 2-fold up-regulated after 6 h 
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treatment and the corresponding tier levels are indicated: Cytotoxicity: NfkBia, E2f1, Tnfsf10, 
Gadd45, Cdkn1a, Ddit, Bax, Tnfrsf1a, and Ccng Inflammation: Cxcl10, Casp1, Nos2, NfkBia, 
Il-18, and Lta, Oxidative stress: Ugt1a2, Cryab, and Hspa1b. Most genes regulated after 6 h 
of treatment were related to inflammation and/or to cell survival/apoptosis pathways. After 24 
h treatment, only five genes showed elevated mRNA levels which were either related to a 
sustained proinflammatory state (Cxcl10 and Serpine 1) or to an oxidative stress response 
(Mt2 and Hmox1). 
In contrast NZO treatment induced expression for oxidative and heat shock stress genes after 
6 h (Hspa1b and Hspb1, Ugt1a2, Hmox1, Mt2) but returned to baseline levels (or even below) 
after the 24 h treatment. Exceptions were NfkBia and Cxcl10, which are be indicative of 
inflammation. 
PEI-based non-viral carrier systems 
Within the first 6 h PEI 25 kDa induced only for a few gene expression changes above a 
factor of 2 with the most notable markers indicating oxidative stress (Ugt1a2 and Mt2), and to 
a lesser extent also anti-apoptotic, survival and proinflammatory (Cxcl10, Csf2, Nfkbia) 
responses. The response pattern changed considerably for the second phase of analysis with 
an increasing contribution of apoptosis-related markers. Compared to the PEG-modified PEI 
copolymers after 24 h PEI 25 kDa treatment was the only polymer causing obvious apoptotic 
gene expression (Bcl2l1, Bax, Anxa5, Ercc4 and Atm) a pattern not at all observed for the two 
lung toxic benchmark particles NZO and CS after 24 h treatment, but after 6 h for CS. 
During the early response after 6 h highly elevated expression levels of E2f1, a cell cycle 
regulating transcription factor, and NfkBia, an important component of the NFκB machinery, 
involved in many proinflammatory and apoptosis/survival signalling pathways, were detected 
for all three PEI polymers, as well as oxidative stress indicating phase II metabolizing enzyme 
Ugt1a2.  
  Chapter 4 
  115 
Overall, during the first 6 h treatment PEGylated copolymers but not PEI 25 kDa caused 
mainly an up-regulation of proinflammatory genes including Cxcl10, Caps1, Nos2, and 
Nfkbia. The cellular stress response markers Cryab and Hsp1b showed a similar expression 
pattern with high levels for Hspa1b only after 24 h for both PEGylated PEIs. Only PEI(25)-
PEG(0.55)30 induced particular high levels of Mif and Serpine 1 after 6 h and Il1b, Nos2 and 
Nfkbia after 24 h, all  well described proinflammatory marker genes (Fig.2A and B). 
Figure 2: Pathway modeling 
 
A 
 
B 
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Figure 2A-B: Pathway modeling 
Network of all more than 2 fold induced genes at 6 h (A) or 24 h (B). Interactions are based on the 
Ingenuity pathway software and the different treatments are indicated. Genes are highlighted 
according to Nel and colleagues [19] (green/oxidative stress, yellow/inflammation, red/cytotoxicity), 
orange (inflammation/cytotoxicity-overlap). 
 
Cytokine Profiling 
For lung particle interactions the proinflammatory effect is a sensitive and critical response to 
foreign material, which is induced already at doses below significant cytotoxicity. To confirm 
the gene array results the induction of a proinflammatory state was also investigated at the 
protein level. A panel of eight representative cytokines (IL-1α, IL-6, TNF-alpha, G-CSF, 
CXCL1 CXCL10, CCL2, and CCL3) was assessed for their release from LA4 cells upon 24h 
treatment with the above selected doses. Corresponding to the gene expression data, CS and 
PEI(25)-PEG(2)10 showed the most prominent proinflammatory response (Fig.3). 
 
Figure 3: Cytokine release 
 
Figure 3: Cytokine release 
Cytokine release was determined in LA4 cells after 24 h treatment. Values are represented as 
fold changes compared to the control (untreated cells; mean±SEM). Statistically significant 
changes with a p-value < 0.05 compared to controls are indicated by an asterisk. 
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Experiments were repeated three times in case of the PEI based polymers and five times in 
case of NZO and CS.  
 
Increased levels were mainly detected for the acute-phase cytokines like CXCL1, CXCL10, 
TNF, IL-6, and G-CSF (CSF2) upon CS and PEGylated PEI treatment, with a more than 10 
fold elevated protein release for IL-6, CXCL10 and G-CSF caused by PEI(25)-PEG(2)10. In 
addition, monocyte chemoattractant protein 1 (MCP-1, also known as CCL2) showed up to 
70-fold elevated levels after 24 h treatment with CS. At the concentration used in the qRT-
PCR array as well as at higher doses of up to 1000 µg/ml for CS and NZO and 50 ug/ml for 
PEI 25 kDa (data not shown), both treatments caused only negligible release levels of the 
investigated proinflammatory cytokines.  
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4.5 Discussion 
 
Cytotoxicity 
To overcome the high cytotoxicity of PEI-based non viral vector systems is a major challenge 
towards an improved safety and efficiency of gene therapy and RNAi. Some modifications of 
standard PEI 25 kDa already yielded promising carriers. For example, as previously 
described[26] PEGylation of PEI 25kDa with a PEG chain length of up to 2 kDa and a 
grafting degree higher than 10 strongly reduced cytotoxicity of PEI 25 kDa. In comparison to 
the lung toxic benchmark particles we showed here similar cytotoxicity levels for PEI 25 kDa 
and NZO, but much less for CS.  
For the qRT-PCR pathway-focused gene array particle concentrations with moderate 
cytotoxic effects were used as clearly shown by the data on membrane damage and metabolic 
activity. By avoiding a state of full-blown cell death we were able to study underlying toxicity 
mechanisms under well-defined cell culture setting. 
 
Stress and Toxicity Pathway Finder 
Lung toxic benchmarks 
Inhalation of CS has long been associated with lung disease such as silicosis and lung cancer 
[27, 28]. The typical involved processes were generation of oxidative species, release of 
inflammatory cytokines and chemokines as well as proliferative factors. In our in vitro study 
we were able to reproduce and distinguish these processes by gene expression profiling and 
by that validate our system. In accordance to previous results we observed a strong up-
regulation of genes related to oxidative stress response and detoxification (Ugt1a2, Cryab, 
Mt2, Hmox1), inflammation (Nfkbia, Cxcl10, Casp1, Nos2, Il18, Lta, Hspa1b, Serpine1, 
Csf2), and cytotoxicity pathways (Tnfsf10, E2f, Gadd45, Cdkn1a, Ddit3, Bax, Tnfrsf1a, 
Ccng1).  
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ZnO particles and Zn2+ ions have been described to stimulate oxygen radical formation and 
cause metal fume fever [17, 18, 29]. In particular Zn is a potent and well known inducer of 
heat shock protein transcription [30], a phenomenon that might be seen as a protective 
mechanism of these chaperons for recovery from stress situations. 
In our study we observed a pronounced stress response characterized by heat shock and 
oxidative stress marker expression like Hspb1, Hmox1, Mt2, Ugt1a2 as well as minor 
indications for proinflammatory reactions (NfkBia and Cxcl10) after 6 h. After 24 h no up-
regulated genes but rather repressed expression levels were detected (Supporting material, 
S2). Even though the transcriptional pathways leading to gene repression are less understood 
compared to those of induction, the repression of the major oxidative stress marker heme 
oxygenase 1 (Hmox1), has been discussed as potential defense strategy upon hypoxic 
conditions. Besides that, Zn exposed cells, have been found to react with an overall inhibition 
of protein synthesis[31].  
PEI-based non-viral vector systems 
PEI-based non-viral vector systems caused all together less alteration of gene expression 
levels as compared to our lung toxic benchmark particles, but we could still detect a 
prominent cytotoxic (PEI 25 kDa) as well as proinflammatory response to PEG modified PEI 
copolymers. 
In detail after 6 h treatment several genes related to inflammatory signalling were especially 
altered upon treatment with PEG modified PEI-based non-viral vectors. After 24 h notably 
more genes, mainly related to apoptosis, were induced by PEI 25KDa (Fig.2 and 4).  
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Figure 4: Expression Synopsis 
 
Figure 4:  Expression Synopsis 
 
Genes were clustered in three tier levels (tier 1 (green): oxidative stress, tier 2: inflammation (yellow), 
tier 3: cytotoxicity (red)) according to the hierarchical oxidative stress model from Nel and 
colleagues[19]. The percentage of altered genes (> 2-fold) after 6 h (left) and 24 h (right) treatment 
with CS (400 µg/ml), NZO (2.5 µg/ml), PEI25kDa (5 µg/ml), PEI(25)-PEG(2)10 (5 µg/ml), and 
PEI(25)-PEG(0.55)30 (5 µg/ml) was calculated based on the number of genes more than 2 fold 
induced, related to the number of genes representing the tier level on the array. 
 
NfkBia and E2f seem to be key players induced by the inflammatory response after 6 h. 
Nfkbia triggers inflammation mediated by chemokines and cytokines as well as apoptotic 
signalling pathways a process that is well described in the literature [32]. The transcription 
factor E2f is a potent activator for genes involved in cell cycle regulation, DNA synthesis and 
replication [33], but is also known to promote apoptotic signaling [34, 35].  
High levels of Cxcl10 and Nos2 were observed after treatment with PEG-modified PEI 
polymers. These genes are well known for their immunomodulatory potential and are known 
to be highly induced during inflammation [36]. Both, PEI(25)-PEG(2)10 and PEI(25)-
PEG(0.55)30 treatment induced stress response proteins, in particular antioxidant defence 
pathways represented by Ugt1a2, Mt2, and Hmox1, which are possibly upstream of the 
inflammatory cascade (Il18, Cxcl10, Nfkbia, Casp1, Nos2). PEI 25 kDa caused high up-
regulation of genes like Bax, Bcl2l1, Atm, Anxa5, and Ercc4 related to apoptotic cell death, 
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whereas PEG-PEI copolymers induced high levels of genes related to inflammation like 
Casp1, Il1b, Hspa1b, Nos2, and NfkBia. Since the observed long lasting inflammatory 
potential of CS [37-40], was found to be associated with its hazard to cause chronic lung 
disease [28, 41], our observation might raise serious concerns about the safety of non-
degradable, PEGylated polymers like PEI(25)-PEG(0.55)30, 
 
Inflammatory response 
Sensitive organs such as the lung are well known for their high sensitivity to particle 
treatment, especially for so called nano-sized particles in a size range below 100nm [41-43]. 
Exposure of the respiratory system to particles triggers proinflammatory effects and can 
directly cause tissue damage and alteration of lung function and adverse cardiovascular 
effects [29, 44]. Therefore any inflammatory stimulation caused by inhalation of a therapeutic 
agent has to be monitored carefully. In our study prominent up-regulation of genes related to 
inflammation (Cxcl10, Nos2, IL-1b, Casp1, NfkBia, Csf2, Mif, Serpine1, Lta, Il-18) was 
observed after treatment with PEI(25)-PEG(2)10, PEI(25)-PEG(0.55)30 and CS. This result is 
in good accordance to other studies [28, 45, 46], where CS was used as positive control for 
lung inflammation. At protein level PEGylated copolymers and CS caused abundant cytokine 
release with patterns similar to our qRT-PCR data. The proinflammatory potential of the PEI-
based non-viral vector systems seems to be promoted by the PEG-modification of PEI 25 kDa 
with a PEG chain length of 2 kDa and grafting densities higher than 10. 
Two different underlying mechanisms could be highlighted when comparing the cytotoxicity 
(apoptosis) pathways triggered by CS after 6h with those by PEI25 kDa after 24 h as 
illustrated in Fig. 2A and B: For CS it seems to be likely that during the onset of the cascade, 
the TNF-receptor has been activated by reactive oxygen species generated by particle surface 
reactivity. This rapid activation will subsequently be transduced, depending on the cellular 
stress levels, via the cellular NFκB - switchpoint into signaling causing either inflammatory 
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(Cxcl10, Lta, Casp1, Il18 and Nos2) or apoptotic responses (Tnfsr10, Cdkn1a, Ccng1, 
Gadd45a). In contrast to this extrinsic apoptotic pathway, PEI 25 kDa caused high induction 
of genes related to the intrinsic apoptotic pathway like Bcl2l1, Bax and DNA damage 
response like Atm and Ercc4. This intrinsic response could be induced depending on the 
endosomal uptake of PEI which causes a dramatic swelling and rupture of the endosome. 
While this release process, called ‘proton sponge effect’ seems crucial for the delivery of 
nucleic acid into the cytoplasm, the thereby generated intracellular stress can induce apoptosis 
via the intrinsic/mitochondrial pathway. 
This redox-sensitive caused response process will have to be balanced by the cellular 
antioxidant and detoxification machinery (Cyp1b1, Cryab, Hmox2, Gsr, Hspb1, and Ugt1a2). 
 
In summary, both benchmark particles revealed significant expression changes only within 
the first 6 h of treatment. CS induced pathways related to oxidative stress, inflammation and 
cytotoxicity, and NZO particles yielded a characteristic early stress protein response. The 
three PEI-based polymers showed certainly related expression pattern, but proinflammatory 
pathways were primarily induced by PEG modified PEI-based copolymers. In addition, the 
response upon PEI 25 kDa could be distinguished through apoptotic pathways triggered in the 
later phase, after 24 h of treatment (Fig.4). The observed alteration of expression levels of 
genes involved in apoptosis and cytokine signaling should be avoided on the one hand, but to 
some extent might also be beneficial for tumour targeting with improved anti-tumour effects 
on the other hand [47-50]. The higher inflammatory potential of the PEG modified PEI 
copolymers should however be considered as one limitation for their pulmonary application 
for various lung diseases where repeated and permanent dosing is required. To examine the in 
vivo relevance of the here described alarming proinflammatory PEI-PEG properties, detailed 
animal studies are currently executed in our lab which shall provide important information 
about degree and persistence of any relevant inflammatory responses. 
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4.6 Supporting Information 
 
S1: Gene table 
Gene table of the RT² Profiler™ PCR Array Mouse Stress & Toxicity PathwayFinder provided by the manufacturer. 
PCR Array Catalog #:  PAMM-003  
   
Position Unigene  Refseq  Symbol Description       Genname 
A01  Mm.1620  NM_009673 Anxa5  Annexin A5       Anx5/R74653 
A02  Mm.5088  NM_007499 Atm  Ataxia telangiectasia mutated homolog (human) AI256621/C030026E19Rik 
A03  Mm.19904  NM_007527 Bax  Bcl2-associated X protein     BAX 
A04  Mm.238213  NM_009743 Bcl2l1  Bcl2-like 1       Bcl(X)L/Bcl-XL 
A05  Mm.1051  NM_009807 Casp1  Caspase 1       ICE/Il1bc 
A06  Mm.336851  NM_009812 Casp8  Caspase 8       Caspase-8/FLICE 
A07  Mm.458815  NM_011124 Ccl21b Chemokine (C-C motif) ligand 21b    6CKBAC2/6Ckine 
A08  Mm.1282  NM_011337 Ccl3  Chemokine (C-C motif) ligand 3    AI323804/G0S19-1 
A09  Mm.244263  NM_013652 Ccl4  Chemokine (C-C motif) ligand 4    Act-2/MIP-1B 
A10  Mm.278584  NM_016746 Ccnc  Cyclin C       AI451004/AU020987 
A11  Mm.273049  NM_007631 Ccnd1  Cyclin D1       AI327039/Cyl-1 
A12  Mm.2103  NM_009831 Ccng1  Cyclin G1       AI314029 
B01  Mm.195663  NM_007669 Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21)   CAP20/CDKI 
B02  Mm.279308  NM_016681 Chek2  CHK2 checkpoint homolog (S. pombe)   CHK2/Cds1 
B03  Mm.178  NM_009964 Cryab  Crystallin, alpha B      Crya-2/Crya2 
B04  Mm.4922  NM_009969 Csf2  Colony stimulating factor 2 (granulocyte-macrophage) Csfgm/Gm-CSf 
B05  Mm.877  NM_021274 Cxcl10 Chemokine (C-X-C motif) ligand 10   C7/CRG-2 
B06  Mm.14089  NM_009992 Cyp1a1 Cytochrome P450, family 1, subfamily a, polypeptide 1 AHH/AHRR 
B07  Mm.214016  NM_009994 Cyp1b1 Cytochrome P450, family 1, subfamily b, polypeptide 1 CP1B/P4501b1 
B08  Mm.389848  NM_007812 Cyp2a5 Cytochrome P450, family 2, subfamily a, polypeptide 5 Coh/Cyp15a2 
B09  Mm.218749  NM_009998 Cyp2b10 Cytochrome P450, family 2, subfamily b, polypeptide 10 Cyp2b/Cyp2b20 
B10  Mm.14413  NM_010000 Cyp2b9 Cytochrome P450, family 2, subfamily b, polypeptide 9 Cyp2b 
B11  Mm.20764  NM_007815 Cyp2c29 Cytochrome P450, family 2, subfamily c, polypeptide 29 AHOH/AHOHase 
        Chapter 4 
  125 
B12  Mm.332844  NM_007818 Cyp3a11 Cytochrome P450, family 3, subfamily a, polypeptide 11 AI256190/Cyp3a 
C01  Mm.10742  NM_010011 Cyp4a10 Cytochrome P450, family 4, subfamily a, polypeptide 10 AI647584/Cyp4a 
C02  Mm.250901  NM_007822 Cyp4a14 Cytochrome P450, family 4, subfamily a, polypeptide 14 AI314743 
C03  Mm.57029  NM_007824 Cyp7a1 Cytochrome P450, family 7, subfamily a, polypeptide 1 CYP7A1 
C04  Mm.110220  NM_007837 Ddit3  DNA-damage inducible transcript 3    CHOP-10/CHOP10 
C05  Mm.27897  NM_008298 Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1  Hsj2/Nedd7 
C06  Mm.18036  NM_007891 E2f1  E2F transcription factor 1     E2F-1/mKIAA4009 
C07  Mm.181959  NM_007913 Egr1  Early growth response 1    A530045N19Rik/ETR103 
C08  Mm.15295  NM_007940 Ephx2  Epoxide hydrolase 2, cytoplasmic    AW106936/Eph2 
C09  Mm.280913  NM_007948 Ercc1  Excision repair cross-complementing 
 rodent repair deficiency, complementation group 1 Ercc-1 
C10  Mm.287837  NM_015769 Ercc4  Excision repair cross-complementing rodent repair deficiency,  
complementation group 4     AI606920/Xpf 
C11  Mm.3355  NM_010177 Fasl  Fas ligand (TNF superfamily, member 6)   APT1LG1/CD178 
C12  Mm.976  NM_010231 Fmo1  Flavin containing monooxygenase 1    FMO1 
D01  Mm.155164  NM_144878 Fmo4  Flavin containing monooxygenase 4    D1Ertd532e 
D02  Mm.385180  NM_010232 Fmo5  Flavin containing monooxygenase 5   5033418D19Rik/AI195026 
D03  Mm.389750  NM_007836 Gadd45a Growth arrest and DNA-damage-inducible 45 alpha AA545191/Ddit1 
D04  Mm.1090  NM_008160 Gpx1  Glutathione peroxidase 1     AI195024/AL033363 
D05  Mm.441856  NM_030677 Gpx2  Glutathione peroxidase 2     GPxGI/GSHPx-2 
D06  Mm.283573  NM_010344 Gsr  Glutathione reductase      AI325518/D8Ertd238e 
D07  Mm.37199  NM_010358 Gstm1  Glutathione S-transferase, mu 1    Gstb-1/Gstb1 
D08  Mm.440885  NM_010359 Gstm3  Glutathione S-transferase, mu 3    AI042769/Fsc2 
D09  Mm.276389  NM_010442 Hmox1 Heme oxygenase (decycling) 1    D8Wsu38e/HO-1 
D10  Mm.272866  NM_010443 Hmox2 Heme oxygenase (decycling) 2    HO-2/HO2 
D11  Mm.347444  NM_008296 Hsf1  Heat shock factor 1      AA960185 
D12  Mm.372314  NM_010478 Hspa1b Heat shock protein 1B     Hsp70/Hsp70-1 
E01  Mm.14287  NM_013558 Hspa1l  Heat shock protein 1-like     Hsc70t/Msh5 
E02  Mm.239865  NM_008300 Hspa4  Heat shock protein 4      70kDa/AI317151 
E03  Mm.330160  NM_022310 Hspa5  Heat shock protein 5      78kDa/AL022860 
E04  Mm.336743  NM_031165 Hspa8  Heat shock protein 8     2410008N15Rik/Hsc70 
E05  Mm.465216  NM_013560 Hspb1  Heat shock protein 1      27kDa/Hsp25 
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E06  Mm.378944  NM_010477 Hspd1  Heat shock protein 1 (chaperonin)    60kDa/Hsp60 
E07  Mm.215667  NM_008303 Hspe1  Heat shock protein 1 (chaperonin 10)   10kDa/mtcpn10 
E08  Mm.358609  NM_008344 Igfbp6  Insulin-like growth factor binding protein 6   IGFBP-6 
E09  Mm.1410  NM_008360 Il18  Interleukin 18       Igif/Il-18 
E10  Mm.15534  NM_010554 Il1a  Interleukin 1 alpha      Il-1a 
E11  Mm.222830  NM_008361 Il1b  Interleukin 1 beta      IL-1beta/Il-1b 
E12  Mm.1019  NM_031168 Il6  Interleukin 6       Il-6 
F01  Mm.87787  NM_010735 Lta  Lymphotoxin A      LT/LT-[a] 
F02  Mm.22670  NM_010786 Mdm2  Transformed mouse 3T3 cell double minute 2 1700007J15Rik/AA415488 
F03  Mm.2326  NM_010798 Mif  Macrophage migration inhibitory factor   GIF/Glif 
F04  Mm.147226  NM_008630 Mt2  Metallothionein 2      AA409533/MT-II 
F05  Mm.256765  NM_008689 Nfkb1  Nuclear factor of kappa light chain gene enhancer  
in B-cells 1, p105      NF-KB1/NF-kappaB 
F06  Mm.170515  NM_010907 Nfkbia  Nuclear factor of kappa light chain gene enhancer  
in B-cells inhibitor, alpha     AI462015/Nfkbi 
F07  Mm.2893  NM_010927 Nos2  Nitric oxide synthase 2, inducible, macrophage  NOS-II/Nos-2 
F08  Mm.7141  NM_011045 Pcna  Proliferating cell nuclear antigen    PCNA 
F09  Mm.27375  NM_023127 Polr2k  Polymerase (RNA) II (DNA directed) polypeptide K MafY/Mt1a 
F10  Mm.3863  NM_008898 Por  P450 (cytochrome) oxidoreductase    4933424M13Rik/CPR 
F11  Mm.255539  NM_009010 Rad23a RAD23a homolog (S. cerevisiae)   2310040P19Rik/AL024030 
F12  Mm.4888  NM_009012 Rad50  RAD50 homolog (S. cerevisiae)    Mrell/Rad50l 
G01  Mm.250422  NM_008871 Serpine1 Serine (or cysteine) peptidase inhibitor,  
clade E, member 1      PAI-1/PAI1 
G02  Mm.276325  NM_011434 Sod1  Superoxide dismutase 1, soluble    B430204E11Rik/Cu 
G03  Mm.290876  NM_013671 Sod2  Superoxide dismutase 2, mitochondrial   MnSOD/Sod-2 
G04  Mm.1258  NM_011609 Tnfrsf1a Tumor necrosis factor receptor superfamily,     
member 1a       CD120a/FPF 
G05  Mm.1062  NM_009425 Tnfsf10 Tumor necrosis factor (ligand) superfamily,  
member 10      A330042I21Rik/AI448571 
G06  Mm.264255  NM_001033161  Tradd TNFRSF1A-associated via death domain 9130005N23Rik/AA930854 
G07  Mm.222  NM_011640 Trp53  Transformation related protein 53    bbl/bfy 
G08  Mm.300095  NM_013701 Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 UGTBr/p 
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G09  Mm.1393  NM_011677 Ung  Uracil DNA glycosylase     UNG1/UNG2 
G10  Mm.4347  NM_009532 Xrcc1  X-ray repair complementing defective repair in  
Chinese hamster cells 1     Xrcc-1 
G11  Mm.143767  NM_020570 Xrcc2  X-ray repair complementing defective repair  
in Chinese hamster cells 2   4921524O04Rik/8030409M04Rik 
G12  Mm.37531  NM_028012 Xrcc4  X-ray repair complementing defective repair in  
Chinese hamster cells 4    2310057B22Rik/AW413319 
H01  Mm.3317  NM_010368 Gusb  Glucuronidase, beta      AI747421/Gur 
H02  Mm.299381  NM_013556 Hprt1  Hypoxanthine guanine phosphoribosyl transferase 1 C81579/HPGRT 
H03  Mm.2180  NM_008302 Hsp90ab1 Heat shock protein 90kDa alpha (cytosolic),  
class B member 1      90kDa/AL022974 
H04  Mm.343110  NM_008084 Gapdh  Glyceraldehyde-3-phosphate dehydrogenase  Gapd 
H05  Mm.328431  NM_007393 Actb  Actin, beta, cytoplasmic    Actx/E430023M04Rik 
H06  N/A   SA_00106 MGDC Mouse Genomic DNA Contamination   MIGX1B 
H07  N/A   SA_00104 RTC  Reverse Transcription Control    RTC 
H08  N/A   SA_00104 RTC  Reverse Transcription Control    RTC 
H09  N/A   SA_00104 RTC  Reverse Transcription Control    RTC 
H10  N/A   SA_00103 PPC  Positive PCR Control PPC 
H11  N/A   SA_00103 PPC  Positive PCR Control PPC 
H12  N/A   SA_00103 PPC  Positive PCR Control PPC 
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S2: Heat map 
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S2: Heat map 
Fold induction of each gene after 6h treatment (left) and 24h treatment (right).is shown (based on our 
qRT-PCR stress and toxicity pathways focused gene array). Red (blue) color indicates up-(down-
)regulation and gene symbols and Unigene IDs are shown. Genes are sorted according to the seven 
clusters of the RT² Profiler™ PCR Array Mouse Stress & Toxicity PathwayFinder provided by the 
manufacturer (except for Ugt1a2 and Casp1).  
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5.1 Abstract 
 
Genotoxicity data of polymeric nanomaterial are scant, but of great concern, especially when 
polymeric non-viral vector systems are used for cancer treatment.  
In this study, we analyzed the mutant frequency (MF) caused by three different poly(ethylene 
imine) (PEI) -based polymers and nanosized zinc oxide particles (NZO) in a transgenic lung 
epithelial cell culture model following eight repeated 72 h incubations. The level of 8-OH-dG 
was additionally determined by using ELISA technique. NZO was included as lung toxicity 
benchmark. The concentrations used in this study served no cytotoxic effects but represented 
PEI-concentrations normally used for in-vitro transfection studies.  
NZO and PEI25kDa showed no mutagenic potential, whereas the two polyethylene glycol (PEG) 
modified PEI copolymers caused slight increase in MF (PEI(25)-PEG(2)10: 1.4-fold, and 
PEI(25)-PEG(0.55)30: 1.2-fold increase in MF vs. ctrl.), but without oxidative damage of DNA. 
In addition, PEI(25)-PEG(2)10 appeared to have proliferative properties due to increased levels 
of cell counts after all exposure rounds (1.3-fold increase vs. ctrl.).  
With regard to genotoxicity PEI-based nanocarriers and NZO particles showed no dramatically 
effects in MF in the FE1 in vitro model. Further clarification of the mutagenic potential is still 
needed for such polymeric non-viral nanocarriers and the FE1 Muta™Mouse in vitro model is 
appropriate to screen the MF, but further analysis for the underlying mechanisms should be 
followed.  
 
Key words: PEI, mutant frequency, FE1, 8-OH-dG 
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5.2 Introduction 
 
Poly(ethylene imine) (PEI) has widely been used as non-viral gene carrier due to its capability to 
form stable complexes by electrostatic interactions with nucleic acids. The major drawback of 
PEI is its high toxicity due to aggregation of huge clusters of PEI on the cell membrane and its 
interaction with blood component [1, 2]. To reduce the cytotoxicity of PEI several studies have 
introduced modified PEIs such as block or graft copolymers containing cationic and hydrophilic 
non-ionic components [3, 4]. Copolymers of PEI and hydrophilic poly(ethylene glycol) (PEG) 
with various molecular weights and graft densities were shown to possess improved cytotoxicity 
and potential for DNA and siRNA delivery [5-7].  
To the best of our knowledge and despite the strong interaction of PEI with nucleic acids, no 
information is available about any mutagenicity or genotoxicity after treatment with PEI 
polymers. Non-viral vectors based on PEI usually contain a excess of free PEI that is not 
complexed with nucleic acids [8]. Therefore, it is of great interest to evaluate the mutant 
frequency induced by different free PEI polymers in lacZ transgenes of Muta Mouse lung 
epithelial cells (FE1). Previous studies comprehensively analyzed the safety and biocompatibility 
of different PEGylated PEI polymers in murine epithelial like typ II cells (LA4) and alveolar 
macrophages (MH-S). We found that the degree of PEGylation correlated both with cytotoxicity 
and with oxidative stress, but not with proinflammatory effects. AB type copolymers with long 
PEG blocks caused high membrane damage and significantly decreased the metabolic activity of 
lung cells. Moreover AB type PEI copolymers with long PEG blocks significantly increased the 
release of lipid mediators such as 8-isoprostanes (8-IP) and prostaglandin E2 (PGE2) in a dose-
dependent manner. The cytokine profiles showed high levels of acute-phase cytokines such as 
TNF, IL-6, and G-CSF but without any structure-function relationship [9].  
In this study, three different PEI-based polymers and nanosized zinc oxide (NZO) are 
investigated on their influence to induce mutations using an recently established lung cell in vitro 
model [10, 11] and the level of 8-hydroxy-2’-desoxyguanosine (8-OH-dG), one of the most 
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abundant oxidative products of cellular DNA, was determined using enzyme-linked 
immunosorbent assay (ELISA) technique. The concentrations which are used in this study ruled 
out any cytotoxic effects according to previous studies in different representative murine lung 
cell lines [9, 12]. Therefore, cytotoxicity was regarded as negligible in this set up. Regarding the 
repeated dosing scheme in this study, the overall concentration during the hole exposures 
(exposure round 1-8) are in one dose range for the PEI-based nanocarriers and NZO, which not 
normally cause any cytotoxic effects[9, 12]. However, it has been shown that modification on the 
PEI 25kDa backbone reduces cytotoxicity, but on costs of proinflammatory events and to some 
extent of oxidative stress parameters [12, 13]. Free radicals could also generated by 
inflammation, but it is unlikely that all such substances are carcinogens solely because they are 
able to cause inflammation. For ultrafine particles (UFP) it has been reported that they could 
enter mitochondria and induce mitochondrial damage because of their small size [14]. UFP may 
pass through cell membranes and combine with DNA. NZO induced also very high oxidative 
stress and inflammation [12, 15, 16] and could therefore also be able to direct interact with DNA 
to cause mutations and contribute to carcinogenesis. Due to its high positive charge density PEI 
is also able to interact directly with DNA. Therefore, the potential of genotoxicity of such PEI-
based polymers for gene therapy or siRNA delivery as well as for NZO requires further 
clarification and the presented mutagenicity analysis should support the understanding of the 
underlying toxicity pathway of these non-viral vector systems for optimized development of 
promising pulmonary nanocarriers.  
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5.3 Materials and Methods 
 
Particles and polymer solutions 
Benzo[a]pyrene (B[a]P) was purchased from Alfa Aesar GmbH & Co KG, Karlsruhe, Germany 
and prepared as a stock solution of 1 mg in 10 ml DMSO (Merck, Darmstadt, Germany). 
Nanosized zinc oxide (NZO) was obtained from Alfa Aesar GmbH & Co KG, Karlsruhe, 
Germany and a stock solution of 1 mg in 1 ml double distilled water was prepared by virogous 
vortexing and sonication for 5 min and three times. Branched poly(ethylene imine) (PEI) with a 
molecular weight of 25 kDa (Polymin, water-free, 99 %) was a gift of BASF, Ludwigshafen. The 
copolymers poly(ethylene imine)-graft-poly(ethylene glycol) (PEI-PEG) with a PEG content of 
approximately 50 % (w/w) were synthesized as previously described [4, 17] by grafting linear 
PEG of 0.55, 2 kDa onto branched PEI 25 kDa. These graft copolymers were designated using 
following nomenclature: PEI(25k)-g-PEG(x)n. The number in brackets (25 k or x, where x= 0.55 
k, 2 k) represents the molecular weight of the PEI or PEG block in Da, and the index n is the 
average number of PEG blocks per PEI molecule. This number was calculated on the basis of 
1H-NMR spectra as described previously [4]. Polymer dilutions were prepared in sterile, sodium 
chloride solution (150mM) to obtain a final concentration of 0.5 µg/ml PEI.  
FE1 MML Cell line 
The development and characterization of the FE1 MML epithelial cell line has been described 
previously by [10]. The cells were cultured in growth medium containing DMEM F12 (1:1) 
medium containing L-glutamine (Invitrogen, Gibco, Germany) supplemented with 2 % FBS 
(Biochrom AG, Germany), 100 U/ml Penicillin G (Biochrom AG, Germany), 100 mg/ml 
streptomycin (Biochrom AG, Germany), and 1 ng/ml human epidermal growth factor (Roche, 
Germany). 
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Phase contrast microscopy 
FE1 MML epithelial cells were observed under an invert microscop (Axiovert 135, Zeiss, Jena, 
Germany) using phase-contrast II module to detect alteration in cell morphology over all eight 
exposure rounds and the washing step.  
Cell incubations for analysis of mutant frequency (repeated dosing scheme) 
The exposure setup was carried out as described previously by [11]. Briefly, 300,000 FE1 MML 
cells were seeded in 10ml growth medium in petri dishes (90 mm; Corning®, Sigma-Aldrich, 
Germany) and incubated at 37 °C and 5 % CO2 for 24 h before exposure. The negative control 
were incubated in pure exposure medium whereas the positive control represented 0.1 µg/ml 
B[a]P. The cells were incubated for 72 h, washed with PBS, trypsinized, and centrifuged at 1200 
x g for 5 min at 4 °C. After resuspenion in medium cells were counted and 300,000 cells were 
reseeded in a new dish. After 24 h, new exposure medium (only containing DMEM F12 (1:1) 
medium containing L-glutamine and supplemented with 1 ng/ml human epidermal growth factor 
(Roche, Germany)) with or without the test substance was added. After 6 h treatment exposure 
medium was removed and fresh growth medium was added to the cells. In a total of eight 
exposure rounds the cells were exposed to the particles or polymers, making the total exposure 
time (8 x 72 h) 576 h. The cumulative dose added was (8 x 0.5µg x 10) 40 µg for PEI polymers 
and (8 x 1µg x10) 80 µg for nanosized ZnO and (5 x 0.1µg x 10) 50 µg for B[a]P. B[a]P 
exposure was only repeated five times because after five times treatment the cells began to grow 
markedly slower than all other cells and only yielded 25 % confluence compared with about 80 
% for all other samples. Therefore, they received pure growth medium for the remaining three 
exposure rounds. After the eight treatments the dishes were washed thoroughly with PBS to 
remove the excess of the particle. To further reduce the load of particles, and thereby easing 
mutation analysis, the cells were trypsinized and reseeded without test substance for 72 h. 
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Isolation of high molecular weight DNA for mutant analysis 
After the ninth exposure/ washing round cells were digest overnight in lysis buffer containing 10 
mM Tris pH 7.6, 10 mM EDTA, 10 mM NaCl, 1 mg/ml proteinase K and 1 % SDS. DNA was 
isolation from FE1 MML cells using chloroform/ phenol extraction and precipitation in ethanol 
as previously described [10]. Freshly isolated DNA was dissolved in TE buffer and stored at 4°C 
for further investigation of mutant frequency.  
LacZ Mutation Analysis 
Transgene mutant frequency was determined using P-gal positive selection assay described by 
[18]. Briefly, galE- host bacterium was used to facilitate isolation and enumeration of mutant 
copies of the lacZ transgene [19]. λgt10lacZ DNA copies were rescued from genomic Muta™ 
Mouse DNA using the Transpack™ lambda packaging system (Stratagene, La Jolla, CA). 
Packaged phage particles were mixed with the host bacterium (Escherichia coli ∆lacZ, galE-, 
recA-, pAA119 with galT and galK [19, 20], plated on minimal agar with 0.3 % w/v P-gal, and 
incubated overnight at 37 ° C. Concurrent titers on nonselective minimal agar were employed to 
enumerate total plaque-forming units (pfu). Mutant frequency was expressed as the ratio of the 
mutant plaques to total pfu.  
8-OH-dG enzyme-linked immunosorbent assay 
8-OH-dG was determined using 8-OH-dG ELISA kit from Japan Institute or the Control of 
Aging, NIKKEN SEIL Co., Ltd. (Catalo-No. KOG-HS1OE). DNA samples were directly used 
without further dilution and the 8-OH-dG detection was carried out following the manufacturer’s 
instructions.  
Statistics 
All mutant frequency data were tested for equal variance using F-test. All data sets were 
analyzed using Student’s t-test in the SAS system v. 8.02 Windows (SAS Institute, Cary, NC).  
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5.4 Results and Discussion 
 
To study mutagenicity a lot of transgenic rodent models are introduced. One of the convenient 
and effective in vivo mutation assay system is the Muta™Mouse system, which contains 80 
copies of a stably integrated λgt10lacZ shuttle vector in the mouse genome [21]. The lung 
epithelial cell line used in this study was derived from the Muta™Mouse, and is a useful in vitro 
tool for assessing mutagenic activity [10]. Cell shape and confluence was observed under phase-
contrast microscopy (Figure 1).  
Figure 1: Phase-contrast microscopy 
A 
 
B 
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Figure 1: Phase-contrast microscopy 
Phase-contrast images of Muta™Mouse flat epithelium isolate 1 (FE1) cells cultured on polystyrene 
dishes 6 h (A) and 72 h post exposure (B). Images are representative for all exposure rounds and all 
samples out of one group (n=10). 
 
At low density, directly after reseeding and 6 h post exposure, the cells are large with distinct 
subcellular inclusions. Whereas at higher density (after 72 h exposure), the cells display less 
cytoplasm and form tight, uniform monolayer according to previously published data [10]. 
Depending on the exposure and the time (exposure round) cell counts were statistically impaired 
after B[a]P (0.1 µg/ml) (Figure 2) and phase-contrast images confirmed this quantification for 
the positive control. None of the particles and polymers tested altered the cell count rate. 
Interestingly, PEI(25)-PEG(2)10 seemed to increase the cell counts, which could be related to an 
slight proliferative effect, but without any statistical significance.  
 
Figure 2: Cell counts 
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Figure 2: Cell counts 
Cells counts were determined using CASYTechnology (innovatis AG, Reutlingen, Germany). 300.000 
cells were seeded after each exposure round (for detailed information see material and methods) and cell 
counts were taken after 72h of exposure. Values represent mean±SD (n=10) of all exposure rounds (in 
total 8) plus washing phase (round 9). Statistical significance is marked as asterisk, **p<0.01 compared 
to negative control (ctrl.). 
 
The effect of nanosized zinc oxide (NZO) and PEI-based polymers on the mutant frequency is 
shown in Table 1. It is obviously that the positive control dramatically elevated the mutant 
frequency (25.5 –fold increase vs. negative control), which is in good accordance to the results 
from Jacobsen et al.[11].  
 
Table 1: The Effect of PEI-based nanocarriers on the Frequency of LacZ 
 
    Pfu screened  total mutants counted MF*105 MF *105 
Sample  No        mean SD 
negative control 1 247175  189  76.3  67.8 9.5 
   2 285775  152  53.0   
   3 250571  179  71.2   
   4 223981  167  74.3   
   5 276995  178  64.1   
positive control 6 138746  2387  1720.4  1733.8 118.7 
   7 187535  3066  1634.9   
   8 212302  3602  1696.4   
   9 161608  2713  1678.8   
   10 168483  3267  1938.8   
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Table 1(continued): The Effect of PEI-based nanocarriers on the Frequency of LacZ 
Pfu screened  total mutants counted MF*105 MF *105 
Sample  No        mean SD  
ZnO 1 ug/ml  11 252890  180  71.0  73.5 7.9 
   12 226798  197  86.6   
   13 222490  149  66.7   
   14 277326  191  68.7   
   15 247755  184  74.3   
PEI(25) 0.5 ug/ml 16 217520  203  93.1  74.4 19.3 
   17 219923  117  53.2   
   18 217686  189  86.6   
   19 200622  171  85.2   
   20 240962  130  54.0   
PEI(25)-PEG(2)10 21 215118  292  135.7  96.8 26.4 
0.5 ug/ml   22 186209  159  85.4   
   23 147278  163  110.7   
   24 171879  120  69.8   
   25 172045  142  82.2   
PEI(25)-PEG(0.55)30 26 208823  149  71.1  80.0 24.7 
0.5 ug/ml  27 171962  87  50.6   
   28 168400  200  118.5   
   29 213047  163  76.5   
Table 1: The Effect of PEI-based nanocarriers on the Frequency of LacZ 
The effect of polymers and particles on mutant frequency of lacZ mutants was determined. Bold values 
represent statistical significant values compare to negative control (***p<0.001). Pfu screened 
represents total number of plaque forming units screened for each sample and MF is mutant frequency.  
 
  Chapter 5 
  145 
Exposure of FE1 cells to the two PEGylated PEI-based polymers caused slightly elevated levels 
of mutant frequency in comparison to control, but without any statistical significance. PEI(25)-
PEG(2)10 caused a 1.4-fold increase in mutant frequency, and PEI(25)-PEG(0.55)30 1.2-fold 
increase. NZO and PEI 25kDa exposure yielded mutant frequency comparable to the negative 
control. From that data, we conclude that PEI(25)-PEG(2)10 is slightly mutagenic and increase 
the proliferation rate in an eukaryotic lung epithelial cell line such as FE1. To get more insight in 
the potency of PEI-based polymers and NZO to induce DNA damage, we investigated the effect 
on oxidation of 8-OH-dG in the cellular DNA with ELISA technique. Again, the positive control 
showed high potential for DNA damage (Figure 3), but none of our polymers and NZO caused 
oxidative damage to DNA detected as 8-OH-dG. Accumulation of 8-OH-dG could lead to 
increased genomic instability that in turn could lead to a more malignant phenotypic behaviour 
of tumours [22]. The presence of 8-OG-dG in DNA leads to G:C and T:A transversion, 
mutagenesis, or cell death unless uncorrectly repaired before DNA replication, which is mainly 
repaired by base excision repair , in case of 8-OH-dG DNA damage.  
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Figure 3: 8-OH-dG ELISA 
 
Figure 3: 
DNA damage was analyzed using 8-OH-dG ELIISA technique as described in materials and methods. 
Values represent mean±SD (n=10), and statistical significance represents **p<0.01 compare to negative 
control (ctrl.).  
 
Thus, to clarify the potential of genotoxcity further investigations should be carried out to 
confirm the data presented in this study. To further elucidate the mechanism behind the slight 
increase in mutant frequency after treatment with PEI(25)-PEG(2)10, assays for determination of 
single strand breakage (comet assay), chromosome damage (micronuclei assay) or other 
mutation assays like the HPRT assay could be performed, but this was out of the scope of this 
study.  
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5.5 Conclusion 
 
In conclusion, for the first time to our knowledge, the mutagenic property of PEI-based polymers 
and NZO was evaluated in a representative lung epithelial in vitro model. Since we recently 
described the higher proinflammatory potential and the induction of oxidative stress induced by 
these polymers and NZO [9, 13], we are now able to rule out mutagenicity for NZO and PEI25 
kDa in an eukaryotic cell line. For the two PEGylated PEI-based nanocarriers the mutant 
frequency was slightly elevated, but without any sign of DNA damage, thus further analysis 
should be performed to understand the underlying mechanism. PEI(25)-PEG(2)10 seemed to be 
proliferative to a low extent, but with regard to carcinogenicity and the possible application of 
this nanocarrier for pDNA or siRNA delivery, e.g. for cancer treatment, this issue should be 
focused more in detail. Ongoing in vivo studies should further investigate the genotoxicity and 
mutagenesis of such polymeric non-viral vector systems. 
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6.1 Abstract 
 
Polymeric non-viral vector systems for pulmonary application of siRNA are promising 
carriers, but have failed to enter clinical trials because of safety and efficiency problems. 
Therefore, improving their transfection efficiency as well as their toxicological profile are 
subject of intensive research efforts.  
Different promising poly(ethylene imine) (PEI) -based nanocarriers with hydrophilic and 
hydrophobic modifications were toxicologically evaluated for pulmonary application in mice.  
Nanocarriers were intratracheal instilled to determine their toxicological profile with 
particular focus on the inflammatory response in the lungs.  
Nanocarriers from both groups caused high, acute inflammation in the lungs with different 
resolution kinetics and cytotoxicity. Hydrophobic modifications caused severe inflammatory 
response and elevated epithelial barrier permeability, but accompanied by an acute 
antioxidant response. The later might, especially for Jeffamine™ modified PEI-based 
nanocarriers, support rapid resolution of the acute inflammation. Hydrophilic modification, 
with high PEG-grafting degrees, reduced the proinflammatory effects without depletion of 
macrophages and disruption of the epithelial/endothelial barrier in the lungs and showed only 
a minor oxidative stress response. 
For pulmonary application, the balance between the transfection efficiency and the cytotoxic 
profile, especially the local pro-inflammatory effects, should be optimized by further 
development of nanocarriers with highly grafted PEG-PEI-based carriers or Jeffamine™ 
modified hydrophobic PEI modifications.  
 
Keywords: PEI, siRNA, toxicity, lung inflammation, oxidative stress, epithelial 
permeability 
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6.2 Introduction 
 
siRNA delivery to the lung represents a promising non-invasive approach to treating lung 
cancer or lung diseases like acute lung injury or disorders like influenza [1-3]. Local delivery 
of siRNAs relevant to lung diseases via the airways is advantageous for gene therapy since 
the target organ is directly accessible. The large respiratory surface area provides improved 
transfection efficiency, with reduced systemic side-effects. Successful siRNA delivery using 
non-viral vector systems to the target cells or tissue is mainly dependent on well balanced 
electrostatic interactions between a positively charged polymer or liposome and a negatively 
charged phosphate backbone of the nucleic acid [4-6]. A wide range of polymers with 
different architectures and functionalities has been engineered to further optimize and to 
increase targeted delivery, biocompatibility and prolonged efficiency [7]. Non-viral vector 
systems provide an attractive alternative to recombinant viral vectors due to reduced 
pathogenicity and immunostimulation [8, 9]. However, cationic transfection reagents used for 
siRNA delivery often exhibited severe cytotoxicity, which precludes their clinical 
applications. Pulmonary delivery of plasmid DNA (pDNA) using poly(ethylene imine) (PEI) -
based nanocarriers was frequently described in the literature [10-12], but only scant 
information is available for PEI mediated delivery of siRNA to the lungs. For instance, 
pulmonary siRNA application was investigated to differentiate off-target effects (caused by 
the polymers or siRNA sequence) from specific knockdown effects, and to explore the 
feasibility of cell specific RNA-targeting [8, 13].  
In this study, we tested the hypothesis that modifications of the PEI backbone reduce not only 
the cytotoxic effects of PEI, but also the inflammatory and oxidative stress response caused 
upon administration of siRNA polyplexes to the lung of mice. Two series of PEI-based 
nanocarriers with different modifications, complexed with siRNA, were investigated to 
elucidate the influence of polymer design on cytotoxic, and inflammatory and oxidative stress 
responses in the lungs. Low (8.3 kDa) and high (25 kDa) molecular weight PEI modified with 
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hydrophobic and hydrophilic poly(ethylene glycol) (PEG) modifications, respectively, were 
analyzed. PEI25 kDa was grafted with hydrophilic PEG at different grafting degrees and 
molecular weights, in contrast to PEI 8.3 kDa which was linked with hydrophobic PEGs, one 
with fatty acid residues and one with a so-called Jeffamine™ residue. As point of reference to 
benchmark the lung toxicity, we included two well defined particulate materials, namely 
crystalline silica (CS) and nanosized zinc oxide (NZO), both extensively documented in the 
literature [14, 15]. Our results emphasize the double edged nature of nanoparticle 
formulations in medicine: For pharmaceutical reasons nano-materials get introduced to reduce 
toxicity and side-effects of drugs, however at the same time the carrier systems themselves 
may impose risks to the patient, possibly similar as known for occupational or environmental 
particle exposures [16, 17]. 
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6.3 Materials and Methods 
 
Materials 
Specifications of the materials used in this study are summarized in the supplementary 
materials, S1. 
Polyplex formation and particle suspension 
Sense and antisense strand of siRNA against GFP (siGFP) was annealed, according to the 
annealing protocol from Metabion (München, Germany). siRNA polyplexes were formed, as 
previously described [6], by mixing equal volumes (25 µl each) of siRNA and polymer 
dilution in Aqua ad injectabilia (Braun, Melsung, Germany) to obtain the desired nitrogen to 
RNA phosphate ratio (N/P ratio) of 6, using 35µg siGFP. Toxicological benchmark particles 
were applied at doses estimated to cause acute lung inflammation related to a level of 
approximately 50 % BAL PMNs. For specific calculation, see online supplement, S2.  
Animal experiments 
Animal experiments were carried out according to the German law of protection of animal life 
and were approved by an external review committee for laboratory animal care.  
Eight-to-twelve-weeks old, female BALB/cAnNcrl (Charles River Laboratories, Sulzfeld, 
Germany) mice were intratracheal instilled as described by Merkel et al.[6]. 24 h, 3 d, or 7 d 
post instillation, mice were sacrificed with an overdose of ketamine/xylazin (1%/0.1%) and 
blood was retro-orbitally collected for further investigation. The lungs of the mice were 
lavaged with phosphate-buffered saline (PBS) solution (37 ° C) as previously described [6]. 
Cytocentrifuged slides of spun-down lavaged cells were prepared for cell differentiation, after 
staining with Mayer-Grünwald stain.  
Body weight loss  
 
Mice were weighed at the day of instillation and again on the day of dissection. For 7 day 
treatment, mice were additionally weighed at day 3. Body weight loss was calculated as the 
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difference between the day of dissection and the day of instillation for each mice in every 
group (n=8).  
Total protein and lactate dehydrogenase (LDH) 
 
Bronchoalveolar lavage fluid (BALF) was centrifuged at 1200 g x 15 min. at 4 ° C. Total 
protein was determined using Bradford method and LDH concentration was determined by 
using Cytotoxicity Detection Kit (Roche Applied Diagnostics, Germany).  
Cytokine and Immunoglobulin M (IgM) measurements 
Ten cytokines/chemokines were detected simultaneously in the BALF using Luminex 
technology (Linco Research, St. Charles, MO). In this study, the secretions of following 
cytokines/chemokines were investigated: IL-1α, IL-6, IL-10, TNF-alpha, G-CSF, CXCL1, 
CXCL2, CXCL5, CXCL10, INF-γ. The assay was performed as described previously [18].  
MCP-1 (CCL2) was quantified in the BALF using mouse CCL-2/JE DuoSet ELISA (R&D 
Systems, Inc., Minneapolis, USA), according to the manufacturer’s instructions.  
Levels of total IgM were measured by ELISA using complementary capture and detection 
antibody pairs. IgM levels were calculated based on a standard curve using recombinant IgM 
as previously described by Braun et al. [19]. Detection limits are summarized in the 
supplementary material (S3). 
Blood parameters 
 
Whole blood was retro-orbitally collected in EDTA-coated tubes and continuously moved 
prior to measurement by the ADVIA 120 Hematology System (Siemens Healthcare 
Diagnostics, Deerfield, USA).  
Determination of oxidative stress parameters  
Glutathione (GSH), malondialdehyde (MDA) levels and catalase activity in the lung tissue 
were determined by HPLC, as previously described by Banerjee et al.[20].  
Statistics 
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All values are presented as mean±standard deviation (SD) of eight animals per group (n=8) 
unless otherwise stated. Significant differences between two groups were evaluated by 
Student’s t-test, or between more than two groups by one-way ANOVA, followed by Tukey’s 
multiple comparison test. Statistical analysis was performed using the program, GraphPad 
Prism 5.0 (GraphPad Software, Inc., La Jolla, CA 92037 USA). 
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6.4 Results 
 
Body weight loss 
 
We followed the body weight of each mouse throughout the experimental period to monitor 
eventual severe acute toxicity. PEI(8.3)-(C16-C18-EO25)1.4 was the only polyplex causing a 
significant body weight loss of almost 15 % at day 3, after exposure (Figure 1).  
Figure 1: Body weight loss 
 
 
 
 
 
Figure 1: Body weight was determined on day of application and on day of dissection. Body 
weight loss [%] was calculated from the difference in body weight on day of application and day of 
dissection, and the percent was calculated as follow: Body weight loss [%] = (|BWapplication–
BWdisscetion|)/BWapplication*100. Values are given as mean ± SD, n=8, asterisks indicate statistically 
significance with ***p<0.001 compare to control animals.
 
In contrast, NZO (15 µg) caused a weight loss of 10 %, already within the first 24 h after 
exposure, moreover the animals behaved very stressed, apathetic, and showed ruffled fur. As 
consequence, NZO (15 µg) experiments were terminated at this point for animal welfare 
reasons, and a low dose NZO (5 µg) was applied, where no body weight loss and no stress 
effects were detected.  
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Epithelial-endothelial permeability 
 
Levels of total protein and immunoglobulin M (IgM) in the BALF were determined to 
evaluate the integrity of the alveolar blood-air-barrier. PEI(25)-PEG(2)10 caused a time-
dependent increase in total protein (Fig.2A), after 24 h and 3 d, and increased IgM levels 
(Fig.2B) over all time points.  
Figure 2A: Total protein  
 
 
Figure 2A: Total protein was determined in broncho-alveolar lavage fluid (BALF) using 
Bradford-method. Values are given as mean±SD, n=8, asterisks represent significance compare to 
sham and control groups with ***p <0.001, **p<0.01, *p<0.05. 
 
Figure 2B: Immunoglobulin M levels 
 
 
Figure 2B: Immunoglobulin M (IgM) levels were analyzed in broncho-alveolar lavage fluid (BALF) 
for each animal in each group. Values are given as mean±SD, n=8, and statistically significance as 
compare either to control or sham group, or both, as indicated by asterisks with ***p<0.001, 
*p<0.01, and *p<0.05. 
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PEI 8.3(Butyl-(PEO-co-PPO)1000)6.2 yielded high levels of total protein and IgM with a 
maximum after 7 d treatment. IgM levels were increased after 3 d and 7 d treatment with 
PEI8.3(C16-C18-EO25)1.4, but no significant changes in total protein were detected at any 
time point. The effect levels observed upon nanoplex treatments indicated a breakdown in the 
integrity of the alveolar−capillary barrier to the same extent as observed for the high dose 
NZO (15 µg) 24 h after treatment.  
 
Cell membrane damage 
Extracellular levels of the cytoplasmatic enzyme lactate dehydrogenase (LDH) were 
quantified in the BALF to determine disruptive effects on the cell membrane caused by the 
nanoplexes, indicating necrosis or late apoptosis. In our study, all nanoplexes caused elevated 
levels of LDH, but at different time points (Fig.3).  
Figure 3: LDH release 
 
 
 
 
Figure 3: Lactate dehyrogenase release was determined in broncho-alveolar lavage fluid 
(BALF).Values are given as mean±SD, n=8, and asterisks represent significance of comparison to the  
sham and control groups with ***p <0.001, **p<0.01, *p<0.05. 
 
We could distinguish nanocomplexes which caused acute membrane damage (PEI25 kDa and 
PEI8.3(Butyl(PEO-co-PP)1000)6.2) and those which caused delayed disruptive effects, yet 
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after 3 d or 7 d treatment (PEI(25)-PEG(0.55)30, PEI8.3 kDa, PEI8.3(C16-C18-EO25)1.4 and 
PEI8.3(Butyl(PEO-co-PP)1000)6.2). Interestingly, PEI(25)-PEG(2)10 was the only 
nanocomplex which showed no significant membrane damage effects over all time points.  
 
Oxidative stress response 
Lung tissues of all animals were investigated for three oxidative stress parameters, depletion 
of the antioxidant glutathione (GSH), levels of the lipid-peroxidation by-product 
malondialdehyde (MDA), and the activity of the antioxidant enzyme catalase. We confirmed 
that the lavage procedure did not influence the oxidative status of the tissue (Fig 4A-C).  
 
Figure 4: Oxidative stress parameters 
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Figure 4: Glutathione (GSH, A) levels, malondialdehyde (MDA, B) levels and catalase activity 
(C) were determined in lung tissue from each animal in each group. Values represent mean±SD, 
n=8, and asterisks indicate statistically significance compare to control animals with 
***p<0.001, **p<0.01, *p<0.05.  
 
After treatment with PEI(25)-PEG(0.55)30 and PEI8.3 kDa, GSH levels in the lungs were 
dramatically decreased, accompanied by elevated MDA levels indicating moderate lipid 
peroxidation (Fig. 4A and 4B). Interestingly, in contrast to all other polyplex treatments, we 
found good correlation between GSH and MDA levels and an acute increase in catalase 
activity after 24h for both modifications of low molecular weight PEI8.3 kDa. After treatment 
with PEI8.3(C16-C18-EO25)1.4, GSH levels were only slightly decreased after 3 d while 
MDA levels were significantly increased after 24 h and 3 d. PEI8.3(Butyl(PEO-co-
PPO)1000)6.2 caused significantly decreased levels of GSH after 3 d and 7 d, but increased 
levels of MDA were found after 24 h. Thus, these two hydrophobic modifications appeared to 
prevent an acute oxidative stress response by increasing an adaptive antioxidant response 
indicated by the elevated activity of catalase in the lungs, after 24 h treatment (Fig 4C). The 
same antioxidative and protective effect was observed for low dose NZO (5 µg) in contrast to 
high oxidative stress and lipid peroxidation after treatment with the cytotoxic high dose NZO 
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(15 µg). In general, the toxicological benchmarks caused high levels of lipid peroxidation and 
the levels caused by all nanoplexes were in the same range like that of CS, in contrast to more 
than 1.5-fold higher levels after NZO (15 µg).  
 
Alteration of pulmonary leucocytes   
After 24 h treatment, all nanoplexes caused a strong PMN influx (>30 %), except for the 
standard PEI 25 kDa and the highly modified PEI(25)PEG(0.55)30. The two toxicological 
benchmark particles, CS and NZO, serving as positive control, and intended for causing a 
acute (after 24h) PMN influx around 40 % [14-16] Due to the dramatic toxic effect (loss in 
body weight and the alarming stressed behavior of the animals) we reduced the dose of NZO 
to 5 µg. This step eliminated the weight loss problem, but also reduced the inflammatory 
response (11.2 % PMN influx); therefore, we analyzed only the 24 h after treatment time 
point in case of NZO. The polyplexes PEI(25)-PEG(2)10 and PEI 8.3(Butyl(PEO-co-
PPO)1000)6.2 even exceeded the level of acute inflammation caused by CS (more than 40 % 
PMN). For all groups, a time-depending resolution of inflammation was observed, resulting 
after 7 d in PMN levels corresponding to the sham group (7 % PMN), except for 
PEI(25)PEG(2)10 treated lungs (12 % PMN). Regarding the inflammatory burden in the 
lungs over the 7 days, nanoplexes could be ranked in the following order of decreasing 
inflammatory potential: PEI(25)-PEG(2)10 < PEI8.3-(C16-C18-EO25)1.4 < PEI8.3-(Butyl-
(PEO-co-PPO)10000)6.2 < PEI8.3 kDa < PEI(25)-PEG(0.55)30 < PEI25 kDa.  
Alveolar Macrophages 
In comparison to the neutrophil response, no macrophage recruitment into the lungs was 
detected. In contrast, nanoplexes, in particular the PEI8.3 kDa derivates and PEI 25 kDa, even 
reduced the number of by BAL recovered alveolar macrophages to levels below 40 %. 
Interestingly, the depletion effect did recover till day 7 for CS but not for the nanoplexes 
(Fig.5).  
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Nanoplexes can be ranked, according to sustained depletion of alveolar macrophages in the 
following decreasing order: PEI8.3kDa > PEI8.3(C16-C18-EO25)1.4 > PEI25kDa > PEI8.3-
(Butyl-(PEO-co-PPO)1000)6.2 > PEI(25)-PEG(2)10 > PEI(25)-PEG(0.55)30.  
 
Figure 5: Correlation macrophages-neutrophils 
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Figure 5: Correlation macrophages-neutrophils  
Macrophage and neutrophil cell numbers [*10E6 cells] were calculated from broncho-alveolar 
lavage (BAL) where, for each animal in each group, 2 x 200 cells per cytospin (n=2/animal) were 
counted. Macrophage numbers (y1-axis, left, black squares) were correlated with neutrophil numbers 
(y2-axis, right, red circles) to determine respective treatment and each time point. Dashed lines 
(macrophages in black and neutrophils in red) approximately represent the baseline levels in all 
figures for better comparison. Values are given as mean±SD, n=8, asterisks indicate statistical 
significance compare to control animals wit ***p<0.001, **p<0.01, *p<0.05. 
 
Cytokine release 
 
The release of representative inflammatory cytokines into BALF was determined to further 
characterize the inflammatory and immunomodulatory effects of the nanoplexes. Overall, 
treatment with PEI(25)-PEG(2)10, PEI8.3(Butyl-(PEO-co-PPO)1000)6.2 and PEI8.3-(C16-
C18-EO25)1.4 caused the highest pro-inflammatory cytokine response. 24 h after treatment 
PEI(25)-PEG(2)10 polyplexes yielded high levels of CXCL10, G-CSF, and IL-6 with 
decreasing cytokine levels till day 3 and 7, being in good correlation with BAL PMN numbers 
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(supplementary material, S4). In the same way, but to a different extent CXCL1 peaks at day 
3 after treatment with PEI(25)-PEG(2)10 and PEI(25)-PEG(0.55)30. The low molecular 
weight PEI polyplexes showed a different cytokine pattern. PEI8.3(C16-C18-EO25)1.4 
caused elevated levels of IL-6, CXCL1, CXCL10, and G-CSF with a maximum after 3 d 
treatment in accordance to the PMN numbers in the BAL. After polyplex treatment with PEI 
8.3kDa only CXCL1 levels were increased, and this only acutely, PEI8.3(Butyl(PEO-co-
PPO)1000)6.2 polyplexes however caused high levels of G-CSF after 24 h treatment and 
elevated levels of CXCL10 after 7d. After 3d treatment, PEI(25)-PEG(2)10 caused high levels 
of TNF-α, in contrast to CS that caused elevated levels of TNF-α after 24 h and 7 d (Fig. 6A). 
 
Figure 6A: TNF-a release 
 
Figure 6B: CXCL 5 release 
 
 
  Chapter 6 
  166 
Figure 6C: MCP-1 release 
 
 
 
Figure 6:  Tumor necrosis factor- alpha (TNF-α) (A), CXCL5 (B), and monocyte chemotractic 
protein 1 (MCP-1/CCL-2) (C) release were determined in broncho-alveolar lavage fluid (BALF) for 
each animal in each group. Values are given as mean±SD, n=4 (TNF-α, CXCL5) and n=8 (MCP-1), 
and statistical significance compare to control animals are indicated by asterisks with ***p<0.001, 
*p<0.01, and *p<0.05. 
 
High levels of CXCL5 could be observed in a reverse manner compared to the neutrophils 
influx into the lungs, especially for PEI25 kDa, PEI(25)-PEG(055)30, PEI8.3 kDa, and 
PEI8.3(Butyl-(PEO-co-PPO)1000)6.2 nanoplexes (Fig. 6B). PEI(25)-PEG(2)10 caused the 
highest release of MCP-1 for all time points and all treatments with a maximum after 3d 
treatment in accordance to levels of total protein and LDH in the BALF, as well as losses of 
body weight. Low molecular weight PEI8.3 kDa and its fatty acid modification also caused 
high levels of MCP-1 with peaks after 3 d treatment, that were comparable to the high body 
weight loss and elevated levels of LDH in BALF of the animals in that group. In comparison, 
MCP-1 levels were highly elevated in mice treated with the high dose of NZO (15 µg) and 
reduced to control levels with the low dose of NZO (5 µg) (Fig6C). 
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Systemic effects 
 
A detailed hematological analysis was conduced in all mice to determine systemic effects 
related to the pulmonary nanoplex applications (supplementary material, S5). While white 
blood cell counts (WBC) remained unchanged over almost all nanoplex treatments and time 
points, as well as for the toxicological benchmarks, PEI25 kDa, PEI(25)-PEG(2)10, 
PEI8.3(C16-C18-EO25)1.4, and PEI8.3(Butyl(PEO-co-PPO)1000)6.2 polyplexes strongly 
decreased WBC counts after 24h treatment. Blood neutrophil numbers increased over time for 
PEI(25)-PEG(2)10 (after 24 h and 3 d), PEI8.3(C16-C18-EO25)1.4 (after 3 d), and 
PEI8.3(Butyl(PEO-co-PP)1000)6.2 (after 24 h) treatment. A comparable systemic response 
has not been observed for CS, but for NZO (15 µg) exposed mice after 24 h with 1.5-fold 
higher numbers of neutrophils in comparison to that of the nanoplexes. Red blood cell 
numbers (RBC) remained unaffected, except for the high dose NZO (15 µg), but platelet 
numbers (PLT) where increased after day 7 by PEI8.3(C16-C18-EO25)1.4 and PEI8.3(Butyl-
(PEO-co-PPO)1000)6.2 treatment to a similar extent as detected for NZO (15 µg). 
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6.5 Discussion 
 
This study comprehensively describes the side-effects of six different PEI-based/siGFP 
polyplexes in the mouse lungs, after intratracheal administration. Two series of PEI-based 
nanocarriers were investigated because of their promising properties regarding pulmonary 
application and safety/cytotoxicity profiles previously assessed in vitro [18, 21]. One series 
represents high molecular weight PEI (PEI25 kDa), with hydrophilic PEG modifications, and 
the other consists of low molecular weight PEI (PEI8.3 kDa), with two different hydrophobic 
PEG modifications (namely C16-C18-fatty acid residues and so-called Jeffamine™ residues). 
PEG modification has been discussed to reduce cytotoxicity of the high positively charged 
branched PEI 25 kDa [18, 22, 23], possibly by the PEG groups shielding the positive PEI 
amine groups, and thus resulting in a reduced zetapotential of the polyplex, which in turn, 
might lead to decreased interactions with negatively charged structures such as the cell 
membrane. In contrast, the hydrophobic modifications of the PEI backbone (represented by 
PEI8.3(C16-C18-EO25)1.4 and PEI8.3(Butyl-(PEO-co-PPO)1000)6.2 respectively) is 
thought to enhance transfection efficiency due to stronger membrane interactions [24, 25] 
and, therefore, to facilitate cellular uptake of the nanocomplexes and to counteract protein 
adsorption, which should ultimately enhance siRNA delivery to the cytosol. However, aiming 
pulmonary applications, these aspects need to be carefully investigated in the lungs. 
 
Toxicological analysis 
Table 1 summarized the observed side-effects caused by PEI-based nanocarriers and provides 
a recommendation for the possible clinical relevance of the respective future application in 
human. PEI-based nanocarriers caused an acute inflammatory response in the lungs, mostly 
independent of the modification and the molecular weight of PEI.  
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Table 1: Summary of the side-effects caused by the nanoplexes and their clinical relevance 
 
Polymer design 
(PEI-based nanocarriers) Applied dosis Side-effects 
Clinical 
relevance 
Cytotoxicity Inflammation 
Disruption of 
alveolar-
capillary 
barrier 
Oxidative stress 
(lung tissue) 
PMN (%)  in 
BALF 
backbone modification PEI siGFP 
BW LDH 
Depletion 
of 
macrophag
es 24h 3d 7d 
Cytokines in 
BALF 
Total 
protein IgM GSH MDA catalase 
Categories: 
 
 - : not suitable 
+/- : optimization 
+ : promising 
carrier 
 
PEI 25kDa non - +++ +++ 11 2 3 
CXCL1, 
CXCL5, 
CXCL10, G-CSF 
- - 
+++ ++ + - 
PEI 25kDa PEG(2kDa)10 +/- + + 44 33 12 
IL-6,CXCL1, 
CXCL10,  
G-CSF, MCP-1 
+++ +++ 
+++ ++ - +/- 
PEI 25kDa PEG(0.55kDa)30 - ++ +/- 15 5 8 IL-6, CXCL1, CXCL5,  G-CSF - - +++ ++ - + 
PEI8.3kDa non - ++ +++ 35 17 7 
IL-6, CXCL1, 
CXCL5,  G-CSF, 
MCP-1 
- - 
+++ ++ - - 
PEI8.3kDa (C16-C18-EO25)1.4 
+++ +++ +++ 
31 35 7 
IL-6, CXCL1, 
CXCL5, 
CXCL10,  
G-CSF, MCP-1 
++ +++ 
++ ++ ++ 
+/- 
PEI8.3kDa Butyl(PEO-co-PPO) 1000)6.2 
30µg 35µg 
+/- +++ ++ 
41 14 6 
IL-6, CXCL1, 
CXCL5, 
CXCL10,  
G-CSF, MCP-1 
+++ +++ 
++ + ++ 
+/- 
CS non 35µg - +/- + 39 20 7 TNF-a, CXCL1, G-CSF - - +++ ++ - n.a. 
NZO non 15µg +++ +++ ++ 50 n.d
. 
n.d
. 
IL-6, CXCL1, 
CXCL10,  
G-CSF, MCP-1 
+++ +++ 
+++ +++ - 
n.a. 
NZO non 5µg - - + 11 n.d
. 
n.d
. 
IL-6, CXCL1, 
G-CSF 
- - 
- - ++ 
n.a. 
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Table1: Summary of the side-effects caused by the nanoplexes and their clinical relevance 
Side-effects of nanoplexes and benchmark particles are shown after intratracheal instillation in mice. 
Effects are summarized over all three time points (24 h, 3 d, 7 d) regarding significant changes 
compare to control animals. (+++) indicates statistical significant changes with p<0.001, (++) 
p<0.01, (+) p<0.05, and (+/-) indicates changes which are not of statistical significant but different 
over time, (-) indicates no statistical changes over time in comparison to control animals. Clinical 
relevance is given in three categories with  (+) compound represents promising properties for clinical 
trials, efficacy should be tested, (+/-) compound needs optimization regarding inflammatory potential, 
should be tested for efficacy, (-) compound offers strong toxicity and needs more optimization to 
reduce toxicity, and (--) shows compound which are not of clinical relevance. 
 
Interestingly, PEI 25 kDa, the gold standard for transfection studies, offered the best pro-
inflammatory profile, but caused dramatic depletion of macrophages in the lungs reducing the 
number of BAL macrophages substantially to less than 60 % of control values. This 
phenomenon could be related to high cytotoxicity caused by strong apoptotic polymer 
properties [26, 27] and eventually also related to alterations in surfactant metabolism [28]. In 
contrast to the cytotoxic standard PEI 25 kDa, the highly PEGylated PEI(25)-PEG(0.55)30 
which also caused only minor inflammatory responses (15 % PMN influx vs. 1 % PMN ctrl.), 
showed no impairment of the BAL macrophage numbers, as compared to the sham or control 
group. However, then again reducing the grafting degree of PEG on PEI25kDa, increased the 
pro-inflammatory potential dramatically as also previously described in vitro [18].  
PEI(25)-PEG(2)10 caused a pronounced PMN recruitment after 24 h that lasted until day 3 
but was resolved by day 7. It also showed disruption of the alveolar-capillary barrier, resulting 
in high levels of total BAL protein and IgM till 7 d after treatment. Noteworthy PMN levels 
were as similar as seen for the highly toxic NZO (15 µg). In addition, PEI(25)-PEG(2)10 
caused over time a severe depletion of macrophage counts, an effect that in fact was not 
compensated by new recruitment of macrophages into the lungs, as would be expected 
because of the extremely high BAL levels of the monocyte chemotactic protein 1 (MCP-1) 
(Fig 6C).The three PEI 8.3 kDa containing polyplexes yielded a strong PMN influx after 24 h 
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together with a dramatic depletion of macrophage numbers over all time points. But since 
PEI8.3kDa polyplexes did not affect markers of epithelial – endothelial barrier integrity, a 
direct correlation between inflammation and barrier disruption seems unlikely. On the other 
hand the two hydrophobic modifications, PEI8.3(C16-C8-EO25)1.4 and PEI8.3(Butyl-(PEO-
co-PPO)1000)6.2 disrupted the epithelial – endothelial barrier. In addition, to the 
inflammatory effects observed for almost all polyplexes, we detected high levels of LDH in 
BALF and reduced levels of GSH in the lungs that indicated high cytotoxicity of PEI-based 
polymers and an imbalance in the redox-system in the lungs, but to a different extent. The 
most prominent release of LDH from lung cells was found for PEI8.3(C16-C18-EO25)1.4 at 
day 3, at this time point also the highest cytokine levels for IL6, CXCL10 and G-CSF have 
been detected accompanied by increased blood neutrophil numbers and body weight loss. A 
sequence indicating together with the till day 3 persisting local, pulmonary inflammation and 
macrophage depletion also severe systemic toxicity of PEI8.3(C16-C18-EO25)1.4 to that 
extent as for the toxicity benchmark NZO (15 µg) . 
Blood cell parameters were determined to obtain information about systemic effects that 
epidemiological studies have described, including sustained local lung inflammation that 
could cause adverse cardiovascular side effects [17]. High systemic inflammation was 
detected after treatment with the highly pro-inflammatory, and disruptive polymers like 
PEI(25)-PEG(2)10, PEI8.3(Butyl-(PEO-co-PPO)1000)6.2, and PEI8.3(C16-C18-EO25)1.4. 
In the same way, lymphocyte counts in the blood were decreased. Thus, these PEI-based 
nanocarriers should be applied with caution to the lungs, especially when considering 
repeated dosing. Lipid peroxidation occurred after all treatments, but was only moderate 
compared to NZO (15 µg). Interestingly, in the same way like low dose NZO (5 µg), we 
observed an acute antioxidant response indicated by high catalase activity after 24 h treatment 
with the two hydrophobic modification of PEI8.3 kDa. 
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Clinical relevance 
To the best of our knowledge this is the first study that evaluated the inflammatory potential 
of different PEI-based nanocarriers for siRNA delivery in the mouse lungs. Clinical progress 
of non-viral vector alternatives is still of huge research interest but has been stopped by their 
inflammatory potential [29] and their lower or lost transfection efficacy [30]. Thus, the urgent 
need of optimal polymer design is still high and the requirement of overcoming the 
inflammatory and immunomodulatory potential beside reduced cytotoxicity, but high efficacy 
has to be more concentrated. Regarding repeated dosing, the inflammatory potency is critical 
due to massive damage of tissue surrounding the target site of action, but e.g. when treating 
lung cancer in a specific way that only tumor cells are targeted the inflammatory potency 
could enhance the elimination of the dead tumor cells. With regard to inflammatory lung 
diseases like chronic obstructive pulmonary disease or viral infections of the lungs, the 
inflammatory potential is most critical because of additive effects which are to be expected 
and might lead to aggravation or exacerbation of the clinical picture.  
In summary, pulmonary application of all polyplexes caused considerable levels of acute lung 
inflammation accompanied by signs of oxidative stress, tissue damage, and systemic 
inflammation depending on the polymer structure. These results suggest that acute lung 
inflammation is one of the critical hurdles for pulmonary application of PEI based gene 
delivery systems. Optimized polymers with reduced cytotoxicity and inflammatory potential 
are required to proceed from bench to bedside. 
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6.6 Supplementary Material 
 
S1 Specifications of polymers and particles  
Poly(ethylene imine) copolymers of PEI 25kDa with hydrophilic modifications 
Branched poly(ethylene imine) (PEI) with a molecular weight of 25 kDa (Polymin, water-
free, 99 %), was a gift of BASF, Ludwigshafen. The poly(ethylene imine)-graft-poly(ethylene 
glycol) (PEI-PEG), with a PEG content of approximately 50 % (w/w), was synthesized as 
previously described [23, 31] by grafting linear PEG of 0.55 kDa and 2 kDa, respectively, 
onto branched PEI 25 kDa. These graft copolymers were designated using following 
nomenclature: PEI(25k)-g-PEG(x)n, where the numbers in brackets indicate the molecular 
weight of the PEI and the PEG block polymer in Daltons (25 k or x =0.55 k, or 2 k), and the 
index n is the average number of PEG blocks per PEI molecule. This number was calculated 
based on the 1H-NMR spectra, as described previously [31].  
Poly(ethylene imine) copolymers of PEI 8.3kDa with hydrophobic modifications 
PEI was synthesized by acid initiated polymerisation from aziridine using ethylendiamine as 
initiator. PEI 8.3 kDa was grafted by N-acylation with butyl-(poly(ethylenoxid-co-
propylenoxid) (Butyl-(PEO-co-PPO)1000) or palmity-/stearyl-polyethylenoxid (C16-C18-
EO)25 mixture, as previously described by [21]. The nomenclature of these polymers is as 
follows: PEI8.3-(x)n, where x represent the respective hydrophobic poylethylenoxid derivate 
and n is the average number of x units per PEI molecule, calculated on the basic of 1H-NMR 
spectra. 
Lung benchmark particles 
Crystalline silica, CS (Min-U-Sil 5), obtained from U.S. Silica Company, Berkerly Springs, 
WV, USA, had a median diameter of 1.7 µm and a BET surface area of 5.1 m²/g (declared on 
the datasheet from the manufacturer). Nanosized zinc oxide, NZO (CAS-No: 1314-13-2) was 
obtained from Alfa Aesar (A Johnson Matthey Company, Karlsruhe, Germany); the 
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manufacturer declares an average particle diameter of 70 nm and a BET surface area from 
12.1 m²/g. 
siRNA 
siRNA against green fluorescence protein (siGFP) was obtained from Metabion (München, 
Germany) with the following sequence – 
 for sense strand: 5’-GGCUACGUCCAGGAGCGCACC-dTdT  
and for antisense strand: 5’-GGUGCGCUCCUGGACGUAGCC-dTdT.  
 
S2  Calculation of the applied dose for lung benchmark particles and PEI polymers 
The applied doses for the toxicological benchmark particles was calculated from the 
respective particle surface area dose (BET), estimated to cause an acute pulmonary 
inflammatory response characterized by approximately 50 % BAL PMNs. The dose response 
calculation was performed according to Stoeger and Schmid 2009[32].  
In brief: a 50% PMN influx is caused by a surface area dose of 0.001m² per gram lung weight 
(mouse lung weight: 0.18 g, and BET surface area for crystalline silica: 5.1 m²/g and for 
NZO: 12.1 m²/g.). According to this, we applied 35 µg CS = (0.001 m²/g x 0.18 g)/ 5.1 m²/g) 
and 15 µg NZO = (0.001 m²/g x 0.18 g)/12.1 m²/g) to cause around 50 % PMN influx in the 
lungs. 
35 µg siGFP (2.39 nmol) was complexes with respective PEI polymer at N/P=6. Thus, we 
applied 28.43 µg of PEI to each animal which received PEI/siGFP polyplex.  
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S3 Detection limits for enzyme – linked immunosorbent assay 
The lower limits of detection were 4.32 pg/ml for G-CSF, 3.77 pg/ml for IFN-y, 5.39 pg/ml 
for Il-1a, 2.82 pg/ml for IL-6, 10.71 pg/ml for IL-10, 6.17 pg/ml for CXCL10, 0.69 pg/ml for 
CXCL1, 2.47 pg/ml for CXCL5, 16.56 pg/ml for Mip2, 0.6 pg/ml for TNF-a, 0.98 pg/ml for 
MCP-1, and 7.81 ng/ml for IgM. 
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S4:  Cytokine release    
     
24h  
  IL-1a  IL-6  IL-10  TNF-a  CXCL1  CXCL5  CXCL10 G-CSF  IFN-y 
  
  mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD  
ctrl.  63.9 5.5 2.8 0.0 35.1 18.9 1.1 0.4 14.8 2.5 8.6 7.7 5.5 1.6 3.5 0.9 9.8 5.6 
Aq.inj.  50.6 10.0 2.8 0.0 38.7 16.9 0.8 0.6 27.3 14.4 25.9 24.1 8.9 4.7 6.6 1.1 9.2 6.8 
Min-U-Sil 35µg  57.4 11.7 1.8 1.0 26.7 19.8 5.5 1.5 175.9 32.7 36.4 11.1 11.9 8.8 47.5 8.3 8.1 6.7 
ZnO 15µg  56.8 9.4 1356.1 990.6 46.2 33.1 2.4 1.2 349.9 183.8 5.1 4.5 108.3 34.1       1933.4 374.2 12.0 1.0 
ZnO 5µg  29.0 10.3 4.7 3.3 10.6 6.4 1.2 0.7 25.3 9.6 3.1 1.0 6.2 0.0 9.0 7.1 3.8 0.0 
PEI 25kDa 43.0 3.8 2.8 0.0 14.6 6.6 0.9 0.4 23.7 4.8 16.1 19.2 8.7 1.7 6.0 2.9 8.3 7.8 
PEI(25)-PEG(2)10 22.3 6.2 228.1 54.0 10.7 7.9 1.2 0.45 137.7 42.9 2.5 0.0 1087.8 163.4   1888.8 242.8 3.8 0.0 
PEI(25)-PEG(0.55)30 54.1 15.7 7.6 3.8 23.8 14.7 0.9 0.5 71.1 11.3 13.5 5.0 7.0 1.4 8.7 2.3 6.6 4.9 
PEI8.3  50.4 16.6 8.8 8.7 18.6 5.3 1.5 0.2 220.5 139.7 39.6 20.7 6.7 5.0 48.6 22.3 5.0 2.2 
PEI8.3(C16-C18-EO25)1.4 37.0 13.7 36.3 38.5 12.8 9.5 1.4 0.5 116.0 29.4 16.3 14.3 118.0 135.1 215.0 258.3 3.4 0.6 
 
PEI8.3 
(Butyl-(PEO-co-PPO)1000)6.244.7 15.3 69.5 36.2 12.8 8.1 1.1 0.2 113.8 47.8 10.8 10.6 90.5 101.9 1217.2 608.2 4.0 0.4 
           
3d                   
Min-U-Sil 35µg  43.8 12.4 2.8 0.0 14.9 9.4 0.9 0.6 92.7 10.4 41.6 13.8 6.2 0.0 10.6 2.8 3.8 0.0 
PEI 25kDa 74.2 12.2 2.3 1.7 49.0 21.4 1.0 0.5 32.2 4.7 14.9 10.8 20.2 12.2 2.8 0.2 15.4 4.7 
PEI(25)-PEG(2)10 12.3 5.7 203.8 87.2 5.3 4.0 4.7 1.4 685.8 125.8 84.1 47.0 561.1 183.7 487.6 97.0 5.9 2.9 
PEI(25)-PEG(0.55)30 63.9 46.2 3.9 0.0 70.5 55.5 0.7 0.0 106.6 52.5 36.9 0.8 21.7 8.4 3.6 1.2 14.6 9.0 
PEI8.3  82.5 44.8 4.2 2.5 32.7 16.7 0.6 0.1 134.4 9.8 45.8 15.9 76.7 23.9 25.5 17.7 8.5 5.2 
PEI8.3(C16-C18-EO25)1.4 14.7 6.1 761.9 758.8 6.8 6.8 2.1 1.3 433.0 243.5 8.6 5.2 1050.3 379.8 1629.5 726.0 5.0 1.0 
PEI8.3 
(Butyl-(PEO-co-PPO)1000)6.217.0 4.8 6.0 4.7 10.7 2.6 0.7 0.0 231.8 98.6 77.9 42.4 74.8 42.0 39.8 19.7 5.1 0.9 
                  
7d           
Min-U-Sil 35µg  48.0 35.9 2.8 0.0 14.0 9.8 25.9 43.6 53.5 15.6 30.2 27.3 6.2 0.0 8.7 8.1 3.8 0.6 
PEI 25kDa 54.2 7.5 2.8 0.0 26.9 22.9 0.7 0.1 39.0 14.7 54.9 28.0 6.2 0.0 4.2 1.8 5.5 2.9 
PEI(25)-PEG(2)10 14.3 6.1 4.1 2.0 5.1 4.3 1.6 0.6 333.9 116.0 51.7 29.0 99.0 31.7 25.4 8.0 3.8 0.0 
PEI(25)-PEG(0.55)30 47.3 23.8 2.8 0.0 8.7 6.5 0.8 0.5 42.2 22.5 37.1 40.3 8.9 4.8 4.7 2.5 6.3 3.0 
PEI8.3  55.8 14.2 2.8 0.0 27.0 11.0 0.6 0.3 34.5 5.0 22.1 14.1 6.2 0.0 4.5 1.1 3.8 0.0 
PEI8.3(C16-C18-EO25)1.4 20.6 17.5 2.8 0.0 7.0 8.6 0.4 0.2 22.3 3.6 2.5 0.0 18.5 11.6 10.5 6.7 3.8 0.0 
PEI8.3 
(Butyl-(PEO-co-PPO)1000)6.229.2 17.9 2.6 0.4 17.9 16.9 1.3 1.1 32.6 17.1 13.5 12.2 67.6 33.9 6.0 0.9 3.8 0.0 
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S4: Cytokine release was determined in broncho-alveolar lavage fluid (BALF) by multiplex-based ELISA technique analyzing 10 characteristically pro- and 
antiinflammatory cytokines. Values are given in pg/ml for each cytokine as mean±SD, n=4. Values for Cxcl2 (Mip2) were below the detection limit of the kit used 
and not shown in the table. Bold values represent statistically significant values compare to control and sham groups, p-values are at least <0.05.  
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S5:  Blood parameters 
 
S5 A  White blood cell parameters 
 
   WBC    Neutrophils              Lymphocytes             Monocytes 
 
(x10E03 cells/µL)          (%)  (x10E03 cells/µL)            (%)   (x10E03 cells/µL)            (%)  (x10E03 cells/µL) 
  
24h   mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
 
ctrl.   6.5 1.5 12.9 2.7 0.8 0.2 82.9 2.8 5.4 1.3 1.7 0.6 0.1 0.1 
Aq.inj.   7.1 1.3 13.6 3.2 1.0 0.2 82.1 3.7 5.8 1.1 1.5 0.7 0.1 0.1 
CS 35µg   5.2 1.0 17.7 3.1 0.9 0.2 78.2 3.1 4.1 0.8 1.3 0.4 0.1 0.0 
NZO 15µg   4.4 1.7 40.8 13.2 1.9 1.2 54.2 13.5 2.2 0.7 2.0 1.6 0.1 0.1 
NZO  5µg   4.7 1.4 17.4 3.3 0.8 0.2 78.3 3.5 3.7 1.2 1.4 0.5 0.1. 0.0 
PEI 25kDa  4.5 1.1 14.4 2.8 0.7 0.2 81.6 2.3 3.7 0.9 1.1 0.3 0.1 0.0 
PEI(25)-PEG(2)10 4.3 1.9 21.6 4.4 0.9 0.2 73.3 4.7 3.2 1.6 1.8 1.0 0.1 0.1 
PEI(25)-PEG(0.55)30 5.1 1.7 16.4 2.2 0.8 0.3 79.6 2.3 4.1 1.4 1.3 0.3 0.1 0.0 
PEI8.3kDa  4.9 1.8 15.6 5.4 0.7 0.3 79.9 5.8 3.9 1.6 1.3 0.5 0.1 0.0 
PEI8.3- 
(C16-C18-EO25)1.4 4.5 1.0 14.1 4.6 0.6 0.2 81.4 4.7 3.6 0.8 1.4 0.4 0.1 0.0 
PEI8.3(Butyl- 
(PEO-co-PPO)1000)6.2 3.4 1.1 24.7 8.0 0.8 0.2 70.9 8.3 2.4 0.9 1.5 0.3 0.1 0.0 
3d                 
CS 35µg   5.4 1.6 16.0 3.7 0.9 0.4 79.3 3.7 4.2 1.2 2.2 0.7 0.1 0.0 
PEI 25kDa  5.5 1.3 15.2 6.6 0.8 0.4 80.7 6.8 4.4 1.1 1.6 0.4 0.1 0.0 
PEI(25)-PEG(2)10 5.5 1.2 21.0 4.2 1.1 0.2 74.6 4.8 4.2 1.1 2.1 0.7 0.1 0.0 
PEI(25)-PEG(0.55)30 6.2 1.5 16.4 2.6 1.0 0.2 79.2 2.7 4.9 1.3 2.0 0.4 0.1 0.0 
PEI8.3kDa  5.1 1.1 13.9 2.6 0.7 0.2 82.1 3.1 4.2 0.9 1.6 0.3 0.1 0.0 
PEI8.3- 
(C16-C18-EO25)1.4 6.0 2.0 26.8 6.9 1.5 0.5 67.2 7.8 3.8 1.6 2.0 0.5 0.1 0.1 
PEI8.3(Butyl- 
(PEO-co-PPO)1000)6.2 6.0 1.6 18.1 3.6 1.1 0.5 77.8 3.9 4.6 1.1 1.7 0.5 0.1 0.0 
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WBC    Neutrophils              Lymphocytes             Monocytes 
 
(x10E03 cells/µL)          (%)  (x10E03 cells/µL)            (%)   (x10E03 cells/µL)            (%)  (x10E03 cells/µL) 
  
7d   mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
 
CS 35µg   5.5 2.8 17.0 5.8 0.8 0.3 78.7 6.2 4.5 2.5 1.5 0.4 0.1 0.1 
PEI 25kDa/  5.2 1.3 14.8 3.5 0.8 0.3 80.8 3.5 4.2 1.0 1.8 0.7 0.1 0.0 
PEI(25)-PEG(2)10 4.9 1.6 16.7 3.2 0.8 0.3 79.4 3.0 3.9 1.2 1.7 0.8 0.1 0.1 
PEI(25)-PEG(0.55)30 6.0 2.0 13.1 3.2 0.8 0.4 82.7 3.2 4.9 1.6 1.7 0.4 0.1 0.1 
PEI8.3kDa  5.3 1.3 19.0 4.1 1.0 0.3 77.2 3.9 4.1 1.0 1.6 0.3 0.1 0.0 
PEI8.3- 
(C16-C18-EO25)1.4 5.9 1.7 20.2 2.1 1.2 0.4 75.3 2.4 4.4 1.2 2.3 0.4 0.1 0.1 
PEI8.3(Butyl- 
(PEO-co-PPO)1000)6.2 5.5 1.9 15.9 4.2 0.8 0.2 79.3 4.6 4.4 1.8 1.8 0.4 0.1 0.1 
 
 
S5 A:  White blood cell parameters 
White blood cell (WBC) parameters are given as mean±SD, n=8 in total numbers [10E3 cells/ µl] and for the different cell populations in percent 
[%] and total cell number [*10E3 cells/ µl]. Blood parameters were determined from hole blood after respective time point for each animal in each 
group using ADVIA 120 Hematology System (Siemens Healthcare Diagnostics, Deerfield, USA). Bold values represent statistical significance, 
p<0.05 compare to control group. 
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S5 B:  Red blood cell and platelet numbers 
 
      RBC (x10E06 cells/µL)  PLT (x10E03 cells/µL) 
24h      mean  SD   mean  SD 
ctrl.      9.9  0.4   965.3  102.7 
Aq.inj.      10.2  0.3   1068.4  67.6  
CS 35µg      10.2  0.3   1008.3  108.9        
NZO 15µg      11.0  1.2   1210.3  164.2        
NZO   5µg      10.1  0.3   979.0  90.2        
PEI 25kDa     9.5  0.5   962.9  104.5        
PEI(25)-PEG(2)10    10.1  0.8   995.3  97.9        
PEI(25)-PEG(0.55)30   10.2  0.3   1061.8  69.1 
PEI8.3kDa     9.3  1.1   951.0  168.7 
PEI8.3(C16-C18-EO25)1.4   9.8  0.3   1049.4  120.1 
PEI8.3(Butyl-(PEO-co-PPO)1000)6.2 10.1  0.4   1077.5  97.9     
3d     
CS 35µg      10.0  0.3   969.3  66.1 
PEI 25kDa     9.9  0.2   1071.5  117.3 
PEI(25)-PEG(2)10    9.8  0.2   1063.4  65.1 
PEI(25)-PEG(0.55)30   9.8  0.3   1015.5  100.9 
PEI8.3kDa     10.0  0.3   1085.6  115.6 
PEI8.3(C16-C18-EO25)1.4   10.3  0.7   912.1  228.4 
PEI8.3(Butyl-(PEO-co-PPO)1000)6.2 9.7  0.2   1055.4  57.5    
7d        
CS 35µg      10.1  0.3   1054.5  89.4 
PEI 25kDa     9.8  0.3   1013.8  50.2 
PEI(25)-PEG(2)10    9.9  0.3   985.8  164.0 
PEI(25)-PEG(0.55)30   9.8  0.6   991.5  129.8 
PEI8.3kDa     10.0  0.3   1058.5  83.6 
PEI8.3(C16-C18-EO25)1.4   9.4  0.2   1233.2  141.8 
PEI8.3(Butyl-(PEO-co-PPO)1000)6.2 10.0  0.2   1275.9  199.2 
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S5 B: Red blood cell parameters 
Red blood cell (RBC) parameters are given as mean±SD, n=8. Red blood cell (RBC) and platetels (PLT) counts are given in 10E3 cells/ µl. Blood parameters 
were determined from hole blood after respective time point for each animal in each group using ADVIA 120 Hematology System (Siemens Healthcare 
Diagnostics, Deerfield, USA). Bold values represent statistical significance, p<0.05 compare to control group. 
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7.1 Abstract 
 
Pulmonary siRNA delivery offers a new way to treat various lung diseases. Poly(ethylene 
imines) (PEIs) are promising cationic nanocarriers and various modifications are still under 
investigations to improve their cytotoxicity and efficacy for siRNA delivery. 
In this study, we analyzed two series of PEI – based nanocomplexes, after in-vitro pre-
selection, for pulmonary siRNA delivery. Ubiquitously enhanced green fluorescent protein 
(EGFP) expressing transgenic mice were intratracheally instilled with 35 µg siRNA 
complexed with the different PEI nanocarriers. Knock down of EGFP expression was 
analyzed by flow cytometry and fluorescence microscopy 5 days post instillation. 
Three of the six polyplexes caused significant knock down of EGFP expression, but only the 
fatty acid modified low molecular weight PEI 8.3 kDa (C16-C18-EO25)1.4 specifically 
reduced EGFP expression in CD45+ leucocytes and CD11b-/CD11+ lung macrophages. 
The hydrophobic/hydrophilic balance of the non-viral vector system appears to be one 
approach for safer and improved siRNA therapeutics for successful pulmonary siRNA 
delivery. 
 
 
Key words: siRNA delivery, EGFP, intratracheal instillation, PEI 
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7.2 Background 
 
RNA interference (RNAi) based therapeutics represent a fundamentally new way to treat 
human disease by addressing targets, that could not yet targeted with tools of the existing 
medicines [1, 2]. The nobel-prize winning discovery of RNAi in the worm Caenorhabditis 
elegans in 1998 [3], and the subsequent demonstration that RNAi operates in mammalian 
cells revolutionized the current understanding of endogenous mechanisms of gene regulation 
and provided powerful new tools for biological research and drug discovery.  
The lung is becoming an attractive target organ to systemic and local treatment of various 
lung disorders using small interfering RNAs (siRNA), because of the enormously increasing 
number of pulmonary diseases with high mortality and morbidity. In addition, pulmonary 
targeting could be achieved by invasive (intravenous injection) as well as non-invasive 
(intranasal, intratracheal and inhalative) application. Delivery of siRNAs to the lungs has been 
described via different routes, using different delivery strategies [4-8]. The clinical success of 
siRNA-mediated treatment is still crucial due to safety and efficacy reasons.  
In this study, we tested a wide range of different non-viral polycationic nanocarriers, with 
promising in vitro properties for siRNA delivery to the lungs [9-11], for their in vivo 
performance in mouse lungs. A lot of non-viral approaches have been made to successfully 
deliver siRNA. Poly(ethylene imine) (PEI) represents the most extensively studied cationic 
polymer for non-viral gene delivery, especially when focusing the lungs [6, 12-18]. Many 
factors such as the molecular weight, degree of grafting, ionic strength of the solution, zeta 
potential, particle size, cationic charge density, molecular structure, sequence and 
conformational flexibility influence the transfection efficiency and cytotoxicity of such non-
viral vector systems. PEI polymers with different molecular weights and branching degrees as 
well as several modifications on the PEI backbone are still under intense investigations for 
successful in vivo use [4, 7, 19-21]. We analyzed the efficacy of two series of PEI-
(polyethylene glycol) (PEG) copolymers, one series comprises of the high molecular weight 
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PEI 25 kDa with two different hydrophilic PEG modifications and another series of the low 
molecular weight PEI8.3 kDa with two different hydrophobic PEG modifications. We 
hypothesized that the modification of the PEI backbone improves siRNA delivery in the 
lungs. The hydrophilic PEG modifications have been shown in vitro to reduce cytotoxicity 
[11, 22, 23], protein adsorption [24, 25] and it is intended to prolong the half life of the 
polyplexes in vivo due to minimizing recognition of the innate immune system and especially 
reducing macrophage clearance [26]. The hydrophobic PEG modifications built more 
amphiphilic polymer structures that appear to enhance transfection efficacy due to better 
interaction with the cell membrane and therefore improved endocytotic uptake [27-30]. 
Therefore, we intratracheal instilled siRNA against enhanced green fluorescent protein 
(siEGFP) complexed with six different PEI-PEG copolymers into EGFP transgenic mice and 
evaluated the knock down efficiency via flow cytometry and fluorescent microscopy. 
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7.3 Methods 
 
Materials 
Synthesis of the polymers and polyplex formation are described in the supplementary 
material, S1. 
Particle size distribution 
The hydrodynamic diameters of the polyplexes were analyzed by dynamic light scattering 
(DLS) measurements using HPPS Malvern Instruments (Malvern Instruments, Herrenberg, 
Germany).  
In vitro cytotoxicity  
Experiments were carried out using murine alveolar epithelial – like type II cells (LA4; 
ATCC No. CCL-196TM) and murine alveolar macrophages, (MH-S; ATCC No. CRL-2019). 
Cell viability was determined using the Cell Proliferation Reagent WST-1 (Roche 
Diagnostics, Germany) according to [31]. Briefly, LA4 and MH-S cells were seeded at a 
density of 0.25*10-6 cells/well in 24-well-plate in cell culture medium containing FBS and 
grown overnight in an incubator at 37 ° C and 5 % CO2. Medium was replaced before cells 
were treated. Cells were incubated with three different polymer concentrations (0.5 µg/ml, 5 
µg/ml, 50 µg/ml corresponding to PEI concentration). After 24 h treatment, the relative 
viability [%] related to control samples (untreated cells) was calculated by following 
equation: Cell viability= (ODsample/ODcontrol) * 100.  
Lactate dehydrogenase (LDH) was determined using Cytotoxicity Detection Kit (Roche 
Diagnostics, Germany) according to the manufacturer’s protocol. Briefly, cells were cultured 
and seeded like that in the WST-1 assay. To avoid interference with assay reagents, the cell 
culture medium was replaced with serum-reduced (2 % FBS) cell culture medium without 
antibiotics before addition of polymers. LDH kinetic was observed after 0.5 h, 1 h, 2 h, 4 h, 6 
h, and 24 h exposure time. The LDH concentration in the cell culture supernatant was 
determined spectrophotometrically at a wavelength of 492 nm using an ELISA reader 
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(Labsystems iEMS Reader MF). Cells treated with 2 % (w/v) Triton X-100 served as a 
control according to the manufacturer’s protocol and revealed maximum LDH release (100 
%) corresponding to ODhigh control. The relative LDH release is defined by the ratio of LDH 
released over total LDH (high control) and was calculated as follows: Cytotoxicity [%] = 
(ODsample – ODlow control)/(ODhigh control – ODlow control) *100, where ODlow control was the 
absorption from the supernatant of the untreated cells. Less than 10 % LDH release was 
regarded as non-toxic effect level in our experiments according to [32].  
In vitro cytokine release 
Ten inflammatory cytokines/chemokines were simultaneously detected in the cell culture 
supernatant using a multiplexing Luminex assay (Linco Research, St. Charles, MO). In this 
study, the secretion of IL-1α, IL-6, TNF−α, G-CSF, CXCL1, CXCL5, CXCL10, IFN-y, IL-
10, and CCL3 was measured. The assay was performed as described previously [33] and 
mean fluorescence intensity (MFI) was detected by the Multiplex plate reader (Luminex 
System, Bio-Rad Laboratories, Germany) for each sample (50 µl) with a minimum of 100 
beads per region being analyzed. The raw data (MFI) were captured using the Multiplex plate 
reader software (Bioplex Manager, Version 2.0). For data analysis, a 5-parameter logistic 
curve fit was applied to each standard curve and sample.  
Animal experiments 
Animal experiments were carried out according to the German law of protection of animal life 
and were approved by an external review committee for laboratory animal care.  
Eight-to-twelve-weeks old, female C57BL/6J-Tg(Bos/GFP)CaBaBii011Dcm (Helmholtz 
Zentrum München, Germany) mice were intraperitoneal (i.p.) injected with a mixture of 
Medetomidin (500 µg/kg body weight), Midazolam (5 mg/kg body weight), and Fentanyl (50 
µg/kg body weight) and fixed in a supine position on a 60 ° incline board by holding their 
upper incisor teeth. The tongue was gently extended using coated tweezers. Mice were 
intubated through mouth and trachea using the flexible tube of a 24-gauge catheter (BD 
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Insyte, Becton Dickinson GmbH, Heidelberg, Germany). Polyplexes (50 µl) were instilled 
followed by 100 µl air. Directly after instillation mice were subcutaneously injected with the 
antagonist mixture of Atipamezol (2.5 mg/kg body weight), Flumazenil (500 µg/kg body 
weight), and Naloxon (1200 µg/kg body weight) to recover from anaesthesia within 5-10 min. 
Mice were treated with siRNA polyplexes for five days.  
Lung homogenate for flow cytometer analysis 
Mice were sacrificed with an overdose of a mixture of ketamine and xylacin (1 %/0.1 %) and 
exsanguinated via vena cava caudalis. Lungs were perfused with 20 ml of sterile HBSS until 
free of blood by visual inspection. The right lungs were fixed, carefully removed and 
transferred into petri dishes containing 0.7 mg/ml collagenase A (Roche, Germany) and 1 
mg/ml DNAse I (Roche, Germany) in RPMI-1640 medium (Biochrom AG, Germany). Lungs 
were minced and cut into small pieces, incubated at 37 ° C for 45 min in a humidified 
atmosphere containing 5 % CO2. Cell aggregates were dispersed by repeated passage through 
a syringe, and filtered through a 200 µm falcon and a 40 µm cell strainer (BD Biosciences), to 
obtain single cell suspension. Subsequently, cells were rinsed with HBSS and PBS containing 
2 mM EDTA and 0.5 % FCS. 
Flow cytometer analysis  
 
For flow cytometer analysis cells were resuspended in PBS containing 2 mM EDTA and 0.5 
% FCS and Fc receptor-mediated and non-specific antibody binding was blocked by addition 
of excess non-specific immunoglobulin (Fc-block, CD16/CD32 purified, clone 2.4G2, BD 
Pharmigen). The following monoclonal antibodies were used at appropriate dilutions for cell 
specific staining: CD11c-PE (HL3, BD Pharmingen), CD11b-APC (M1/70, BD Pharmingen), 
GR-1-PE (RB6-8C5, Biolegend), CD19-PE (1D3, BD Pharmingen), CD45-biotinylated (30-
F11, BD Pharmigen), CD-4-PE (RM4-5, BD Pharmigen), CD-8a-PE (Ly-2, 53, -67, BD 
Pharmigen), CD-19-PE (1D3, BD Pharmigen), MHC II – biotinylated (2G9, BD 
Pharmingen). Staining was performed at 4 ° C in the dark for 30 min. After staining, cells 
  Chapter 7 
 192 
were washed twice in PBS containing 2 mM EDTA and 0.5 % FCS. Biotinylated primary 
antibodies were further incubated for 5 min with APC-conjugated streptavidin (BD 
Pharmingen), followed by one additional wash with PBS containing 2 mM EDTA and 0.5 % 
FCS. A FACSCalibur flow cytometer (BD Biosciences) was used for flow cytometric 
characterization of cell populations. The BD Cell quest Pro software package was used for 
data analysis (BD Biosciences). 
Lung histology 
Left lungs were inflated with 4 % paraformaldehyde (PFA), pH 7.4 via the trachea after 
dissection and fixed in 4 % PFA, pH 7.4 solution before they were paraffin-embedded using 
standard procedure. Paraffin sections (3 µm) were deparaffinized and stained with 4’,6-
diamindino-2-phenylindole (DAPI) (Molecular Probes, Invitrogen, Germany) for fluorescent 
detection. A total of 6 individual images from different regions of the lung per animal were 
analyzed and representative images are shown. 
Fluorescent microscopy 
A Olympus BX51 fluorescent microscope was used to determine the EGFP expression in lung 
tissue slides. For excitation of EGFP fluorescence, an excitation filter with a wavelength of 
470/40 x was used and fluorescence emission was detected using a 525/50 m long-pass filter. 
DAPI was detected using a 350/50 x excitation filter and fluorescence was detected by a 
460/50 m long-pass filter. All of the fluorescent images were acquired with the same settings 
with respect to exposure time using CellF Imaging Software for Fluorescence microscopy 
(Olympus Deutschland GmbH, Hamburg, Germany). 
Statistics 
All values are presented as mean±standard error (SEM) of four to six animals per group (n=4-
6) unless otherwise stated. Significant differences between two groups were evaluated by 
Student’s t-test, or between more than two groups by one-way ANOVA, followed by Tukey’s 
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or Dunnett’s multiple comparison test. Statistical analysis was performed using the program, 
GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA 92037 USA). 
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7.4 Results  
 
Particle size distribution 
Particle size distribution was determined because nanocomplex size limits the desired uptake 
and transfection efficiency in the target cells. Nanocomplexes showed average diameters in 
the range of 100nm to highly aggregated nanocomplexes with an average diameter of 600 nm 
(Fig 1). Interestingly, the highly positively-charged polymer, PEI25 kDa, yielded the smallest 
nanocomplexes with an average diameter of 91.5 ±84 nm. In contrast, the low molecular 
weight PEI8.3 kDa formed the largest and most polydisperse nanocomplexes with an average 
diameter of 596.3 ±104.5 nm, indicating a strong agglomeration in water. The two 
hydrophobic modifications of PEI8.3 kDa formed nanocomplexes in an acceptable size range 
of 120-200 nm. The excessive PEGylated modification of PEI25kDa, PEI(25)-PEG(0.55)30, 
caused high agglomeration, with average diameters around 400nm, whereas the more 
moderately PEGylated PEI(25)-PEG(2)10 was characterized by a more preferable size 
spectrum of 110.6 ± 92.8 nm.  
Figure 1: Particle size distribution 
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Figure1: Particle size distribution 
Hydrodynamic diameter (z-ave, black bars) and polydispersity index (PDI, blue circles) were 
determined using dynamic light scattering (DLS) measurements. Values are given as mean ± SD for 
each treatment group, measurements were repeated three times. All polyplex solutions were prepared 
in Aqua ad injectabilia (Braun AG, Melsung, Germany) as described in supplement material, S1. 
 
In vitro cytotoxicity 
Cell viability was tested for free polymers after 24 h treatment of two alveolar cell lines 
representing the pneumocytes type II (LA4) and macrophages (MH-S).  
This in vitro testing represents a worst case scenario because it is well described in the 
literature that after release of siRNA and also during complex formation a huge amount of 
free polymer remains in the cytoplasm [34], and the free PEI polymer seemed to be necessary 
for optimal siRNA delivery [35] and in addition, the toxic part of the polyplexes used in vivo 
is the polycationic carrier. Cell viability was reduced in a dose-dependent manner for all 
polymers (supplementary material, S2) and the hydrophilic PEG modified PEI-PEG 
copolymers strongly reduced the cytotoxicity in vitro as previously described [10, 11, 23]. 
However, the hydrophobic modification of the PEI8.3 kDa showed comparable cytotoxicity 
as seen for PEI 8.3 kDa, but still lower than PEI 25 kDa, and strong membrane interaction 
indicated by a huge amount of lactate dehydrogenase (LDH) in the supernatant in a time-
dependent manner in both cell lines tested (Fig.2). The stronger membrane disruption could 
be explained by the more hydrophobic properties of these polymers that enhance the 
interaction with the negatively charge phospholipids in the cell membrane.  
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Figure 2: LDH kinetic  
 
Figure 2: LDH kinetic 
LDH release was determined using Cytotoxicity detection kit (Roche) after 0.5 h, 1 h, 2 h, 4 h, 6 h, and 
24 h polymer treatment in LA4 cells (left) and MH-s cells (right). For each time point three 
independent experiments were carried out and the values were expressed as mean ± SD. Less than 
10% LDH release were regarded as non-toxic effect level in our experiments [32]. Significant 
difference to control was presented as asterisk with *p<0.05, **p<0.01; ***p<0.0001. It has to 
mentioned that data for PEI25 kDa, PEI(25)-PEG(2)10, and PEI(25)-PEG(0.55)30 already published 
by Beyerle et al. [10].. 
 
Cytokine release in vitro 
Beside the cytotoxic effect, the proinflammatory effect of such nanocarriers is crucial, 
especially when nanocarriers were directly applied to the lungs. Thus, the supernatants of the 
cell viability testing in the two alveolar cell lines (LA4 and MH-S) were further analyzed to 
determine the release of ten characteristically inflammatory cytokines. As recently described 
[10] the reduced cytotoxicity of the hydrophilic PEI-PEG copolymers is on cost of a moderate 
proinflammatory potential of these polymers, more prominent for PEI(25)-PEG(2)10 than 
PEI(25)-PEG(0.55)30. The low molecular weight PEI 8.3 kDa and its hydrophobic 
modifications showed only slightly increased levels of CXCL1, CXCL10, and IL-6 in LA4 
and MH-S, but without any statistical significance (Table 1).  
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Table 1:  Cytokine release 
A 
LA4   CXCL1 CXCL10 G-CSF IL-6  
fold change  mean SD mean SD mean SD mean SD 
PEI25kDa  
0.5µg/ml  0.41 0.03 0.62 0.26 0.31 0.00 8.68 2.83 
5µg/ml   0.39 0.05 1.11 0.15 0.24 0.09 6.24 1.67 
50µg/ml  0.11 0.03 2.88 0.08 0.28 0.04 1.29 0.21 
PEI(25)-PEG(2)10  
0.5µg/ml  1.10 0.48 0.79 0.44 0.41 0.44 1.49 0.50 
5µg/ml   4.36 0.41 2.38 2.80 12.29 10.92 9.72 8.38 
50µg/ml  4.32 0.37 2.34 2.80 8.94 0.39 7.25 3.62 
PEI(25)-PEG(0.55)30 
0.5µg/ml  0.51 0.00 2.23 2.19 0.31 0.00 15.29 4.19 
5µg/ml   0.52 0.24 38.01 42.11 0.31 0.00 6.60 5.29 
50µg/ml  0.60 0.37 9.59 8.53 0.31 0.00 4.76 2.46 
PEI8.3kDa  
0.5µg/ml  0.55 0.25 b.d.l.  b.d.l.  b.d.l.  
5µg/ml   0.65 0.20 b.d.l.  b.d.l.  b.d.l.  
50µg/ml  1.94 1.00 b.d.l.  b.d.l.  b.d.l.  
PEI8.3(C16-C18-EO25)1.4  
0.5µg/ml  0.50 0.53 b.d.l.  b.d.l.  b.d.l.  
5µg/ml   0.61  b.d.l.  b.d.l.  b.d.l.  
50µg/ml  1.52  b.d.l.  b.d.l.  b.d.l.  
PEI8.3(Butyl-(PEO-co-PPO)1000)6.2  
0.5µg/ml  0.83 0.40 b.d.l.  b.d.l.  b.d.l.  
5µg/ml   2.35 0.55 b.d.l.  b.d.l.  b.d.l.  
50µg/ml  0.34 0.21 b.d.l.  b.d.l.  b.d.l.  
B 
MH-S   CXCL1 CXCL10 G-CSF IL-6  
fold change  mean SD mean SD mean SD mean SD 
PEI25kDa  
0.5µg/ml  0.54 0.06 b.d.l.  4.71 2.78 1.23 0.07 
5µg/ml   0.76 0.11 b.d.l.  5.10 5.52 1.83 0.57 
50µg/ml  0.64 0.23 b.d.l.  10.23 12.34 2.13 1.27 
PEI(25)-PEG(2)10  
0.5µg/ml  1.76 1.24 1.03 0.03 5.47 2.98 0.50 0.01 
5µg/ml   2.91 1.07 1.03 0.01 36.12 31.83 17.25 17.34 
50µg/ml  2.01  1.03  1.79  1.00  
PEI(25)-PEG(0.55)30 
0.5µg/ml  0.48 0.01 b.d.l.  4.34 4.79 1.27 0.80 
5µg/ml   0.61 0.13 b.d.l.  4.73 0.93 1.57 0.40 
50µg/ml  0.77 0.26 b.d.l.  1.24 0.21 1.20 0.57 
PEI8.3kDa  
0.5µg/ml  0.86 0.10 0.79 0.50 2.41 3.40 1.54 0.94 
5µg/ml   1.11 0.49 1.29 1.12 1.40 1.63 1.60 0.60 
50µg/ml  0.91 0.45 1.12 0.65 1.61 1.12 2.17 0.41 
PEI8.3(C16-C18-EO25)1.4  
0.5µg/ml  0.51 0.45 1.78 0.74 b.d.l.  b.d.l.  
5µg/ml   1.52  1.51  b.d.l.  b.d.l.  
50µg/ml  0.14  0.33  b.d.l.  b.d.l.  
PEI8.3(Butyl-(PEO-co-PPO)1000)6.2  
0.5µg/ml  0.85 0.58 1.44 0.94 b.d.l.  1.50 0.51 
5µg/ml   1.47 0.27 1.44 0.52 b.d.l.  2.01 0.25 
50µg/ml  0.76 0.75 2.71 3.21 b.d.l.  b.d.l. 
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Table1: Cytokine release 
Cytokine release was determined in LA4 (A) and MH-S(B) cells after 24h polymer exposure. Values 
are given as mean±SD (n=3) of the fold change compare to control (untreated cells), b.d.l. is below 
detection limit. Bold values are statistically significant, *p<0.05. 
 
Thus, from that in vitro data we conclude that these polymers could be applied in vivo for 
evaluating their performance in RNAi.  
 
Quantification of EGFP down regulation by FACS Analysis 
After intratracheal instillation of 35 µg siRNA complexed six different polyplexes we 
detected a significant knock down of enhanced green fluorescent protein (EGFP) expression 
in the lungs compare to untreated animals (ctrl.) for three polyplexes (PEI(25)-PEG(2)10: 
75±4 %; PEI8.3kDa: 66±9 % ; PEI8.3(C16-C18-EO25)1.4: 69±9 % (Fig. 3 and 
supplementary material, S3). However comparing siEGFP results to the treatment with the 
unspecific siRNA against luciferase (siGL3), failed to detect any anti-EGFP specific 
significant knock down effect (p <0.05), even thought the EGFP expression appeared still 
higher in the animals treated with the unspecific siGL3 as compared to siEGFP. In 
comparison to control animals and the other three specific polyplexes, the EGFP expression 
was slightly reduced with the unspecific siGL3 (PEI(25)-PEG(2)10: 50±11 %; PEI8.3 kDa: 
58±9 %; PEI8.3(C16-C18-EO25)1.4: 30±16 %) From that data, the most unspecific off-target 
effect was seen for the treatment with the low molecular weight PEI 8.3 kDa polymer used to 
complex and delivery siRNA. Keeping that in mind, the most effective polyplexes could be 
arranged in following order with decreasing specific knock down efficacy: PEI8.3(C16-C18-
EO25)1.4 > PEI825)-PEG(2)10 > PEI8.3 kDa. Fluorescence microscopy confirmed the 
obvious knock down effect in lung EGFP expression with these three polyplexes mentioned 
above, which seem to be more prominent in the alveolar region of the lungs (Fig. 4). 
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Figure 3: FACS analysis 
 
Figure 3: FACS analysis 
Flow cytometer data from GFP transgenic mouse lungs 5 day postinstillation with six different 
polyplexes with specific siGFP or as indicated in the figure with unspecific siGL3. 10.000 cells were 
counted and dead cells were excluded by propidium iodide (PI) staining. Values shows the percent of 
the vital GFP+ cell population and represents mean±SEM (n=4-6). Asterisks represents statistical 
significance with *p<0.05, **p<0.01 compare to control animals (gray bars).  
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Figure 4: Fluorescence microscopy 
A  4.1 
PEI25kDa   PEI(25)-PEG(2)10  PEI(25)-PEG(0.55)30 
   
B  4.1 
PEI8.3kDa   PEI8.3(C16-C18-EO25)1.4 PEI8.3(PEO-co-PPO)1000)6.2 
          
C 4.1 
PEI(25)-PEG(2)10/siGL3 PEI8.3kDa/siGL3          PEI8.3(C16-C18-EO25)1.4/siGL3 
       
D 4.1 
CABA ctrl.   C57/BL6 ctrl. 
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A 4.2 
PEI25kDa   PEI(25)-PEG(2)10   PEI(25)-PEG(0.55)30 
         
B 4.2 
PEI8.3kDa   PEI8.3(C16-C18-EO25)1.4 PEI8.3(PEO-co-PPO)1000)6.2 
                
C 4.2 
PEI(25)-PEG(2)10/siGL3   PEI8.3kDa/siGL3          PEI8.3(C16-C18-EO25)1.4/siGL3 
            
D 4.2 
CABA ctrl.   C57/BL6 ctrl. 
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Figure 4.1-4.2: Fluorescence microscopy 
5 days post instillation the left lungs were paraffin-embedded and processed for fluorescent 
microscopy. Nuclei are shown in blue (DAPI), and EGFP signal is shown in green. Exposure time was 
kept constant to compare the EGFP signal in the different treatment groups. Images are 
representative images out of 6 individual images from the respective region of the lungs per animal, 
magnification 40 x. Figure 4.1 is showing the upper airways and Figure 4.2 the alveolar region. A 
represents PEI25kDa, PEI(25)-PEG(2)10, PEI(25)-PEG(0.55)30 from left to right, B showed 
PEI8.3kDa, PEI8.3(C16-C18-EO25)1.4 from left to right, in C is given the unspecific complexes with 
siGL3 of PEI(25)-PEG(2)10, PEI8.3kDa, PEI8.3(C16-C18-EO25)1.4 from left to right, D showed the 
controls,enhanced grenn fluorescent protein expressing CABA mice and C57/BL6 control mice.  
 
Cell specific targeting 
To get an impression about a selective (cell-type) targeting of specific leukocyte subtypes by 
the PEI-based nanocarriers, we investigated the lung homogenate by flow cytometry using 
different leukocyte specific cell surface markes to differentiate leucocytes (CD45+), from B-
lymphocytes (CD45+/CD19+), T-lymphocytes (CD4+ positive: CD45+/CD4+ and CD8+ 
posititve: CD45+/CD8+), granulocytes (Gr1+), neutrophilic granulocytes (Gr1+/CD11b+), 
lung macrophages (CD11b-/CD11c+), and dendritic cells (CD11b+/CD11c+ or 
HCII+/CD11c+). Particular high reduction of the EGFP expression was found for 
CD45+/GFP+ cells after treatment with PEI(25)-PEG(2)10/siGFP, PEI8.3(C16-C18-
EO25)1.4/siGFP, and PEI8.3kDa/siGL3 (Fig 5.). Again PEI8.3 kDa showed very high off-
target effect and the knock down efficacy was not specific, because the knock down effect 
with the unspecific siGL3 was stronger than with the specific siGFP when using PEI 8.3 kDa 
polymer for siRNA complexation. 
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Figure 5: Cell specific targeting 
A leukocytes (GFP+/CD45+) 
 
B lung macrophages (GFP+/CD11b-/CD11c+) 
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Figure 5: Cell specific targeting 
Single-cell suspension obtained from collagenase/DNAse digested lungs from enhanced green 
fluorescent protein (EGFP) transgenic CABA mice, stained with CD45 (A) and CD11b (B) and CD11c 
(B). Treatment groups are mention above each dot plot and percent of total GFP+/CD45+ (A) or 
GFP+/CD11c+, CD11b- (B) cells is indicated in red as mean of n=4-6.  
 
Because of the small amount of lung macrophage numbers [36] in the homogenate the 
reduction of EGFP expression was not statistically significant, but a trend was seen in 
macrophage specific targeting for specific (siEGFP) and unspecific (siGL3) treatment with 
polyplexes containing PEI(25)-PEG(2)10 and PEI 8.3 kDa polymer and for specific (siEGFP) 
treatment with PEI8.3(C16-C18-EO25)1.4 polymer (Figure 6B).Interestingly, it appeared that 
the fatty acid modified low molecular weight PEI-PEG copolymer was intended for slight 
knock down EGFP expression in lung macrophages (CD11b-/CD11c+:21 %, MHCII-
/CD11c+: 29 %), and to a much stronger extent in leucocytes (39 %). PEI 8.3kDa/siGFP 
showed also slight knock down in lung macrophages (CD11b-/CD11c+:17 %, MHCII-
/CD11c+: 33 %), but this data should be regarded with caution because of the high off-target 
effects observed after treatment with this polymer when regarding cell specific targeting, e.g. 
CD45+ leucocytes.  
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7.5 Discussion 
 
Treatment of lung diseases by tools of combined cell specific targeting and RNAi technique 
represents a new way for novel treatment strategies and would be a great challenge for 
nanomedicine. So far, pulmonary application of siRNA in vivo is still rare and entry to clinical 
trials often failed due to safety or efficacy reasons. Therefore, new and improved approaches 
for promising nanocarriers for pulmonary siRNA delivery are still needed and under intense 
investigations. In this study, we analyzed the efficacy of six different PEI-based non-viral 
vector systems on siRNA delivery directly to the lungs focusing leucoytes as target cells 
because it would be a great challenge to target this cell type for lung disease like chronic 
obstructive pulmonary disorder (COPD) or asthma bronchiale. Two series of PEI 
modifications (high molecular weight vs. low molecular weight and hydrophilic vs. 
hydrophobic PEGs) were investigated because of their promising in vitro properties [10, 11, 
23]. High molecular weight PEI 25 kDa has been successfully delivered siRNA as well as 
pDNA to the lungs [4, 8, 35], but the cytotoxicity is very high and limits the dosing regime. 
Therefore, low molecular weight PEI and several modifications on the PEI backbone were 
developed and analyzed [22, 37]. Low molecular weight PEI was shown to transfect various 
cell lines in vitro with pDNA [38, 39]. Hydrophilic PEG-PEI copolymers were used to reduce 
cytotoxicity, protein binding, and increase solubility in vitro [11, 19, 23, 40, 41] and have 
been shown to successfully deliver siRNA to mouse lungs [7]. Fatty acid modification on a 
natural occurring, cationic charged molecule like spermine was shown to successfully deliver 
pDNA in to the dermis and intramuscular in mice [42]. They found an increase in toxicity 
with increasing length of hydrocarbon chains, which could be explained by the detergents-like 
properties which are more prominent with longer hydrocarbon chains on the polycation 
spermine and could cause higher membrane disruption than more hydrophobic molecules. 
The higher membrane damage effect of the more hydrophobic modified PEI-PEGs in our 
study revealed similar results like that in the above mentioned study and the decrease in cell 
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viability was much stronger for the low molecular weight PEI8.3 kDa polymers than for 
PEI25 kDa polymers and more prominent in the alveolar epithelial cell line. Alshamsan et al. 
[27] has investigated the in vitro transfection efficacy of oleic acid and stearic acid modified 
PEIs for siRNA delivery in B16 melanoma cells and found a pronounced higher transfection 
efficacy for the hydrophobically modified PEI-based polymers over a wide range of other 
commercially available transfection reagents for siRNA delivery.  
In our study, we tried to introduce a panel of promising variations on the PEI backbone to 
study the efficacy of the in vitro tested carriers for siRNA directly to the lung. Although, 
recently published studies [4, 35] described successful delivery of siRNA against different 
proteins of the influenza virus A to the lungs by using PEI 25 kDa, we were not able to show 
specific knock down in EGFP expression in our mouse model using PEI25 kDa. Nevertheless, 
one of the hydrophilic PEG modification PEI(25)-PEG(2)10, and the low molecular weight 
PEI8.3 kDa, and the fatty acid modification PEI8.3(C16-C18-EO25)1.4 yielded strong 
reduction of EGFP expression in the lungs. To test if these knock down effects were 
sequence-specific for EGFP we applied the three most effective polyplexes complexed with 
an unspecific siRNA against luciferase (GL3). Surprisingly, we found for all unspecific 
polyplexes also slight reduction of EGFP expression, whereas the low molecular weight 
PEI8.3kDa (58±9 %) and PEI(25)-PEG(2)10 (50±11 %) caused the highest unspecific knock 
down effect and PEI8.3(C16-C18-EO25)1.4 (30±16 %) showed only a moderate unspecific 
knock down compare to control animals. PEI25kDa, PEI(25)-PEG(0.55)30 and PEI8.3(Butyl-
PEO-co-PPO)1000)6.2 polyplexes induced no significant changes in EGFP expression in 
comparison to control animals, therefore we did not look for unspecific knock down effects 
using siGL3. Regarding the cell specific targeting in the lung, we could distinguished a broad 
range of leucocytes-related cell types and found out that with the most efficient carrier 
PEI8.3(C16-C18-EO25)1.4 targeted in most cases leucocytes (CD45+) and to a small extent 
lung macrophages (CD11b-/Cd11c+), but knock down efficiencies were not higher than the 
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overall knock down in EGFP expression. Therefore, it seemed to be likely that leucocytes-
related cell types in the lung are targeted to a small amount but the main target cell types are 
out of our staining strategy and represent rather endothelium or epithelium [4, 5, 36]. The 
fatty acid modification on the PEI 8.3 kDa backbone offers some advanced properties for 
transfection. The hydrophobic residue caused i) weaker interaction between the polymer and 
siRNA, which could facilitate siRNA delivery, and ii) stronger membrane interaction for 
improved uptake. Successful targeting lung macrophages was also described by a study of 
Griesenbach et al. [5], where they found FITC-labbeled siRNA complexed with the cationic 
lipid Genenzyme lipid (GL69) most likely in alveolar macrophages in comparison to 
antisense oligonucleotides (asODN), which were found to target alveolar epithelial cells.  
Because of the high proinflammatory potential of the analyzed polymers and polyplexes in 
vitro as well as in vivo as recently described [9, 10] and the high unspecific knock down 
effects observed in this study, further evaluation of the stimulation of the innate immune 
system after polyplex application is still needed to improve polymer design with limited off-
target effects.  
For the first time, we could describe the leucocytes specific cell type targeted following 
intratracheal instillation of PEI-based nanocarriers by siRNA delivery. In that way, the 
hydrophobic moiety, namely the fatty acid residue (C16-C18-EO25) on PEI8.3 kDa, appear to 
be most promising for specific knock down in lung cells and offers new strategies to develop 
more effective nanocarriers. The next generation of cationic polymers for siRNA should 
balance the hydrophilic and hydrophobic properties for improved polyplex uptake, reduced 
cytotoxicity and immunostimulation and efficient delivery of siRNA.  
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7.6 Supplementary data 
 
S1 Synthesis of the polymers and siRNA information 
 
Poly(ethylene imine) copolymers of PEI 25 kDa with hydrophilic modifications 
Branched poly(ethylene imine) (PEI) with a molecular weight of 25 kDa (Polymin, water-
free, 99 %) was a gift of BASF, Ludwigshafen. The polyethylene imine-graft-poly(ethylene 
glycol) (PEI-PEG) with a PEG content of approximately 50 % (w/w) was synthesized as 
previously described [22, 23] by grafting linear PEG of 0.55 kDa and 2 kDa, respectively, 
onto branched PEI 25 kDa. These graft copolymers were designated using following 
nomenclature: PEI(25k)-g-PEG(x)n. The number in brackets (25 k or x, where x=0.55 k, 2 k) 
represents the molecular weight of PEI or PEG block in Daltons, and the index n is the 
average number of PEG blocks per PEI molecule. The number was calculated on the basic of 
1H-NMR spectra as described previously [22]. 
Poly(ethylene imine) copolymers of PEI 8.3 kDa with hydrophobic modifications 
PEI was synthesized by acid initiated polymerisation from aziridine using ethylendiamine as 
initiator. PEI 8.3 kDa was grafted by N-acylation with butyl-(poly(ethylenoxid-co-
propylenoxid) (Butyl-(PEO-co-PPO)1000) or palmity-/stearyl-polyethylenoxid (C16-C18-
EO)25 mixture as previously described by [37].The nomenclature of these polymers are 
following: PEI8.3-(x)n, where x represent the respective hydrophobic poylethylenoxid 
derivate and n is the average number of x units per PEI molecule, which is calculated on the 
basic of 1H-NMR spectra.  
siRNA against green fluorescence protein (GFP) was obtained from Metabion (München, 
Germany) with following sequence for sense strand: 5’-GGCUACGUCCAGGAGCGCACC-
dTdT and for antisense strand: 5’-GGUGCGCUCCUGGACGUAGCC-dTdT. siRNA against 
luciferase GL3 (siGL3) was purchased from MWG (Ebersberg, München) with following 
sequence for the sense: 5’– CTTACGCTGAGTACTTCGATT -3’ and the antisense strand: 
5’– AATCGAAGTACTCAGCGTAAG-3'. 
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Polyplex formation  
Sense and antisense strand for siRNA against GFP was annealed using annealing buffer 
containing 30 mM HEPES-KOH pH 7.4, 100 mM KCl, 2 mM MgCl2, 50 mM NH4Ac 
according to the annealing protocol from Metabion. siRNA polyplexes were formed as 
previously described [7]. siGL3 was purchased already as annealed double-strand and was 
directly used. Polyplexes were formed by mixing equal volumes (25 µl each) of siRNA and 
polymer dilution in Aqua ad injectabilia to obtain the desired nitrogen to RNA phosphate ratio 
(N/P ratio) of 6 using 35 µg siRNA. Polymers were diluted in Aqua ad injectiabilia (Braun 
AG, Melsung, Germany) and vigorous vortexed directly before use.  
 
S2 Cell viability 
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S2 Cell viability 
Cell viability was determined by using WST-1 reagent (Roche Diagnostics, Germany) after 24 h 
polymer treatment. Values represents mean±SD of three independent experiments and statistical 
significance is indicated by asterisks with *p<0.05, **p<0.01, ***p<0.001.  
 
S3 GFP expression 
 
S3: Histograms of EGFP expression in all treatment groups. y-axis shows the cell counts and x-
axis the EGFP signal. M1 is the cell population containing low EGFP expressing cells and M2 
represents the cell population which expressing high EGFP (cells of interest). Histograms were 
depicted as representative from n=4-6 animals of each group. 
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8 Summary and Perspectives 
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8.1 Summary  
 
In this thesis, toxicity of PEI-based non-viral vector systems for siRNA application into the 
lungs was comprehensively described and analyzed in vitro as well as in vivo.  
Chapter 1 introduced in basic information about the lung anatomy and physiology and general 
considerations for pulmonary application as well as gave an overview of the two major groups 
of non-viral vector systems for pulmonary application and highlighted their impact in 
nanomedicine and nanotoxicology. The search for more predictive toxicity tools for 
(polymeric) non-viral vector systems is still of great concern in the community and was 
pointed out in this chapter. 
Chapter 2 described the toxicicological and immunomoldulatory effects of two different PEI-
based nanocarriers for siRNA delivery in different murine lung cells. Two different PEI 
nanocarriers (branched vs. linear, and low vs. high molecular weight PEI) were evaluated 
regarding standard toxicity endpoints, but also immunomodulatory effects caused by the pure 
polymers and their respective polyplexes with siRNA. The results pointed out, that epithelial 
cells were much more sensitive in response to such polymers and the polyplexes appeared to 
be less toxic than the pure polymers. In addition, the immunomodulatory effects of such 
polymeric non-viral vector systems should be further investigated for their underlying 
mechanism. 
Chapter 3 hypothesized that poly(ethylene glycol) (PEG) reduces the cytotoxicity of high 
molecular weight, branched PEI25 kDa and investigated the cell-compatibility and 
cytotoxicity of a panel of different PEI-PEG polymers in vitro. This in vitro study highlighted 
the inflammatory potential of such PEI-PEG polymers which seemed to be higher when 
cytotoxicity was extremely reduced.  
Hypothesizing that inflammatory and oxidative stress response play an important role when 
using PEI-based nanocarriers, especially for pulmonary application, in Chapter 4 a toxicity 
and stress pathway focused gene expression profiling was described for selected PEI-PEG 
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polymers. This gene array clearly stressed the inflammatory potential of the modified PEI-
PEG polymers with reduced apoptotic signalling pathways, but increasing inflammatory and 
oxidative stress response, in contrast to PEI25 kDa.  
Due to the higher proinflammatory potential and elevated oxidative stress parameters, the 
question of genotoxicity was addressed in Chapter 5. The mutant frequency of selected PEI-
based nanocarriers was investigated by using a transgenic lung epithelial cell culture in vitro 
model, but was regarded to be less and PEI-based nanocarriers were not mutagenic in such an 
in vitro model. 
After toxicity analysis in vitro two main questions raised (i) what kind of effects would be 
induced by the polymers or their polyplexes in vivo when directly administered to the lungs 
and (ii) could we find any in vitro/ in vivo correlation for biomarkers indicating toxicity, 
inflammation and/or oxidative stress? 
Chapter 6 focused on the in vivo toxicity, inflammatory, and oxidative stress response of 
selected PEI-based nanocarriers for siRNA in mice after intratracheal instillation and tried to 
answer the two upcoming questions from the in vitro studies. Almost all modified PEI-based 
nanocarriers showed very high acute inflammation, but with different resolving kinetics. 
Hydrophobic modification of low molecular weight PEI and highly hydrophilic PEGylated 
PEI-based nanocarriers seemed to be well tolerable in contrast to moderate hydrophilic 
PEGylated and fatty-acid modified PEI-based polymers which showed very high and 
sustained inflammation in the lungs.  
In contrast to safety issues (which represent the main part of this thesis) in chapter 7 the in 
vivo efficacy and the cell–type specific targeting was reported of PEI-based nanocarriers, 
same carriers selected as in Chapter 6, for pulmonary siRNA delivery. Surprisingly, the 
highly inflammatory PEI-based nanocarriers yielded high knock down effects, but only the 
fatty acid modified PEI-based nanocarrier, seemed to avoid off-target effects. Leucocytes 
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were targeted to some extent, but seemed not to be the main targeted cell type in the lung after 
PEI-based nanocarriers application for siRNA delivery. 
Thus, for clinical trials the polymers should be carefully optimized and evaluated for 
cytotoxicity, high acute inflammatory and oxidative stress response and their in vivo 
performance of siRNA delivery. Development of polymers with reduced cytotoxicity and 
negligible off-target effects, but high in vivo efficacy represents one of the biggest challenges 
for the next decades before entry to clinics. In addition, optimized in vitro models for 
predictive toxicity are still needed. 
 
8.2 Perspectives 
 
Predictive in vitro tools for cytotoxicity is one issue to be overcome when using so called 
nanocarriers for human application. A lot of information of the behaviour and properties of 
nanocarriers in the lungs could be obtained from the intense investigations of ultrafine 
particles (UFP) in the field of environmental health. In all our studies two anorganic particles 
were included, namely crystalline silica (CS) and nanosized zinc oxide (NZO), which are well 
known for their cytotoxicity and inflammatory effects in the lungs. These particles were for 
the first time introduced as lung toxic benchmarks. Further investigations and establishments 
of in vitro models should include such as particles to obtain an idea of the relevance of the in 
vitro reults with regard to risk assessment and safety. Considering the rapid growth of 
nanotechnology and the variety of nanomaterials potentially used in the future, identifying, 
quantifying and managing potential health risks is essential, especially in the respiratory tract 
that may serve as the portal of entry for inhaled nanoparticles and nanofibers. 
Epidemiological studies have shown that a sudden surge in the level of UFP can be linked to 
increased cardio-respiratory morbidity and mortality including asthma, chronic obstructive 
pulmonary disease (COPD) and artherosclerosis. Thus, the potential risk of therapeutic 
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nanoparticles should be carefully evaluated, and robust and reliable predictive in vitro tools 
should be introduced.  
In this thesis, the Chapter 2-5 dealt with a wide range of in vitro analysis in different lung 
mono cell culture systems and described various toxicity endpoint measurements. To integrate 
the lung cell interplay, between the over 40 different cell types in the lung, and to be more 
realistic, the main focus in future should be addressed on the development of robust and 
reliable in vitro models. More than one cell type in culture should be included and the co-
culture models should be easy to handle, but more predictive in regard to the interaction 
between the different cell types. In parallel, more than one mono cell line representing 
different orgin (human vs. murine) and/or cell type (e.g. epithelial, endothelial cells, 
fibroblasts, macrophages) should be analyzed for cytotoxicity. Nevertheless, in this thesis the 
mono cell culture systems (using different cell types) highlighted the immunomodulatory and 
proinflammatory potential from such PEI-based non-viral vector systems (Chapter 2-5), 
which could be confirmed in the vivo toxicity study in Chapter 6. To uncover the underlying 
mechanism of inflammation and oxidative stress as well as cytotoxicity caused by polymeric 
non-viral vector systems for siRNA delivery into the lungs represents one challenge for the 
near future to develop safe and efficient carrier systems. Further studies should be analyze 
more in detail the underlying toxicity pathways regarding gene expression pattern and 
following the "hits" by measuring protein expression of relevant proteins involved in the 
repsective pathway, e.g. cytochrom c release for the intrinsic apoptotic pathway detected by 
Bcl or Bax. For more evidence of the apoptotic behaviour of PEI assays should be included 
which analyze more in detail the two distinct apototic pathways, e.g. regarding caspase 
activity. With regard to the higher inflammatory potential of the PEI-modifications further 
models are still needed to evaluate the mechanism behind, e.g. complement activation.  
Little is known about the cell-type-specific targeting of non-viral vector systems for siRNA 
delivery into the lungs. Combination of cell specific targeting and RNAi technique represents 
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a new way for treatment of various diseases and would be a great challenge for nanomedicine. 
Chapter 7 described for the first time, in addition to the in vivo performance of six different 
PEI-based nanocomplexes with siRNA, the cell-type specific targeting of such polymeric 
non-viral vector systems. Since leucocytes were targeted to some extent, but do not represent 
the major cell-type which was addressed by polymeric siRNA delivery systems, further 
evaluation of other cell types, which are more represented in the lung, like epithelium or 
endothelium, but also interstitial cell types like fibroblasts or smooth muscle cells, is still 
needed. More sophisticated techniques, e.g. immunofluorescence and MACS technology for 
flow cytometry or the combination with non-invasive imaging techniques (e.g. PET, MRT, 
CT) may help to distinguish more in detail the main targeted lung regions (upper vs. lower 
airways). 
In summary, the in vitro/ in vivo correlation of the obtained data is still needed to provide 
more information for an optimized development of preditive toxicity in vitro models and 
better guidance of sophiticated in vivo studies.  
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8.3 Zusammenfassung 
 
Die vorliegende Arbeit beschreibt sehr ausführlich die Toxizität von Polyethylenimine (PEI)-
basierten nicht-viralen Vektorsystemen für die pulmonare Verabreichung von siRNA und 
zeigt die toxikologische Analyse dieser Carrier in vitro als auch in vivo. 
Kapitel 1 führt in die Lungenanatomie sowie –physiologie ein und gibt allgemeine Hinweise, 
die bei einer pulmonaren Applikation von Bedeutung sind. Außerdem wird ein Überlick 
gegeben über die zwei bedeutendesten Gruppen von nicht-viralen Vektorsystemen für eine 
pulmonare Verabreichung und die Bedeutung dieser Klassen im Zusammenhang mit der 
sogenannten „Nanomedizin“ und „Nanotoxikolgie“ dargestellt. Die Entwicklung und der 
Nutzen von geeigneten in vitro Toxizitätsuntersuchungs- und -beurteilungsmöglichkeiten für 
polymer-basierte nicht-virale Vektorsysteme zur besseren Vorhersage ihrer Toxizität in vivo 
stellt eine große Herausforderung an alle Wissenschaftler im Bereich der „Nanomedizin“ dar 
und ist in Kapitel 1 besonders hervorgehoben worden. 
Kapitel 2 beschreibt die toxikologischen und immunmodulatorischen Effekte von zwei PEI-
basierten Nanocarriern für siRNA Freisetzung in verschiedenen Mauszelllinien. Die zwei 
PEI-basierten Nanocarrier (verschweigt gegenüber linear und PEI mit geringem und hohem 
Molekulargewicht, sowie reine Polymere gegenüber den Komplexe mit siRNA) wurden 
hinsichtlich ihrer Toxizität und immunmodulierender Effekte mit klassichen toxikologischen 
Endpunktmessungen untersucht. Die Ergebnisse zeigen eine deutlich höhere Empfindlichkeit 
der alveolaren Epithelzellen nach Behandlung mit PEI, wobei die Polyplexe eine geringere 
Toxizität aufweisen als die reinen Polymere. Außerdem zeigen die Polymere und Polyplexe 
ein gewisses immunmodulatorisches Potential, das weiter hinsichtlich des zugrundeliegenden 
Mechanismus untersucht werden sollte. 
Kapitel 3 postuliert, dass die Kopplung von Polyethylenglycol (PEG) an PEI die Zytotoxizität 
von hochmolekular, verzweigtem PEI 25kDa reduzieren kann und untersucht die Zell-
Kompatibilität und Zytotoxizität von mehreren unterschiedlich PEGylierten PEI-PEG 
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Kopolymeren in vitro. Diese in vitro Studie zeigt klar, dass mit zunehmender PEGylierung die 
Zytotoxizität zwar abnimmt, dafür aber das entzündungsfördernde Potential der PEG-PEI 
Kopolymere zunimmt. 
Ausgehend davon, dass eine möglicherweise auftretende Entzündungsantwort und ein 
oxidativer Stresseffekt eine entscheidende Rolle bei der Verabreichung und Anwendung 
solcher PEI-basierten Nanocarrier, vor allem für die pulmonare Anwendnung, spielt, 
beschreibt Kapitel 4 ein Toxizitäts- und Stress-basiertes Genexpressionsprofiling für 
ausgewählte PEI-PEG Polymere. Dieser Genarray hebt wiederum deutlich das 
entzündungsfördernde Potential der PEI-PEG Copolymere gegenüber dem reinen PEI 25kDa 
hervor, wobei mit zunehmender PEGylierung apoptotische Signalwege vermindert auftreten 
und Entzündungsprozesse sowie oxidative Stresseffekte verstärkt werden. 
Wegen des erhöhten entzündungsfördernden Potentials und der verstärkten oxidativen 
Stressantwort, wurde die Frage einer möglichen Genotoxizität der PEI-basierten Polymere in 
Kapitel 5 untersucht. Die Mutationsfrequenz von ausgewählten PEI-basierten Polymeren 
wurde in einem transgenen Lungenepithelzell - Zellkultur-Model getestet. Es konnte gezeigt 
werden, dass das mutagene Potential von diesen PEI-basierten Nanocarriern in diesem Model 
als sehr gering bis vernachlässigbar klein eingestuft werden konnte. 
Nachdem die Toxizität in vitro ausführlich getestet wurde, stellten sich folgende zwei Fragen: 
a) Was für Effekte werden hervorgerufen nach direkter pulmonarer Verabreichung der 
Polymere oder ihrer Polyplexe in der Lunge?  
b) Gibt es eine mögliche in vitro/ in vivo Korrelation für einen oder mehrere Biomarker, die 
Hinweise auf Toxizität, Entzündung und oxidativen Stress geben? 
Kapitel 6 beschäftigt sich in erster Linie mit der Beurteilung der Toxizität, Entzündung und 
der oxdativen Stressantwort in vivo nach intratrachealer Verabreichung von ausgewählten 
PEI-basierten Nanocarriern für siRNA in Mäusen und versucht die oben genannten zwei 
Fragen zu beantworten.  
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Fast alle modifizierten PEI-basierten Nanocarrier zeigen eine sehr starke, akute 
Entzündungsreaktion in der Lunge, jedoch mit unterschiedlichen Kinetiken hinsichtlich der 
Entzündungsauflösung. Hydrophobe Modifikationen an gering molekularem PEI 8.3 kDa als 
auch hydrophile, stark PEGylierte PEI 25 kDa Kopolymere scheinen gut vertragen zu werden, 
im Gegensatz zu eher weniger PEGylierten PEI 25 kDa Kopolmeren und Fettsäure-
modifizierten PEI8.3 kDa Kopolymeren, die eine sehr starke und anhaltende 
Einzündungsreaktion in der Lunge hervorrufen. 
Zusätzlich zu den Toxizitätsstudien, die den Hauptteil der vorliegenden Arbeit ausmachen, 
wird in Kapitel 7 die Wirksamkeit und ein Zelltyp spezifisches Targeting von PEI-basierten 
Nanocarriern (die gleichen, die auch in der Toxizitätstudie in Kapitel 6 untersucht wurden), 
nach intratrachealer Verabreichung in transgenen EGFP-Mäusen analysiert. 
Interessanterweise zeigt sich, dass die, in Kapitel 6 beschriebenen stark 
entzündungsfördernden PEI-basierten Polymere die höchste Knockdown Effizienz zeigen, 
allerdings mit einem hohen Anteil an "off-Target" Effekten. Nur das Fettsäure modifizierte 
PEI -Polymer scheint weniger bis keine "off-Target" Effekte zu erzeugen. Es konnte weiterhin 
gezeigt werden, dass Leukozytenpopulation zu einem gewissen Anteil Zielzellen nach 
Verabreichung der PEI-basierten siRNA-Komplexe in der Lunge darstellen, allerdings 
scheinen zusätzlich noch Epithel- oder auch Endothelzellen in der Lunge erreicht zu werden. 
Welche Zellpopulationen außer Leukozyten noch von siRNA/PEI Komplexen nach 
intratrachealer Verabreichung erreicht werden, soll in weiterführenden Studien mit diesen 
Polyplexen untersucht werden. 
Für klinische Studien im Menschen sollten die Polymere weiterhin sorgfältig optimiert und 
untersucht werden, um eine sichere und effiziente Anwendung zu gewährleisten. Die 
Entwicklung von PEI-basierten Polymeren mit einer verminderten bis vernachlässigbaren 
Zytotoxizität, vernachlässigbaren "off-Target" Effekten, aber einer ausreichenden 
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Wirksamkeit, stellt eine der wichtigsten Herausforderung im Bereich der Nanomedizin und 
siRNA Therapie für die nächsten Jahre dar. 
8.4 Ausblick 
 
Die Entwicklung geeigneter, vorhersagender und verlässlicher in vitro Testmöglichkeiten für 
Zytotozitätsbeurteilung von sogenannten Nanocarriern für die Anwendung beim Menschen 
stellt eine große Herausforderung für die Wissenschaft im Bereich der “Nanomedizin” dar. 
Viele Informationen über das Verhalten und die Eigenschaften von Nanocarriern in der Lunge 
sind bereits aus den sehr intensiven Untersuchungen mit ultrafeinen Partikeln im Bereich der 
Umweltmedizin und –gesundheit bekannt. Aus diesem Grund, wurden zwei anorganische 
Partikel, nämlich kristallines Silica (CS) und "nanogrosses" Zinkoxid (NZO), in allen Studien 
untersucht, da ihre Toxizität sowie die Entzündungsauslösung in der Lunge hinreichend 
bekannt sind. Zum ersten Mal wurden diese Partikel als sogenannte Referenzpartikel für 
Lungentoxizität eingeführt. Weiterführende Untersuchungen sowie bei der Entwicklung 
geeigneter in vitro Modelle sollten solche Partikel mit untersuchen, um eine bessere 
Risokoabschätzung und Beurteilung des Risiko für eine erhöhte Sicherheit der zu 
untersuchenden Partikel zu erhalten.  
Berücksichtigt man die enorme und schnelle Verbreitung von Nanotechnologien und die 
Vielfalt verschiedenster Materialien im Nanobereich, die bereits genutzt und eingesetzt 
werden, aber auch die, die sich noch in der Entwicklung befinden, so stellt die richtige 
Beurteilung, Identifizierung, Quantifizierung und das Management des potentiellen 
Gesundheitsrisikos, vor allem in Bezug auf den Respirationstrakt, eine essentielle 
Herausforderung für die Wissenschaft dar. Viele epidemiologische Studien konnten bereits 
beweisen, dass ein Zusammenhang zwischen der erhöhten Exposition von ultrafeinen 
Partikeln und kardiovaskulären sowie respiratorischen Erkrankungen und damit auch von 
Morbidität und Mortalität besteht. Deshalb ist es von entscheidender Bedeutung, das 
potentielle Risko von therapeutisch eingesetzten Nanopartikeln genau zu untersuchen und 
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robuste sowie verlässliche, vorhersagbare in vitro Modelle zu entwicklen, um eine sichere 
Anwendung am Menschen zu gewährleisten. 
In der vorliegenden Arbeit, werden eine Vielzahl von in vitro Analysen in verschiedenen 
Lungenzellmodellen in Kapitel 2-5 beschrieben und die Toxizität von PEI-basierten nicht-
viralen Vektorsystemen mit verschiedenen Tozititätsendpunktmessungen untersucht.  
Um die große Anzahl an verschiedenen Zellen in der Lunge (mehr als 40) zu berücksichtigen 
und die Interaktionen zwischen den verschiedenen Zelltypen realistischer untersuchen zu 
können, wäre die Entwicklung von einfachen, robusten und verlässlichen in vitro 
Zellkulturmodeln mit mehr als einem Zelltyp wünschenswert. Parallel zu solchen Modeln 
wäre auch die Untersuchung in Monokulturen, aber von verschiedenen Zelltypen (z.B. 
Epithel-, Endothelzellen, Fibroblasten, Markophagen) oder auch von unterschiedlichen 
Spezies (Mensch gg. Maus) sinnvoll.Trotzdem läßt sich sagen, dass in der Mono-Zellkultur, 
wie sie in der vorliegenden Arbeit verwendet wurde, auch erste brauchbare Ergebnisse finden 
lassen können. Zumindest konnte das in Kapitel 2-5 gefundene entzündungsfördernde und 
immunomodulatorische Potential der PEI-basierten nicht-viralen Vektorsysteme in vivo 
(Kapitel 6) bestätigt werden. Nun sollte in weiterführenden Studien der zugrundeliegende 
Mechanismus der Entzündung und des oxdiativen Stress sowie der Zytotoxiztät genauer 
untersucht werden, um bessere und sichere polymer-basierte Nanocarrier zu entwicklen. 
Weiterführende Studien sollten den zugrundeliegenden Mechanismus aufklären, indem 
ausgehend von Genexpressionmustern verschiedene relevante Proteine untersucht werden, die 
in einem bestimmten Pathway eine Schlüsselrolle spielen, z.B. Freisetzung von Cytochrom C 
beim intrinsischen Zelltod. Um eine erhöhte Evidenz für das apoptotische Verhalten von PEI 
zu erhalten, sollten weitere Untersuchungen hinsichtlich einer Caspaseaktivierung für eine 
bessere Untercheidung von intrisischen und extrinsichen apoptotischen Pathway durchgeführt 
werden. Im Hinblick auf das erhöhte entzündungsfördernde Potential der PEI-Modifikationen 
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sind weitere Modelle notwendig, die den zugrundeliegenden Mechanismus aufklären können, 
z.B. Untersuchungen zur Komplementaktivierung. 
Bisher wenig untersucht ist das Zelltyp spezifische Targeting von nicht-viralen 
Vektorsystemen für siRNA Freisetzung in der Lunge. Die Kombination von Zelltyp 
spezifischen Targeting und RNAi Technik stellt einen neuartigen Weg zur Behandlung 
verschiedener Erkankungen dar und wäre eine Revolution für die „Nanomedizin“. 
Kapitel 7 beschreibt, zusätzlich zur Wirksamkeit in vivo, das Zelltyp spezifische Targeting 
(Leukozyten) von sechs verschiedenen PEI-basierten Nanocarriern für siRNA Freisetzung. Es 
konnte gezeigt werden, dass Leukozyten zwar zu einem gewissen Teil erreicht werden, dass 
sie aber nicht den Hauptanteil an Zellen ausmachen, in denen eine spezifische 
Runterregulation von "enhanced green-fluorescent protein" (EGFP) beobachtet werden 
konnte. Weiterführende Studien sollten andere Zelltypen wie Epithel- oder Endothelzellen, 
die einen Großteil der Lungenzellen ausmachen, miteinbeziehen und von weiterführenden 
Techniken wie Immunfloureszenz und MACS Technology für die Durchflusszytometrie 
sowie die Einbindung von nicht-invasiven bildgebenden Verfahren (PET, MRT, CT) 
Gebrauch machen, um eine genaue Unterscheidung der verschiedenen Lungenbereiche 
(Bronchial vs. Alveolar) und Zelltypen zu erreichen. 
Zusammenfassend läßt sich sagen, dass eine in vitro/ in vivo Korrelation der vorliegenden 
Daten noch durchzuführen ist, um noch mehr Informationen liefern zu können für eine 
optimierte Entwicklung von vorhersagenden Toxizitäts- in vitro Modellen und für eine 
bessere Anleitung aussagekräftiger in vivo Versuche. 
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9.1 Abbreviations 
 
AMD   Age related macular degeneration 
ATP   Adenosine triphosphate 
CF   Cystic fibrosis 
COPD   Chronic obstructive pulmonary disease 
dae   Aerodynamic diameter 
DC   Dendritic cell 
DE   Deposition 
DME   Diabetic Macular Edema 
dsRNA  Double stranded RNA 
FRC   Functional residual capacity 
EGF   Epidermal growth factor 
GTP   Guanosine trisphosphate 
KSP   Kinesin spindle protein 
MAPK  Mitogen-activated protein kinase  
MF   Mutant frequency 
mRNA  Messenger RNA 
miRNA  micro RNA 
NfKB   Nuclear factor kappa beta 
NOD   Nucleotide-binding oligomerization domain 
8-OH-dG  8-hydroxy-2'-deoxyguanosine  
PAI I   Plasminogen activator inhibitor 
PEG   Poly(ethylene) glycol 
PEI   Poly(ethylene imine) 
PM   Particular matter 
RNAi   RNA interference 
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RSV   Respiratory-Syncytial-Virus  
RV   Residual volume 
shRNA  Short hairpin RNA 
siRNA   Small interfering RNA 
t   Time 
TGF-beta  Transforming growth factor beta 
TLR   Toll-like receptor 
V   Volume 
VC   Vital capacity 
Vd   Dead space volume 
VEGF   Vascular epidermal growth factor 
Vt   Tidal volume 
UFP   Ultrafine particles 
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